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          Influenza virus A and B are common pathogens that cause respiratory disease in humans. 
Recently, a highly virulent H5N1 subtype avian influenza virus caused disease outbreaks in 
poultry around the world. Drug resistant type A viruses rapidly emerged, and the recent H5N1 
viruses were reported to be resistant to all current antiviral drugs. There is an urgent need for 
the development of new antiviral drugs target against both influenza A and B viruses. This 
dissertation describes work to identify small molecule inhibitors of influenza protein NS1 by a 
high throughput fluorescence polarization assay.  
          The N-terminal GST fusion of NS1A (residue 1-215) and NS1B (residue 1-145) were 
chosen to be the NS1A and NS1B targets respectively for HT screening. In developing the 
assay, the concentrations of fluorophore and protein, and chemical additives were optimized. A 
 VII
total of 17,969 single chemicals from four compound libraries were screened using the 
optimized assay. Six true hits with dose-response activity were identified. Four of them show 
an IC50 less than 1 μM. In addition, one compound, EGCG, has proven to reduce influenza 
virus replication in a cell based assay, presumably by interacting with the RNA binding domain 
of NS1.  
          High throughput, computer based, virtual screenings were also performed using four 
docking programs. In terms of enrichment rate, ICM was the best program for virtual screening 
inhibitors against NS1-RBD. The compound ZINC0096886 was identified as an inhibitor 
showing an IC50 around 19 μM against NS1A, and 13.8 μM against NS1B.  
          In addition, the crystallographic structures of the NS1A effector domain (wild type, 
W187A, and W187Y mutants) of influenza A/Udorn/72 virus are presented. A hypothetical 
model of the intact NS1 dimer is also presented. Unlike the wild type dimer, the W187Y 
mutant behaved as a monomer in solution, but still was able to binding its target protein, 
CPSF30, with wild type binding affinity. This mutant may be a better target for the 
development of new antiviral drugs, as the CPSF30 binding pocket is more accessible to 
potential inhibitors. The structural information of those proteins would be very helpful for 
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Chapter 1: Introduction 
 
 
1.1 Influenza virus 
          Influenza viruses are the causative agents for an infectious and debilitating disease 
commonly referred to as the flu.  The virus has a complex replicative cycle and undergoes rapid 
evolutionary divergence (Krug 2003). In its most aggressive form, the virus was responsible for 
one of the most devastating pandemics in human history: the notorious Spanish flu caused 20 to 
40 million deaths worldwide in the early twentieth century (Palese 2004). The outbreaks of 
deadly avian influenza H5N1/1997 and H5N1/2004 in Asia and Europe are reminders of the 
potential for the emergence of a new pandemic (Webby and Webster 2003; Li, Guan et al. 
2004; Jan 2007; Khanna, Kumar et al. 2008). The current swine influenza H1N1 outbreak in 
North America prompted the World Health Organization (WHO) to set the pandemic alert to 
phase 5, one level below an official pandemic. 
1.1.1 Categories of influenza virus 
          There are three types of influenza viruses: type A, B and C, which are classified based on 
the immunological relatedness of nucleocapsid (NP) and matrix (M) proteins (Schulman 1971). 
Both influenza A and B viruses contain eight RNA genomic segments, whereas influenza C 
virus contains only seven  (Cheung and Poon 2007). All the virus types can naturally infect 
human beings, although influenza C virus seldom causes disease symptoms. In contrast, 
influenza A and B viruses are virulent pathogens which will lead to the common flu symptoms 
in humans;  influenza A virus has been responsible for all the known influenza pandemics 
(Schulman 1971; Cheung and Poon 2007).     
          Influenza A virus can be further subdivided into different subtypes based on the antigenic 
variation of the surface hemagglutinin (HA) and neuraminidase (NA) glycoproteins. So far, 
sixteen subtypes of HA (H1-H16) and nine subtypes of NA (N1-N9) have been identified 
(Laver, Colman et al. 1984; Fouchier, Munster et al. 2005). Each of these subtypes can be 
isolated from wild aquatic birds, some may also be found in pigs, seals, horses and whales 
(Claas, Osterhaus et al. 1998; Fouchier, Schneeberger et al. 2004). The ability of these avian 
viruses to jump host species barriers makes influenza an almost uneradicable disease (Weber 
and Stilianakis 2007).  
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1.1.2 Structure and genome of influenza virus 
          The genomes of both influenza A and B viruses are composed of eight segments of single 
stranded RNA (Lamb, 2001). The proteins encoded by the corresponding genome segments of 
both viruses also share similar functions. In Influenza A virus, the three largest segments 
encode three viral polymerase subunits, PB1, PB2 and PA respectively (Enami and Enami 
1996; Elleman and Barclay 2004; Burleigh, Calder et al. 2005). An alternate reading frame in 
PB1 encodes a non-structural apoptotic protein PB1-F2. The three medium sized segments 
encode three structural proteins, hemagglutinin (HA), nucleocapsid protein (NP) and 
neuraminidase (NA) respectively (Schulman 1971). The last two, smallest, segments, M and 
NS, encode two proteins each. The M segment encodes the matrix protein (M1) and the ion 
channel protein (M2), while the NS segment encodes the non-structural (NS) proteins NS1A 
and NS2A, see figure 1.1. 
          It is known that PB2, PB1, and PA form a polymerase complex for viral transcription and 
replication (Huang, Palese et al. 1990; Perales and Ortin 1997; Honda, Mizumoto et al. 2002). 
PB2 polymerase contains a nuclear localization signal, which helps to transport the polymerase 
into the nucleus of infected cells (Mukaigawa and Nayak 1991; Perales, de la Luna et al. 1996). 
It also has a cap-binding protein functioning that aids in generating the cap structures necessary 
for viral mRNA transcription (Ulmanen, Broni et al. 1981; Blaas, Patzelt et al. 1982; Braam, 
Ulmanen et al. 1983; Ulmanen, Broni et al. 1983). PB2 was found to associate with the PB1 
subunit through amino terminus by mutageness and immunoprecipitation assays (Digard, Blok 
et al. 1989; Li, Rao et al. 2001; Fechter, Mingay et al. 2003).        
          PB1 polymerase is encoded by RNA segment 2. It plays an important role in the RNA 
polymerase complex as the subunit responsible for elongation of the primed nascent viral 
mRNA (Poole, Elton et al. 2004). PB1 is critical in the assembly of three polymerase protein 
subunits, and localizes in the nucleus of infected cells (Biswas and Nayak 1994; Gonzalez, 
Zurcher et al. 1996; Kobayashi, Toyoda et al. 1996; Honda, Mizumoto et al. 2002).  
          PA subunit is the smallest polymerase, and is encoded by RNA segment 3. The carboxyl 
terminus of PA is found to be critical for viral transcription by mutagenesis assay (Sanz-
Ezquerro, de la Luna et al. 1995; Sanz-Ezquerro, Zurcher et al. 1996; Fodor and Smith 2004). 
Sequence comparison suggests that it has helicase activity, although the exact functions of PA 








Figure 1.1: Schematic diagram of structure of the influenza A virus. The eight RNA genomic 










          Hemagglutinin (HA), encoded by segment 4, is an integral membrane protein responsible 
for binding the flu virions to sialic acid containing receptors on host cell surfaces (Staudt and 
Gerhard 1983). HA is initially synthesized as a precursor polypeptide, and then undergoes a 
series of post-translational modifications (Skehel, Bayley et al. 1982; Horimoto, Nakayama et 
al. 1994; Webby, Perez et al. 2004). First, the amino-terminal 14 residues are removed, 
followed by palmitic acidification at the cysteine residue near the carboxyl-terminus. 
Afterward, the protein is cleaved into two disulphide-linked subunits (HA1 and HA2) by 
trypsin-like proteases of the host cell (Connor, Kawaoka et al. 1994; Vines, Wells et al. 1998). 
HA, the major flu antigen, is subject to a high rate of mutation due to the viral RNA 
polymerase error-prone activity. Among all sixteen subtypes of HA (H1-H16) identified so far, 
the amino acid sequences of HA variants differ by at least 30% from each other (Staudt and 
Gerhard 1983; Connor, Kawaoka et al. 1994; Vines, Wells et al. 1998).   
          Nucleoprotein (NP) is encoded by segment 5, and is actively synthesized in the infected 
cells. The binding of NP to single-stranded RNA is not sequence specific (Kistner, Muller et al. 
1989). It is estimated that one NP molecules binds 15-20 nucleotides (Winter and Fields 1981; 
Kobayashi, Toyoda et al. 1994; Albo, Valencia et al. 1995). Together with viral polymerase, 
NP and vRNA form a so called viral ribonucleoprotein (vRNP) complex, which is a supercoiled 
ribbon structure with the polymerase complex at the end of viral genome (Beaton and Krug 
1986; Shapiro and Krug 1988; Biswas, Boutz et al. 1998). It is also believed that the 
phosphorylated NP plays an important role in “switching” of RNA polymerase activity from 
mRNA synthesis to complementary (cRNA) and viral RNA synthesis (Shapiro and Krug 1988; 
Kistner, Muller et al. 1989). NP is also found to be involved in the viral RNA nuclear transport 
(Martin and Helenius 1991; O'Neill, Jaskunas et al. 1995; Whittaker, Bui et al. 1996; Neumann, 
Castrucci et al. 1997). The detailed mechanisms of switching and transportation are still waiting 
to be revealed. Like HA, NP is also a major target of host immune response (Shapiro and Krug 
1988).  
          Encoded by segment 6, Neuraminidase (NA) is also an integral membrane glycoprotein. 
The structure of NA shows that the monomer protein is composed of four domains: a 
mushroom-shaped globular head, a thin stalk, a transmembrane domain and a cytoplasmic 
domain (Varghese and Colman 1991). NA is not required for virus replication, as demonstrated 
by a NA-deficient virus (Li, Schulman et al. 1993; Hausmann, Kretzschmar et al. 1997). The 
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actual role of NA is to remove terminal sialic acids from the glycoproteins on the virion 
surface, thereby helping to release the progeny virions from the infected cell (Palese, Tobita et 
al. 1974; Palese and Compans 1976; Liu, Eichelberger et al. 1995).  
          Segment 7 of influenza A virus encodes two proteins: the matrix protein (M1) and the ion 
channel protein (M2) (Shih, Nemeroff et al. 1995). M1 is a collinear transcript of segment 7, 
whereas M2 is encoded by a spliced mRNA variant of segment 7 (Ye, Liu et al. 1999). 
Collinear transcripts arise with common initiation but different termini. Being the most 
abundant influenza virion protein, M1 forms a shell underneath the viral lipid membrane to 
interact with the virus-specific ribonucleoprotein (vRNP) and cytoplasmic domains of various 
integral membrane proteins (Wakefield and Brownlee 1989; Ye, Baylor et al. 1989; Elster, 
Fourest et al. 1994). It is reported that M1 binds to viral RNA in a sequence nonspecific 
manner. Once M1 binds to vRNP, it accelerates the nuclear export of vRNP, and at the same 
time inhibits the import of vRNP (Ye, Robinson et al. 1995; Bui, Whittaker et al. 1996; Huang, 
Liu et al. 2001; Sakaguchi, Hirayama et al. 2003). In 2004, Elleman and Barclay demonstrate 
that the M1 matrix protein alone controls the filamentous phenotype of influenza A virus 
(Elleman and Barclay 2004). Unlike M1, M2 is an integral membrane protein (Lamb, Zebedee 
et al. 1985). The native protein exists in a homotetramer conformation, and acts as an ion 
channel that modulates the pH of the Golgi during HA synthesis (Pinto, Holsinger et al. 1992; 
Wang, Lamb et al. 1994). Thus it helps to stabilize the native conformation of newly 
synthesized HA during viral assembly. M2 also plays an important role in the acidification of 
the interior of the virion particle during virus uncoating (Henkel and Weisz 1998; Park, 
Castrucci et al. 1998).  
          Like segment 7, segment 8 also encodes two proteins: nonstructural proteins NS1 and 
NS2. NS1 message is a collinear transcription of segment 8, whereas NS2 is encoded by a 
spliced mRNA of segment 8 (Alonso-Caplen and Krug 1991; Nemeroff, Utans et al. 1992). 
NS1 is not incorporated into virions, and is the only nonstructural protein in influenza virus 
(Greenspan, Palese et al. 1988; Nemeroff, Qian et al. 1995). NS1 has been shown to have 
multiple functions, including binding dsRNA and interfering with host translation and mRNA 
processing (Hale, Randall et al. 2008).  After expression it localizes in the host cell nucleus. 
The details will be discussed in a separate chapter in the following section.  
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          The name of NS2 is somewhat misleading as NS2 is found to incorporate into viral 
particles in low amounts (Richardson and Akkina 1991; Yasuda, Nakada et al. 1993). Unlike 
NS1, NS2 primarily localizes in the cytoplasm (Richardson and Akkina 1991; Yasuda, Nakada 
et al. 1993). The role of NS2 is to promote replication of vRNA and to mediate the export of 
newly synthesized vRNP from the nucleus to the cytoplasm, although the detailed mechanism 
still remains unknown (O'Neill, Talon et al. 1998; Neumann, Hughes et al. 2000).  
          In summary, influenza A virus is a small enveloped pleomorphic particle with a diameter 
of 80-120nm. The viral particles contain a lipid bilayer envelope derived from the host cell 
membrane. HA, NA, and M2 are embedded in that lipid envelope, and project like spikes. 
Under the lipid envelope, there is an electron dense layer composed of M1 protein. Inside the 
virion, the genome of influenza virus is composed of eight unique segments of single stranded 
RNA. The RNA is encapsidated by multiple NP molecules to form RNP complexes. The viral 
RNA polymerase complex is composed of PB2, PB1, and PA. NS2 is also present in the virion 
in low amounts.  
1.1.3 Transcription and replication of influenza virus 
          Transcription and replication of the influenza viral genome takes place in the nucleus of 
infected cells (Herz, Stavnezer et al. 1981; Jackson, Caton et al. 1982). Like other negative-
stranded RNA viruses, the RNA-dependent RNA polymerase encoded by the three largest flu 
genome segments converts the single-stranded virion RNA (vRNA) into viral mRNAs. The 
viral mRNAs are exported into the cytoplasm, and translated by host proteins into the proteins 
of new virus particles, see figure 1.2.  
          The viral mRNA requires a type I cap structure (m7GpppNm, where N is any nucleotide) 
and a polyadenylated tail (Braam, Ulmanen et al. 1983). The whole transcription process starts 
by the recognition of the cap structure of host pre-mRNA by PB2 subunit of viral RNA 
polymerase. Once PB2 recognizes and binds the cap structure of host pre-mRNA, it cleaves 
about 10 nucleotides downstream from the cap structure. The resulting capped RNA fragments 
are used by viral polymerase as transcription primers. Transcription is initiated by incorporating 
a G or C onto the 3’ end of the primers which based pair with viral RNA template. The 
elongation of the mRNA chain proceeds until reaching a polyadenylation signal, which consists 
of 5–7 U residues approximately 17 nucleotides from the 5' end of vRNA. Finally, the viral 


















template and elongating RNA chain (Krug, Broni et al. 1979; Plotch, Bouloy et al. 1979). In 
other words, it iteratively copies the U-track at the end of vRNA to nascent mRNA. It is well 
demonstrated that the 5’ cap structure, together with poly(A) tail are essential for mRNA 
stabilization and nuclear export (Bouloy, Plotch et al. 1980). 
          A second population of RNA transcripts is complementary RNA (cRNA); these are full-
length copies of the vRNA that can be used as templates for progeny vRNA synthesis. Unlike 
viral mRNA synthesis, the synthesis of cRNA is initiated on its own promoter without a primer, 
and is not terminated with a polyadenylated tail (Hay, Skehel et al. 1982). Instead, 
dinucleotides are generated by viral RNA polymerase to serve as primers for the chain 
elongation. As observed from in vitro replication system, the RNA synthesis is significantly 
increased in the presence of additional dinucleotide primers (Biswas, Boutz et al. 1998). It is 
also observed that the amount of vRNA synthesis from cRNA template is 10 times higher than 
that of cRNA synthesis from vRNA template (Vreede, Jung et al. 2004). This phenomenon 
could be due to the difference in the initiation activity. In addition, the synthesis of cRNA is 
dependent on the continued production of functional viral proteins, whereas the synthesis of 
mRNA continues in the absence of protein synthesis. Therefore, it was suggested that cRNA is 
unstable and tends to be degraded until there are enough copies of newly synthesized 
polymerases or NP, which stabilize cRNA by forming RNP structure (Nagata, Takeuchi et al. 
1989; Shimizu, Handa et al. 1994; Nagata, Kawaguchi et al. 2008). However, the question 
remains unsolved as to what form of polymerase complexes are required for the switch from 
the capped RNA primer dependent mRNA synthesis to unprimed cRNA synthesis, and how 
this switch is initiated (Nagata, Kawaguchi et al. 2008). The replicated vRNA and newly 
synthesized viral proteins are then assembled into a virion, and further bud from the cell 
surface.  
1.2 Vaccination and antiviral therapies 
          Currently, the most effective way to prevent influenza infection is vaccination with killed 
or attenuated virus (Nichol 2006; Ada 2007). Almost all flu vaccines on the market are 
produced from virus grown in fertile hens' eggs, and then inactivated by either β-propiolactone 
or formaldehyde (Nichol, Lind et al. 1995). The resulting vaccines consist of whole virus,  
detergent-treated split virus product, or purified hemagglutinin (HA) and neuraminidase (NA) 
surface antigens. Due to adverse affect on young children, whole-virus vaccines are not widely 
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available (Heikkinen, Ruuskanen et al. 1991; Nichol, Lind et al. 1995; Block 2004). In contrast, 
split virus products and purified HA/NA surface antigen are well tolerated and  safe (Laver 
1985). Ideally, the vaccine will be most effective when the strains included in the vaccine are a 
good antigenic match with the current circulating strains of influenza. Currently licensed 
influenza vaccines are trivalent, inactivated formulations that consist of HA proteins from 
H1N1, H3N2 and influenza B strains respectively (Laver 1985). Those three strains were 
chosen by the WHO Global Influenza Surveillance Network based on their best predicition of 
which strains will be predominant in the coming year. The vaccine is designed to block the 
function of HA and NA proteins, as both of them are the primary targets of the protective 
antibody response. As a result of vaccination, antibodies against HA can neutralize subsequent 
viral infection, and antibodies against NA can modify the severity of disease. Unfortunately, 
the HA protein mutates from year to year, by the process called “antigenic drift” (Luther, 
Bergmann et al. 1984; Yamada, Brown et al. 1984; Lipkind and Shihmanter 1986). By 
randomly accumulating amino acid changes, HA is said to “drift” from one shape to another, 
thereby making the human immune system less able to recognize the new strain. As a result, 
antiviral drugs targeting non-surface proteins are gaining much more attention in the war 
against influenza virus (Ferguson, 2005; Germann, 2006). 
          Currently, there are two classes of antiviral drugs available: the M2 inhibitors 
(amantadine and rimantadine), and the neuraminidase inhibitors (zanamivir and oseltamivir). 
Amantadine and rimantadine were developed to block the ion channel activity of M2 protein 
(Rees, Harkins et al. 1997; Ellis and Zambon 2002). Therefore, viral replication is inhibited by 
the blockade of hydrogen ion flow. It has been reported that the inhibition of viral replication 
could be achieved at micromolar concentration (Rees, Harkins et al. 1997). However, these 
drugs are ineffective against influenza B virus because it doesn’t encode M2 protein (Gubareva, 
Kaiser et al. 2000). Both drugs are found to be 70–90% effective in preventing and relieve the 
symptoms caused by naturally occurring influenza A, but amantadine has more adverse effects, 
including insomnia, headache and vomiting, which are troublesome in elderly people and very 
young children (Nicholson 1996; Margo and Shaughnessy 1998). The main drawback to the 
use of M2 inhibitors is that drug resistance emerges rapidly during treatment (Suzuki, Saito et 
al. 2003). Sadly, those drug-resistant variants are fully pathogenic and transmissible to others. 
Both amantadine and rimantadine resistant strains have been characterized by mutations in the 
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transmembrane domain of the M2 protein (Suzuki, Saito et al. 2003). The most common one is 
a single nucleotide change in codon 31, which results in a single amino acid substitution in the 
membrane spanning region (Intharathep, Laohpongspaisan et al. 2008; Monto 2008). Recently, 
the highly virulent H5N1 strain was reported to be resistant to both amantadine and rimantadine 
(Harrod, Emery et al. 2006). 
          Other drugs, like Zanamivir and Oseltamivir, have been developed to target the NA 
protein, which is expressed in both influenza A and B viruses (Woods, 1993; Ryan, 1994; Kim, 
1997; Mendel, 1998). Although NA is not required for replication, it is required for releasing 
newly assembled virons from the infected cell surface by cleaving terminal sialic acid residues 
from glycoconjugates (Oxford, Mann et al. 2003). As a result, NA inhibitors inhibit the release 
of virions from infected cells, cause aggregation of virions at the cell surface and retard further 
spreading to other healthy cells. Zanamivir, also called Relenza or GG167, is the first 
neuraminidase inhibitor commercially developed (Monto, Webster et al. 1999). The debut of 
zanamivir is an important milestones of the rational drug design.  Zanamivir was designed 
based on the structure of the transition state analogue of NA, DANA (2-deoxy-2,3-dehydro-N-
acetylneuraminic acid). The resulting binding affinity increased 5000 fold compare to that of 
sialic acid, the native substrate of NA (von Itzstein, Wu et al. 1993; Zimmerman, Ruben et al. 
1997). Because of its poor oral bioavailability, zanamivir has to be administered through 
inhalation (Englund 2002).  
          Oseltamivir, also called Tamiflu or GS4104, was designed based on another potent 
transition state analogue of sialic acid hydrolysis.  The drug has good oral bioavailability (Li, 
Escarpe et al. 1998). In 1999, Oseltamivir was approved as the first orally effective drug for the 
treatment of flu infection (Sidwell, Bailey et al. 1999). Mutant strains resistance to zanamivir 
and Oseltamivir have been reported, although the frequency is much less than those to 
amantadine and rimantadine (Moscona 2004). In 2005, H5N1 virus that is resistant to the 
Oseltamivir has been isolated (Puthavathana, 2005). During the 2007-2008 flu season, 11% of 
H1N1 virus was found to be Oseltamivir resistant (Lowen and Palese 2007). Two mechanisms 
of resistance have been identified: the NA dependent resistance and the NA independent 
resistance (Aoki, Boivin et al. 2007; Ferraris and Lina 2008; Lackenby, Thompson et al. 2008). 
The NA dependent resistance involves single amino acid substitution in the active site of the 
NA, which alters its sensitivity to the drug. The NA independent resistance involves mutations 
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in the HA receptor-binding site, thereby reducing the efficiency of virus binding to cellular 
receptors. Therefore, virus can free from the infected cells without the need for NA. The 
emergence of drug resistant strains emphasizes the need for new antiviral drugs 
1.3 Antiviral defense mechanism 
          When influenza virus invades humans, the innate immune responses of the host provide 
immediate defense against infection. Several components are involved in the innate immune 
system, including mucus, macrophage, interferon α/β (INFα/β), cytokines (IL-1, IL-6 and TNF 
α), natural killer (NK) cells (Hartshorn, Karnad et al. 1990). Representing the first barrier 
against infection, the innate immune response also provides the appropriate signals required for 
the subsequent adaptive immune response, in which antigen-specific memory cells (T and B 
cells) and their products functions as antigen-specific effectors, such as cytotoxic T 
lymphocytes and antibodies, to target the virus (Hartshorn, Karnad et al. 1990; Tamura and 
Kurata 2004).  
          The detection  of influenza viral RNA in cytoplasm is accomplished by two related 
cytosolic RNA helicases, termed retinoic acid-induced gene I (RIG-I, also know as DDX58) 
and melanoma differentiation-associated gene 5 product (MDA5, also known as IFIH1) 
(Andrejeva, Childs et al. 2004; Yoneyama, Kikuchi et al. 2004). Binding to viral dsRNA by 
RIG-I and MDA5 initiates the conformational changes which leads to recruiting additional 
cellular factors, including the recently identified interferon β promoter stimulator 1(IPS-1), 
mitochondrial antiviral signaling (MAVS) protein, and virus-induced signaling adaptor (VISA) 
(Kawai, Takahashi et al. 2005; Seth, Sun et al. 2005). As a result, different cellular kinases, 
including interferon regulatory factor-3 (IRF3) kinase, TNF-receptor-associated factor family 
member-associated nuclear factor-κB activator binding kinase 1(TBK1) and inhibitory κBα 
protein kinas (IKK-ε), are activated. Then, the activated IRF3 kinase, together with nuclear 
factor-κB (NF-κB) and activating protein 1(AP-1), bind to the promoter of IFNβ promoter and 
initiate transcription (Garcia-Sastre 2006). 
          Once IFNα/β has been synthesized, it is secreted and binds to the IFNα/β receptor on 
neighboring cells.  As a result, two members of the Janus tyrosine kinase family (JAK1 and 
Tyk2) are activated. JAK1 and Tyk2 in turn phosphorylate STAT1 (signal transducers and 
activators of transcription) and STAT2 transcription factors (Stark, Kerr et al. 1998; Le Bon, 
Schiavoni et al. 2001). The phosphorylated STAT1 interacts with STAT2 and p48/IRF-9 to 
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form the transcription factor IFN-stimulated gene factor 3 (ISGF3). The ISGF3 complex then 
binds to specific DNA sequences called IFN-stimulated regulatory elements (ISREs), 
promoting the transcription of approximately 100 to 300 genes. Among these genes, those 
encoding the dsRNA-activated protein kinase (PKR), the 2’,5’-oligoadenylate synthetases (2’-
5’A synthetases), and the Mx proteins are demonstrated to interfere with viral replication by 
different mechanisms, including binding to viral nucleocapsids, translation inhibition, RNA 
degradation, RNA editing, and apoptosis induction (Biron 2001; Weber, Kochs et al. 2004). 
Overall, the secretion of IFNα/β by virus-infected cells contributes to the induction of an 
antiviral state in neighboring uninfected cells. 
          The serine-threonine protein kinase PKR is one of the most extensively studied 
interferon-induced protein kinase (Ludwig and Planz 2008). Although the level of PKR 
increases in cell in response to IFN, it remains inactive unless it interacts with viral dsRNA. 
The binding of dsRNA to PKR causes a conformational change of the protein, which causes the 
C-terminal kinase domain of PKR to release the N-terminal dsRNA binding domain (Williams 
1999). As a result, PKR becomes autophosphorylated and dimerized as an active kinase. The 
activated PKR phosphorylates α-subunit of the translation initiation factor eIF-2 α (Williams 
1999). This leads to the inactivation of eIF-2 α, which in turn results in the inhibition of protein 
synthesis. Like PRK, the 2’-5’(A) synthetases need to be activated by viral dsRNA (Silverman 
2007). Once activated, 2’-5’(A) synthetases polymerize ATP into 2’-5’ linked oligoadenylates 
of different length. The resulting 2’-5’ A molecules bind to and activate a latent ribonuclease, 
RNase L. Activated RNase L induces the degradation of RNAs, including viral mRNAs and 
rRNAs,  therefore consequently inhibits viral replication and protein synthesis. Finally, the Mx 
proteins were discovered as IFN-induced proteins which inhibit replication of specific groups 
of viruses, including influenza virus, rhabdovirus and orthomyxovirus. The Mx proteins bind 
GTP and have an intrinsic GTPase activity that is necessary for their intracellular antiviral 
actions. Although the detailed mechanism of that action is still unknown, it was proposed that 
Mx proteins interfere with virus replication through a dynamin-like force-generating 
mechanism by wrapping around viral nucleocapcids (Horisberger 1995; Haller, Staeheli et al. 
2007).  
          Despite the host's sophisticated innate immune system, influenza viruses continue to 
successfully infect them and cause disease. The success of influenza viruses is partly due to the 
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acquisition of viral genes that antagonize the host immune response. In the case of influenza A 
virus, this IFNα/β antagonistic function is encoded by the NS1 gene. 
1.4 The influenza virus NS1 protein 
1.4.1 NS1 from influenza A virus (NS1A) 
          The NS1 protein of influenza A virus (NS1A) is not a structural component of the virion, 
but is highly expressed in infected cells (Krug 1993). It has a strain specific length of 230 to 
237 residues, and an approximate molecular mass of 26 kDa. The NS1A protein is a 
multifunctional protein that participates in both protein-protein and protein-RNA interactions 
(Hale, Randall et al. 2008). Two functional domains identified are the N-terminal 73 amino 
acids RNA-binding domain (RBD) and C-terminal effector domain (residue 74-230), see figure 
1.3. The full length NS1A exists as a homodimer with both the RNA binding domain and 
effector domain contributing to multimerization (Chien, Tejero et al. 1997; Liu, Lynch et al. 
1997). The RBD binds non-specifically to double-stranded RNA (dsRNA), and indirectly 
protects the virus against the antiviral state induced by interferon α/β. This protection is 
achieved by blocking the activation of the 2'-5'-oligo(A) synthetase/RNase L pathway, which 
inhibits virus replication by degradation of viral RNA (Min and Krug 2006). It was also found 
that out-competing 2'-5'-oligo(A) synthetase for interaction with dsRNA is a predominant 
function of NS1A RNA-binding domain (Min and Krug 2006). Mutation studies of NS1A RBD 
show that Arg38 and Lys41 are  two amino acids  critical for the dsRNA binding activity 
(Chien, Xu et al. 2004). A recombinant influenza A virus expressing the mutant (R38A)-NS1A 
protein is attenuated 1000-fold in replication (Min and Krug 2006). These results suggest that 
the NS1A RBD is a valid target for the development of antiviral drug. The RBD also interacts 
with the retinoic acid-inducible gene I (RIG-I) binding domain (Samuel 2007; Uematsu and 
Akira 2007). The RIG-I protein functions as an intracellular viral sensor, which can be 
activated by influenza virus ssRNA/dsRNA. The binding of RIG-I to RBD of NS1A inhibits 
the ability of viral detection by the cell (Hornung, Ellegast et al. 2006; Pichlmair, Schulz et al. 
2006).  
          The C-terminal effector domain of NS1 was found to interact with at least four different 
proteins:  elongation initiation factor 4GI (eIF4GI), protein kinase R (PKR), cleavage and 
polyadenylation specificity factor (CPSF) and poly(A)-binding protein II (PAB II) (Hale, 




Figure 1.3: Structural domains of NS1A protein. 
 
 
Figure 1.4: Schematic diagram of NS1 functions. Star1: Directly limits the antiviral state by 
blocking the activation of OAS/RNaseL; Star2: Inhibits the induction of IFN-beta at pre-
transcriptional level; Star3: Post-translational block of the processing and nuclear export of all 
cellular mRNAs; Star4: Enhancement of viral mRNA translation. Redrawn and modified from 
(Hale, Randall et al. 2008). 
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protein are sufficient to bind eIF4GI (Aragon, de la Luna et al. 2000; Burgui, Aragon et al. 
2003). It was suggested that NS1 recruits eIF4GI specifically to the 5’ untranslated region of 
viral mRNA, thus preferentially enhances the translation of the viral mRNA (Burgui, Aragon et 
al. 2003). The direct binding of PKR to  residues 123 to 127 of NS1A is necessary and 
sufficient to block the activation of PKR, and thereby inhibit the antiviral effect of PKR (Li, 
Min et al. 2006; Min, Li et al. 2007).  
 The effector domain also binds to the 30 kDa subunit of CPSF, thus inhibiting the 
maturation and exportation to the cytoplasm of the host cellular antiviral mRNAs (Li, Rao et al. 
2001; Noah, Twu et al. 2003; Twu, Noah et al. 2006). The second and third zinc fingers (F2F3) 
of CPSF were shown to interact with NS1A (Twu, Noah et al. 2006). A recombinant Udorn 
virus expressing  NS1A with mutations spanning the CPSF binding sites (residues 184 to 188) 
induced a high level of interferon β (INF β) mRNA, and was attenuated 1000 fold in replication 
(Noah, Twu et al. 2003; Twu, Noah et al. 2006). An engineered MDCK cell lines which 
constitutively expressing epitope-tagged F2F3 in the nucleus effectively blocked the binding of 
endogenous CPSF to NS1A, thereby selectively inhibited the influenza virus A replication 
(Noah, Twu et al. 2003; Twu, Noah et al. 2006). All these observations suggest that the 
CPSF30 binding site can be targeted for development of new antiviral drugs.  
          The function of PABII in cells is to facilitate the elongation of poly(A) tails during the 
generation of mRNAs. The binding of PABII to residues 215 to 230 of NS1A prevents PABII 
from properly extending the ploy(A) tail of cellular pre-mRNA, thus retarding pre-mRNA 
export from the nucleus (Chen, Li et al. 1999).  
          Finally, the effector domain is also crucial for the function of the RBD. It was revealed 
that dimerization of these two domains is essential for the NS1A protein to interact with RNA 
or other cellular proteins (Wang, Basler et al. 2002; Fernandez-Sesma 2007). Taken together, 
NS1A is a very potent inhibitor of host cell innate immunity and allows influenza A virus to 
efficiently escape  host defenses and to further establish infection (see figure 1.4). 
          Well before the very recent structure of full length NS1A from an H5N1 virus became 
available, the structures of the two function domains were solved independently. The NMR and 
X-ray structure of the 73-residue N-terminal domain of NS1A shows that the protein is active 
as a dimer (Qian, Chien et al. 1995; Chien, Xu et al. 2004). The structural analysis revealed a 
unique six-helix structure for the dimer, which differs from that of other known dsRNA-
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binding proteins. The dimeric protein binds dsRNA as part of its function in the viral cycle. 
According to the sedimentation equilibrium measurements, the NS1A73 dimer binds to a 16-bp 
synthetic dsRNA with a 1:1 stoichiometry (Chien, Xu et al. 2004). In 2008, the crystal structure 
of NS1A73 dimer bound to a self-complementary 21-nucleotide RNA (with 19 base pairs) was 
determined (Cheng, Wong et al. 2009). The complex structure reveals that RBD recognizes the 
A-form dsRNA in a major groove binding mode. The critical Arg38 was found to penetrate into 
the dsRNA helix and to form hydrogen bonds with the phosphate groups of two nucleotides 
from two different RNA strands. Furthermore, a hydrogen bond network is formed by Arg38 
and its symmetrically related molecules to anchor dsRNA along the binding surface. The 
structure of the RBD and dsRNA complex also explains why the RBD of NS1 has the ability to 
distinguish between dsRNA and dsDNA.  The inter-molecular contacts are directed towards the 
phosphate backbone of the A helix, and the 2′-OH groups of the RNA strands. 
          The X-ray structure of the NS1A effector domain (residues 79-205) from the mouse-
adapted influenza A/PR8/34(PR8) virus strain was solved in 2006 (Bornholdt and Prasad 
2006).  Like the N-terminal domain, the effector domain forms a dimer in solution. Each 
monomer consists of seven β-stands and three α-helices. The structure is believed to be a novel 
fold, which can be described as an α-helix β-crescent fold, as the β-strands form a crescent-like 
shape around the α-helix. The NS1A from the PR8 virus strain does not bind CPSF30 because 
it does not have the required consensus human recognition sequence at residue 103 (it has S 
instead of F) and residue 106 (I instead of M) (Das, Ma et al. 2008). The CPSF30 binding site 
is crucial for virus replication and is a proven target for new antiviral drug development. As a 
result, the structure of effector domain that is capable of binding CPSF30 would be extremely 
helpful for structure based drug design.  
          Recently, the x-ray structure of the full length NS1A (R38A,K41A) from an H5N1 strain 
(A/Vietnam/1203/2004) was solved by Bornholdt and Prasad (Bornholdt and Prasad 2008). 
R38 and K41 of the protein were mutated to alanine.  This double mutant completely abrogated 
aggregation and allowed the protein to be sufficiently concentrated for crystallization. 
Compared to the individually determined structures of RNA binding domain and effector 
domain, the overall polypeptide folding of RBD and effector domain from H5N1 showed only 
minor structural alterations. The most striking difference is the dimer interaction between the 
two domains. The two domains of each NS1A molecule separately interact with their respective 
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domains from the neighboring NS1A molecules, related by crystallographic two-fold 
symmetry. This results in the formation of a chain of NS1A molecules with alternating dimers 
of RBD and dimers of effector domain. The authors proposed a model for full length NS1 
interacting with dsRNA in which NS1A cooperatively oligomerizes in the presence of dsRNA 
to from a tubular structure with dsRNA in the hollow central tunnel. This model explains why 
NS1A is able to sequester varying lengths of dsRNA in infected host cells. It was further 
substantiated by cryo-electron microscopy images of native full-length NS1 from influenza A 
virus H0N1 strain (A/PR8/34) with different length of dsRNA.  
1.4.2 NS1 from influenza B virus (NS1B) 
          The NS1 encoded by influenza B virus (NS1B) shares little sequence homology with 
NS1A protein, and has a larger size (281 residues) with molecular mass around 32kDa. Like 
NS1A, NS1B also has two functional domains: the N-terminal dsRNA-binding domain (residue 
1-93) and C-terminal effector domain (residue 94-281) (Wang and Krug 1996; Yuan and Krug 
2001). Although the sequence identity of RBD between the two viruses is only 20%, the x-ray 
structures show that they share  conserved surface features (Wang, Riedel et al. 1999; Yuan, 
Aramini et al. 2002). The dsRNA-binding surface of both NS1A and NS1B proteins have 
highly conserved patches of basic and hydrophilic amino acids which are complementary to the 
polyphosphate backbone conformation of the A-form dsRNA. The NS1B RBD would also be 
expected to protect influenza B virus against the interferon α/β-induced antiviral state by out-
competing 2'-5'-oligo(A) synthetase for interaction with dsRNA. The direct binding of 
interferon stimulated gene protein 15 (ISG15) to the residues 1 to 104 of NS1B is necessary 
and sufficient to block the antiviral ability of ISG15 (Yuan, Aramini et al. 2002). The ISG15 is 
an IFN-inducible protein that enhances the IFN-mediated antiviral response, including RNA 
splicing, antiviral ability and cytoskeleton regulation (Ritchie and Zhang 2004). Although the 
size is larger, the effector domain of NS1B does not bind either CPSF30 or PABII (Wang and 
Krug 1996; Yuan and Krug 2001). There is also no evidence to show direct interactions 
between the NS1B effector domain and eIF4GI or PKR. This may explain why NS1B does not 
inhibit the posttranscriptional processing of cellular mRNAs.  As NS1 is the major IFNα/β 
antagonist, the difference in NS1A and NS1B very likely contributes to the different biological 
properties of influenza A and B viruses.  
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1.5 Project goals 
          The goal of this project is to identify small molecule ligands of the NS1 protein of 
influenza A/B viruses.  The ligands are to be targeted to the dsRNA binding region of the RBD 
and the F2F3 binding region of the effector domain.  Such ligands will serve as chemical 
“platforms” for future rational based drug design. Research in Dr.Krug’s laboratory has 
validated both the N-terminal RNA-binding domain and C-terminal effector domains as 
efficacious targets for new antiviral drugs.  
          A fluorescence polarization (FP) assay was developed for the high throughput screening 
of small compounds library against the NS1 RBD protein. The focus of my study is to refine 
and optimize this FP assay to screen several commercially available small-compound libraries, 
including ChemBridge fragment library (4000 compounds), ChemBridge kinase library (13000 
compounds), NCI clinical trial compound library (400 compounds), and natural product library 
(4000 compounds). The “hit” compounds with Kd <100 μM were further validated and refined 
using structure-based analyses. Several confirmed “hit” compounds were soaked or co-
crystallized with appropriate protein receptors in an effort to elucidate their binding modes.  
Another goal of this project was to crystallize related NS1 proteins, including different domains 
of the NS1 protein as well as the full length NS1. The structural information of those proteins 















Chapter 2:  Verification and Optimization of the Fluorescence 
Polarization (FP) Assay as a High Throughput Screening (HTS) 




          Structural and biochemical data show that the RNA binding domain of NS1A is a valid 
target for the development of antiviral drugs (Min and Krug 2006). A fluorescence polarization 
(FP) assay has been developed for the high throughput screening of small compounds library 
against RBD of NS1 protein. Fluorescence polarization is a spectroscopic method that is based 
on the molecular movement of the fluorescent molecules in solution (Nasir and Jolley 1999; 
Roehrl, Wang et al. 2004). When excited with polarized light, the fluorescent molecules emit 
light in the same polarized plane if the molecule remains stationary. If the fluorescent dye 
tumbles significantly during the fluorescent life time, the emitted light is depolarized relative to 
the excitation plane; this would be the case if the dye were attached to a small, mobile 
molecule. Conversely, if the fluorescent dye is attached to a very large, slowly rotating 
molecule during excitation state, the emitted light remains highly polarized. Therefore, 
fluorescence polarization provides a direct measurement of the extent of fluorescent dye 
binding to macromolecules, including proteins, nucleic acids and other biopolymers. 
Experimentally, the degree of polarization is determined by measuring the fluorescence 
intensities parallel and perpendicular to the plane of the excitation light. To simplify the 
expression mathematically, fluorescence polarization is expressed in terms of anisotropy. As 
fluorescence polarization provides direct measurement of the binding of a fluorescent labeled 
molecule to a target molecule, it is widely used to determine the binding affinity of molecular 
interactions. 
          Here we determine the equilibrium dissociation constant, Kd, for binding of fluorescein-
labeled dsRNA to different NS1A /NS1B constructs by the FP assay. To facilitate our search 
for ligand/inhibitors, we were aiming to find the NS1 construct with highest binding affinity to 
dsRNA. The rotation of fluorescent labeled molecules is influenced by temperature, molecular 
volume, and most importantly, by the solution viscosity which can be affected by the presence 
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of additive chemicals. Therefore, the impact of additive chemicals on the FP assay, including 
tRNA, BSA and DMSO, will be tested and optimized. 
2.2 Materials and methods 
2.2.1 Construction of various NS1 variants 
          The NS1A(1-215)-pGEX4T3, NS1B(1-104)-pGEX3X, NS1B(1-145)-pGEX3X, and 
NS1B(1-218)-pGEX3X plasmids were provided by Dr.Robert Krug. The 215 residue NS1A(1-
215) was PCR amplified with primers GGGAATTCCATATGGATTCCAACACTGTGTCAA 
GTTTTCAGGTAG and CCGCTCGAGAGTAAGTGGAGGTCTCCCATTCTCATTACTGCT 
TCC. And the product was digested with NdeI and Xhol restriction endonucleases, and cloned 
into pET43.1a plasmid DNA (Novagen) cleaved with NdeI and Xhol. The first 73 amino acids 
of NS1A was PCR amplified with primers CATGCCATGGATTCCAACACTGTGTCAAGTT 
TTCAGGTAG and CCGCTCGAGGCCCTGAAAATACAGGTTTTCAGATTCTTCCTTC. 
The TEV protease recognition site was engineered in the 3’ primer. Then the PCR product was 
digested with NcoI and Xhol restriction endonucleases, and cloned into pET28b plasmid DNA 
(Novagen) cleaved with NcoI and Xhol. The integrity of all cloned DNA(s) were confirmed by 
DNA sequencing. 
2.2.2 Construction of plasmid mutations 
          The mutations were introduced by site-directed mutagenesis, according to the Stratagene 
protocol (Stratagene). Around 50 ng of plasmid and 150 ng of each primer were combined with 
reaction buffer (20 mM Tris–HCl (pH 7.5), 8 mM MgCl2, 7.5 mM DTT, 50 μg/ml of bovine 
serum albumin (BSA)), 150 μM dNTP mix, 1 units of KOD Hot Start DNA Polymerase 
(Novagen), and deionized water to final volume of 50 μl. Primer sequences of NS1A mutant 
(R38A) and NS1B mutants (R50A, R53A and R50A-R53A) are shown in table 2.1. Reaction 
mixture was further treated with 10 units of DpnI (New England Biolabs) at 37 °C for 2hrs. 
Then 1 μl of treated reaction mixture was transformed into E. coli DH5α competent cells. The 
presence of the expected mutations was confirmed by DNA sequencing. 
2.2.3 Protein purification 
          This purification procedure is the same for all proteins expressed from genes cloned in 
pGEX vector. Escherichia coli strain Rosetta 2 (DE3) (Novagen) containing the plasmid was 







NS1A mutant Primer sequence 
R38A-5’ CATTTCTTGATCGGCTTCGCGCGGATCAGAAGTCCCTAAG 
R38A-3’ CTTAGGGACTTCTGATCCGCGCGAAGCCGATCAAGAAATG 
























NaCl) containing ampicillin (100 μg/ml) at 37 °C. The cells were then diluted 1:100 in 4 × 0.5 l 
medium and grown to a cell density of approximately 4 × 108 per ml. IPTG was added to final 
1 mM and the cells then grown overnight at 25 °C. Protein was purified according to a 
procedure developed by Sigma Aldrich. Briefly, cells were collected by centrifugation, 
resuspended in 50 ml column buffer (CB: 50 mM HEPES (pH 7.5), 50 mM NaCl) and 
disrupted in a French pressure cell. Cellular debris was pelleted by centrifugation at 5,000g for 
60 min at 4 °C. The supernatant was applied to a column containing glutathione agarose beads 
(3 ml bed volume, equilibrated with CB), and washed with 100 ml of CB, then eluted with 10 
ml elution buffer (EB: 10mM reduced glutathione, 50 mM Tris, pH 8.0). Fractions containing 
the GST fusion protein were pooled together and dialyzed against FP binding buffer (50 mM 
Tris (pH 8.0), 50 mM KCl, 1 mM DTT, 0.02% NaN3). The protein was concentrated by using 
an Amicon bioseparator fitted with a 25 mm YM-3 membrane and applying 60–70 lb/in2 N2 
for 7–10 h at 4 °C.  
          This purification procedure is the same for all proteins expressed from genes cloned into 
the pET28b vector. Escherichia coli strain Rosetta 2 (DE3) (Novagen) containing the plasmid 
was grown overnight in broth medium (1% (w/v) tryptone, 0.5% (w/v) yeast extract, 0.5% 
(w/v) NaCl) containing ampicillin (100 μg/ml) and chloramphenicol (34 μg/ml) at 37 °C. The 
cells were then diluted 1:100 in 2 l medium and grown to a cell density of approximately 4×108 
per ml. IPTG was added to 1 mM and the cells then grown overnight at 25 °C. Protein was 
purified essentially according to a procedure developed by Novagen. Briefly, cells were 
collected by centrifugation, resuspended in 25 ml column buffer (CB: 50 mM Hepes, pH 8.0, 
300 mM NaCl, 20 mM Imidazole) and disrupted in a French pressure cell. Cellular debris was 
pelleted by centrifugation at 5000 xg for 60 min at 4 °C. The supernatant was applied to a 
column containing Ni-NTA His binding beads (2 ml bed volume, equilibrated with CB), and 
washed with 100 ml of CB, then eluted with 10 ml elution buffer (EB: 50 mM Hepes, pH 8.0, 
300 mM NaCl, 250 mM Imidazole). The C-terminal His tag were removed by digestion with 
TEV protease (50 Unit) overnight at room temperature. The sample then underwent size-
exclusion chromatography with a 50 mM Tris (pH 8.0), 300 mM KCl, 1 mM DTT, 0.02% 
NaN3 buffer. Fractions containing the target protein were pooled together and dialyzed against 
FP binding buffer (50 mM Tris (pH 8.0), 50 mM KCl, 1 mM DTT, 0.02% NaN3). The protein 
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was concentrated to 1–2 ml using an Amicon bioseparator fitted with a 45 mm YM-3 
membrane and applying 60–70 lb/in2 N2 at 4 °C. 
2.2.4 Fluorescence polarization (FP) assay 
          All fluorescence measurements were made using an Envision (Perkin Elmer Inc) 
spectrofluorometer. The two 16 mer RNA oligonucleotides with sequence CCAUCCUCUA 
CAGGCG (sense) and CGCCUGUAGAGGAUGG (antisense) were (5′-fluorescein) labeled. 
Approximate 1:1 molar ratios of sense RNA and antisense RNA were mixed in 50 mM Tris 
(pH 8.0), 100 mM NaCl buffer. The mixed solutions were heated to 90 °C for 2 min and then 
slowly cooled to room temperature to anneal the duplexes. Samples were excited at 490 nm, 
and emitted light was collected through an orange glass filter (OG 515, Schott). The binding 
affinity for the NS1 and double stranded (ds)RNA complexes were determined by measurement 
of the steady-state anisotropy of fluorescence as a function of added protein. The concentration 
of dye labeled dsRNA was 5 nM. The binding buffer contains 50 mM Tris (pH 8.0), 50 mM 
KCl, 1 mM DTT, 0.02% NaN3. The concentration of protein was plotted against anisotropy of 
fluorescence and fit to a hyperbola equation to get the dissociation constants. The nonlinear 
regression analysis was performed in the program GraFit 5.0 (Erithacus Software). 
2.2.5 Unlabelled dsRNA competition assay 
          The FP assay was performed with 5 nM fluorescein labeled dsRNA, 300 nM GST-
NS1A(1-215) and different concentrations of unlabeled dsRNA (ranging from 0 nM to 400 
nM).  
2.2.6 Effect of DMSO, tRNA, BSA coating 
          The FP assay was performed with 5 nM fluorescein labeled dsRNA, 300 nM GST-
NS1A(1-215), and in the presence/absence of 1% DMSO, 50 ng/μl tRNA, and 2% BSA coating 
respectively.  
2.2.7 Z’ factor calculation for high throughput assay 
          For a 384 well plate, the first 12 columns are loaded with a 300 μM protein and 5 nM 
dsRNA mix, and the last 12 columns are loaded with dsRNA only. FP measurements were 
made, and the Z’ factor calculated according to this equation: Z’ = 1-(3*SDf+3*SDb)/(Ub-Uf). 
Here, SD stands for the standard deviation of the free (SDf) and bound (SDb) samples 
respectively. U stands for average value of the free (Ub) and bound (Uf) samples respectively. 
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2.3  Results  
2.3.1 FP results for binding to various NS1A constructs  
          Figure 2.1 shows the results of the FP assay for binding a 5’-fluorescein labeled dsRNA 
to various NS1A constructs, including NS1A(1-73), N-terminal GST fusion NS1A(1-215), and 
C-terminal His-tagged NS1A(1-215). All FP values were expressed in millipolarization (mP) 
units, and plotted against protein concentration (μM). As expected from previous studies, the 
R38A mutant of both NS1A(1-73) and GST fusion NS1A(1-215) did not cause any change in 
the FP signal of the dye labeled dsRNA. That is, the mutant protein failed to bind dsRNA. 
          Table 2.2 summarizes the binding affinities of dsRNA to the three NS1A constructs, at 
two pH values. The N-terminal GST fusion NS1A(1-215) protein show the tightest binding 
with a Kd around 0.16 μM. While the C-terminal His-tagged NS1A(1-215) and the NS1A(1-73) 
bind to dsRNA almost 100 fold more weakly than the GST fusion protein. By lowering the pH 
from 8.0 to 6.0, the NS1A(1-73) could achieve the same bind affinity toward dsRNA as the 
GST fusion protein. The GST fusion protein also leads the best yield of expression from E. coli. 
The yield of NS1A(1-73) peptide was not as high and required more purification steps, in 
addition to removing the C-terminal his tag. The yield of the C-terminal His-tagged NS1A(1-
215) was very low because most of protein was found in the insoluble fraction, and presumably 
denatured.   Finally, in establishing our FP assay, we showed that the 5’-fluorescein labeled 
dsRNA bound to the GST-NS1A(1-215) could be successfully displaced by unlabelled dsRNA, 
as shown in figure 2.2; this showed that in principle at least, the construct could reveal the 
binding of ligands that compete with dsRNA. Overall, the GST-NS1A(1-215) construct was the 






















Figure 2.1: FP signal of 5’-fluorescein labeled dsRNA binding to the (a) NS1A(1-73), (b) GST-
NS1A(1-215), (c) NS1A(1-215). The wild type is shown as open circle and the corresponding 










Kd (μM) 0.16 13 14 0.2 
Yield ++ -- + + 













Figure 2.2: Competitive assay between labeled (5nM) and unlabeled dsRNA with GST-
NS1A(1-215) (300nM). 
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2.3.2 FP results of various NS1B constructs (including wild type and mutants) 
       Figure 2.3 showed the results of FP assays for binding a 5’-fluorescein labeled dsRNA to 
various N-terminal GST fusion NS1B constructs, including GST-NS1B(1-104), GST-NS1B(1-
145) and GST-NS1B(1-218). All FP values were expressed in millipolarization (mP) units, and 
plotted against protein concentration (μM). As expected, both the R50A mutant of GST-
NS1B(1-104) and the double mutant R50A-R53A of GST-NS1B(1-145) failed to cause any 
change in FP signal, that is did not bind the oligonucleotide. Table 2.3 summarizes the binding 
affinities of dsRNA to all three NS1B constructs. The N-terminal GST fusion NS1B(1-145) 
protein showed the tightest binding with a Kd around 0.05μM. While the GST-NS1B(1-104) 
not only bind dsRNA around 30 fold weaker, but also showed much weaker FP signal than the 
GST-NS1B(1-145). As shown in figure 2.3 panel a, the maximum change of mP unit is too 
small to constitute a significant positive signal. Although GST-NS1B(1-218) showed similar 
binding affinity toward dsRNA as that of GST-NS1B(1-145), the yield of that protein was 
extremely low. In addition, the impurity of GST-NS1B(1-218) made it hard to accurately 
quantify the amount of the protein used in the assay. Overall, the GST-NS1B(1-145) construct 
was the best candidate for FP assay against NS1B. 
2.3.3 The effect of additives on the FP assay (including DMSO, tRNA and BSA) 
          All the compounds in our library collections are dissolved in 100% DMSO to a final 
concentration of ~10mM.  As a consequence, DMSO will be transferred to all inhibitors assays.  
The effect of DMSO concentration on fluorescence polarization assay was tested. As shown in 
Figure 2.4, up to 1% of DMSO is tolerated by the fluorescence polarization assay. Above 1%, a 
significant decrease of polarization was observed, probably due to the denaturation of the 
double stranded RNA. This means that compounds from the libraries must be diluted at least 
100 fold, producing a maximum assay concentration of ~100 μM. As shown in figure 2.5 panel 
a, the titration curves of FP signal vs. protein concentration in the presence and absence of 1% 
DMSO can almost overlap with each other.  
 In a common protein dsRNA binding assay, 50 ng/μl tRNA was used to prevent non-
specific binding of dsRNA to protein (Chien, 2004). Our FP assay showed that there was no 
strong impact of tRNA on the assay, see figure 2.5 panel b. There is also a concern that the 
protein-dsRNA complex may stick to the surface of the well, which may give a false positive 















Figure 2.3: FP signal of 5’-fluorescein labeled dsRNA binding to the (a) GST-NS1B(1-104), 
(b) GST-NS1B(1-145), (c) NS1B(1-218). The wild type is shown as open circle and the 




 GST-NS1B(1-104) GST-NS1B(1-145) GST-NS1B(1-218) 
Kd (μM) 1.4 0.05 0.18 
Yield + ++ -- 
 










Figure 2.4: Effect of DMSO concentration on FP signal of (a) dsRNA and (b) complex of 
















Figure 2.5: FP signal of 5’-fluorescein labeled dsRNA binding to the GST-NS1A(1-215) in the 
presence and absence of (a) 1%DMSO, (b) 50ng/μl tRNA, and (c) 2%BSA coating. The open 
circles represent the FP signal in the presence of corresponding additives, and the filled circles 













adding the binding solution mix;  the FP assay results showed that the change of binding 
constants with or without BSA coating were negligible, see figure 2.5 panel c.  
2.3.4 Z’ factor for the high throughput FP assay 
          Before an experimental screening is carried out it is essential to quantify the robustness 
of the assay.  For this purpose the Z’ factor of this high throughput assay was calculated. The Z' 
factor is computed from experimental observations, via the expression Z=1-
(3*SDf+3*SDb)/(Ub-Uf).  Basically, Z’ factor is a measure of the quality of a high-throughput 
screening (HTS) assay (Arai 2001). An assay can be considered validated for high throughput 
screening after three independent experiments have been shown to result in reproducible and 
suitable Z’ factor values. If the Z’ factor is above 0.9, it means the assay is an excellent one. If 
it is between 0.7 and 0.9, then it is a good one. If Z’ factor is below 0.5, that means the assay is 
not a working one at all. The Z’ factors of our assay from three independent experiments are 
0.87, 0.88 and 0.85 respectively. Therefore, the average Z’ factor for our assay is 0.87, which 
means our high throughput assay is a good one. 
2.4 Discussion 
          Fluorescence polarization (FP) assays are among the most widely used high throughput 
screening methods for drug discovery (Roehrl, Wang et al. 2004; Roehrl, Wang et al. 2004; 
Rishi, Potter et al. 2005). It is compatible with the requirements of high throughput assay, 
which includes: (1) minimal experiment steps; (2) stable and homogeneous experiment 
reagents; (3) highly sensitive and rapid readout; (4) amenable to automation (Roehrl, Wang et 
al. 2004; Zhang, Huang et al. 2006). Here we used FP assay to determine the binding affinity of 
fluorescein-labeled dsRNA to different NS1A /NS1B constructs. Usually, the concentrations of 
the fluorophore and its binding partner are the major factor determining the interference of the 
potential inhibitors. A high concentration of fluorescein-labeled dsRNA and NS1 complex 
would result in reduced sensitivity for weak inhibitors. To maximize the effective concentration 
of potential inhibitors, we were looking for the NS1 construct that allowed us to use a low 
protein concentration. In other words, we chose the NS1 construct with the highest binding 
affinity to dsRNA. 
          Our FP assay showed that the N-terminal GST fusion NS1A(1-215) is the best choice 
among all the NS1A constructs. There is a serious aggregation problem for C-terminal His-
tagged NS1A(1-215) protein during preparation, which makes it impossible for large scale 
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purification. The RNA binding domain of NS1A, NS1A(1-73), binds to dsRNA almost 100 
fold weaker than does the GST-NS1A(1-215) fusion construct. Decreasing the pH of the buffer 
from 8.0 to 6.0 could achieve the same binding for the NS1A(1-73) toward dsRNA as that of 
the GST fusion protein. However,  fluorescein is strongly quenched at pH 6, reducing its utility 
as a probe. As shown in Figure 2.6, the intensity of fluorescence dropped by three fold when 
pH is 6.0, which means that we would have to use three fold more of reagents at pH6.0 to 
achieve the same amount of signal intensity at pH8.0. It’s unclear why the GST-NS1A(1-215) 
binds dsRNA much tighter than NS1A(1-73). Since the R38A mutant of GST-NS1A(1-215) 
didn’t bind dsRNA at all, the N-terminal GST domain is obviously not directly involved in the 
interaction with dsRNA. It is known that GST behaves as a dimer in solution. It’s very likely 
that the N-terminal GST protein facilitates the dimer formation of NS1A(1-215). That could 
explain why the GST fusion protein has the highest binding affinity toward dsRNA. The GST-
NS1B(1-145) showed the tightest binding affinity toward dsRNA with a Kd around 0.05μM. 
The other two GST fusion NS1B proteins were excluded mainly because of the poor purity and 
low yield.  
          The FP assay conditions were optimized with different additive chemicals, including 
DMSO, tRNA and BSA. DMSO is frequently used as a solvent for commercial chemical 
compound library due to its excellent solvating power. To maximize the effective concentration 
of potential inhibitors, we were looking for the highest DMSO concentration that our assay 
could tolerate. It turned out that up to 1% DMSO can be tolerated in our assay. Other potential 
assay complications, like non specific RNA binding, were assessed using tRNA addition and 
BSA coating. We established a useful assay with an excellent Z’ factor of 0.87. In summary, 
















Figure 2.6: Comparison of pH-dependent fluorescence of the Oregon Green 488 ( ), 
carboxyfluorescein ( ) and Alexa Fluor 488 ( ) fluorophores. Fluorescence intensities were 
measured for equal concentrations of the three dyes using excitation/emission at 490/520 nm. 










Chapter 3: High Throughput Screening (HTS) of Compound 




          The high throughput fluorescence polarization assay is typically designed as competitive 
equilibrium binding assay.  It usually detects changes in polarization caused by changes in the 
effective mass of the fluorescently labeled molecule.   As molecular mass increases, as when 
the labeled molecule binds to a target protein, polarization decreases.  When a small ligand 
competes successfully with the fluorescently labeled molecule, the dye is displaced, tumbles 
more quickly, and polarization increases. Here, a high throughput FP assay was developed to 
screen small compound libraries against dsRNA binding by the NTD domain of NS1 protein. 
Fluorescein-labeled dsRNA is pre-incubated with the N-terminal GST fusion to NS1A (residue 
1-215) protein. Then the decrease of fluorescence polarization indicated the displacement of 
dsRNA by potential inhibitors. Our goal was to find a small molecule that can bind to NS1A in 
such a way that it precludes RNA binding. The compound libraries chosen to be screened are: 
ChemBridge fragment library (4000 compounds), ChemBridge kinase library (11250 
compounds), NIH clinical trial collection (446 compounds), and Microsource Discovery 
spectrum collection (2000 compounds).  
3.2 Materials and methods 
3.2.1 Protein purification 
          The GST fusion protein NS1A(1-215) and NS1B(1-145) were expressed and purified 
according to the method described in chapter 2.  
3.2.2 Fluorescence polarization and high-throughput screening 
          High-throughput FP assays were performed on an Envision spectrofluorometer (Perkin 
Elmer) using an excitation filter of 490 nm, and an emission filter of 540 nm. The blank 
correction and fluorescence gain were calibrated. Assays were conducted in 384-ShallowWell 
black polystyrene plates (Nunc). The “blueprint” of an assay plate is shown in figure 3.1. The 
FP assay was performed with 5 nM fluorescein labeled dsRNA, 300 nM GST-NS1A(1-215) in 








Figure 3.1: Blueprint of assay plate. The dsRNA and protein mixtures were loaded in the first 
two columns to serve as positive controls (marked in red frame). The dsRNA alone was loaded 
in the last two columns to serve as negative control (marked in black frame). The compounds 
were transferred into the dsRNA protein mixture in the middle section (column 3 to 22; marked 













handling automatic working station, a Janaus robot (Perkin Elmer), was used to aliquot 20 μl 
protein-dsRNA mixtures into each well, and to transfer 0.1 μl of test compounds from their 
storage plates  into the 20 μl mixture. The final inhibitor concentration was a nominal 50 μM, 
and the final concentration of DMSO will be 0.5%. It must be noted however, that the solubility 
of the compounds in the new aqueous environment is unknown and it is likely that most 
compounds are actually present at concentrations below the nominal value.  Data analysis and 
data mining were performed using software developed by Collaborative Drug Discovery Inc. 
For secondary confirmation, FP assays were performed with cherry-picked compounds at two 
different concentrations (10 μM and 50 μM). 
3.2.3 Dose response assay for “hit” compounds 
          A compound giving a decrease in FP in a HT assay is a possible ligand or “hit”.  Hit 
compounds were subsequently tested in a dose response assay; they were diluted serially in 
binding buffer (50 mM Tris (pH 8.0), 50 ng/μl tRNA, 50 mM KCl, 1 mM DTT, 0.02% NaN3), 
at a final concentration of DMSO of 0.5%. Like in the HTS assay, the concentration of 
fluorescein labeled dsRNA was 5 nM, and the concentration of protein (NS1A/NS1B) was 300 
nM. We control for positional variation during HTS and dose response assay to minimize 
positional artifacts such as edge effects. 
          A concern is that many compounds in the libraries contain aromatic rings which might 
intercalate into dsRNA and give a false positive reading in this fashion.  Hit compounds were 
also tested for their ability to intercalate by competing them against ethidium bromide, a well 
known intercalator, according to the method described by Boger (Boger, Fink et al. 2001). This 
assay assumes that if the compound binds to DNA/RNA, it will displace prebound ethidium 
bromide that can be measured by a decrease of fluorescence (Boger, Fink et al. 2001; Rishi, 
Potter et al. 2005). One DNA hairpin was prepared by IDT Inc, with sequence: 
TGACGTCAAAAAATGACGTCA. The final concentrations of hairpin and ethidium bromide 
were 2 μM and 1 μM respectively. Test compounds were added to the test plate with same 
concentration gradient as in the dose response assay.  
3.2.4 Compound 4141340-spectrum scan 
          The spectrum scan of compound 4141340 and its derivatives was performed on a 
NanoDrop 2000c instrument (Thermo Fisher).   
3.2.5 Circular dichroism measurements 
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          Circular dichroism spectra were recorded using a Jasco 715 spectropolarimeter, equipped 
with a thermostated cell holder and a NesLab-111 circulating water bath. CD spectra were 
recorded in cells with an optical path length of 0.1cm. Experiments were performed in 25 mM 
NaH2PO4 (pH 6.5), 25 mM NaCl, and 25 mM NaN3 buffer. Three scans were repeated for each 
experimental condition. 
3.2.6 Thermal denaturation experiments 
          Thermal denaturation profiles were obtained by recording the temperature dependence of 
the ellipticity at 227 nm in the range 6–80 °C. The temperature was continuously changed at a 
rate of 0.5 °C/min. Experiments were performed in 25 mM NaH2PO4 (pH 6.5), 25 mM NaCl, 
and 25 mM NaN3 buffer. Tm was determined by locating the maxima/minima of the first 
derivative of the curve describing the melting profile (CD versus T). 
3.3 Results 
3.3.1 High throughput screening results 
          A total of 17,969 compounds from four libraries have been screened against the RBD of 
NS1. From the ChemBridge fragment library, a total 52 hits were identified showing inhibition 
greater than 20% based on millipolarization change and +/- 30% fluorescence intensity change. 
As shown in table 3.1, six compounds among these showed inhibition greater than 50%, 
without any apparent intercalation into dsRNA. Among those six hits from the fragment library, 
only compound 4141340 (ChemBridge library number) and compound 5792605 showed 100% 
inhibition in the initial screen and a robust dose response activity, see Figure 3.5. 
          For the ChemBridge kinase library, a total 40 hits were identified showing inhibition 
greater than 50% based on polarization change and +/- 30% fluorescence intensity change. 
Among the 40 hits, there are six compounds showing inhibition greater than 60% at 
concentration of 50 μM (table 3.2), and one compound, 7869182, showing an IC50 around 0.8 
μM against NS1A, and 0.6 μM against NS1B (Figure 3.2).  
          As shown in table 3.3, seven compounds were identified from the NIH clinical collection 
showing inhibition greater than 40% based on polarization change and +/- 30% fluorescence 
intensity change. The compound SAM001247031 is the only one from those seven hits giving 
an IC50 around 0.29 μM against NS1A, and 0.18 μM against NS1B without disrupting dsRNA.  
          As for the Microsource Discovery spectrum collection, there were eight compounds 















































































































































































































































Figure 3.2: FP signal of dsRNA displacement by compound 7869182. The dose-response 
against GST-NS1A(1-215) is shown in blue, and the dose-response against GST-NS1B(1-145) 
















Figure 3.3: FP signal of dsRNA displacement by compound SAM001247031. The dose-
response against GST-NS1A(1-215) is shown in blue, and the dose-response against GST-
NS1B(1-145) is shown in red. 
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Table 3.4: Structures and inhibitory activities of selected compounds from Microsource 
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Figure 3.4: FP signal of dsRNA displacement against GST-NS1A(1-215) by compound (a) 




 compounds among those showed a significant dose response and did not disrupt dsRNA. They 
are tannic acid, with IC50 0.48 μM against NS1A, and aurin tricarboxylic acid with IC50 0.5 μM 
against NS1A, see Figure 3.4.  
3.3.2 The dose response of compound 4141340 and its derivatives  
          The scientific name of compound 4141340 is 3a,4,5,9b-Tetrahydro-3H-cyclopenta[c] 
quinoline-4-carboxylic acid. Compound 5792605, is 8-Fluoro-3a,4,5,9b-Tetrahydro -3H-
cyclopenta[c] quinoline-4-carboxylic acid; it is a derivative compound of 4141340. Three more 
derivative compounds of 4141340 were found using the program SciFinder Scholar: 8-Benzyl- 
3a,4,5,9b-tetrahydro-3H-cyclopenta[c] quinoline-4-carboxylic acid (4B), 8-Carboxyl-3a,4,5,9b-
tetrahydro-3H-cyclopenta[c] quinoline-4-carboxylic acid (4C) and 8-Methyl-3a,4,5,9b-tetra-
hydro-3H-cyclopenta [c] quinoline-4-carboxylic acid (4M). As shown in table 3.5, those five 
compounds have different functional groups at the position 8 of quinoline. All five compounds 
can displace dsRNA fully at around 20 μM concentration, as shown in the dose-response curves 
(Figure 3.5). The calculated IC50 against NS1A and NS1B were summarized in table3.5. 
Basically, they all gave an IC50 around 10 μM against either NS1A or NS1B.  
          When 4141340 was freshly dissolved in 100% DMSO, it did not show the same color as 
seen in the compound plate when purchased from the vendor. The freshly dissolved 4141340 
showed a light brown color, while the one in the compound plate was green. Interestingly, the 
freshly dissolved 4141340 didn’t show any inhibition effect, nor did any of the four derivatives. 
As shown in Figure 3.6, compound 4141340 and its derivatives changed color from light brown 
to dark green within a week. The dose response experiments shown in the above section were 
carried by using those aged compounds. A full spectrum scan from 220nm to 750nm was 
conducted for the freshly dissolved 4141340 and one-week old 4141340 respectively. A new 
absorbance peak at 624nm showed up in the spectrum profile of aged compound, which 
indicates that the compound might undergo some chemical changes (see Figure 3.7). The same 


























































Table 3.5: Structures and IC50 of compound 4141340 and its four derivatives (4B, 4C, 4F and 















































Figure 3.5: FP signal of dsRNA displacement against (a) GST-NS1A(1-215), (b) GST-NS1B(1-
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Figure 3.6:  The color changing profile of compound 4141340 and its derivatives in six days. 














Figure 3.7: The full spectrum scan of freshly dissolved (blue) and aged (red) compound 










3.3.3 CD spectra and thermal melting profile of NS1A in the presence of SAM001247031 
          The structure of NS1A(1-73) was characterized chiroptically by circular dichroism. A 
quantitative analysis of the experimental CD profile suggests the structure is 68.6% α–helix and 
10.7% random coil. This is in reasonable agreement with the observed X-ray structure of 
NS1A, which is 80% α-helix and 18% random coil. We then assessed the effect of compound 
SAM001247031 on the structure.  As shown in Figure 3.8, SAM001247031 did not induce 
significant change in CD spectra even at concentration of 400 μM.   
          To explore the compound induced structural changes more fully, we carried out thermal 
denaturation experiments on both wild type and the R38A mutant NS1A(1-73) in the presence 
of different concentration of SAM001247031 (Figure 3.9).  Monitoring ellipticity at 227 nm, 
we observed that SAM001247031 appears to stabilize the wild type NS1A(1-73), increasing the 
Tm by 11.05 °C at a concentration of 400 μM, see table 3.6. In contrast, SAM001247031 did 
not alter the Tm of the R38A mutant NS1A(1-73) significantly, only 1.15 °C even at a 
concentration of 400 μM. This huge Tm difference on wild type and R38A mutant proteins 
suggests that SAM001247031 stabilizes the structure of NS1A by interacting with the critical 





























Figure 3.8: Effects of different concentration of compound SAM001247031 on NS1A(1-73) 


















































Figure 3.9: Effects of different concentration of compound SAM001247031 on the 227nm 
thermal melting profile of (a) wild type NS1A(1-73), and (b) NS1A(1-73) R38A mutant. 
 
 
NS1A(1-73) [SAM001247031] (μM) Tm (°C) ΔTm (°C) 
Wild type 0 38.72 - 
Wild type 100 41.16 + 2.44 
Wild type 200 44.58 + 5.86 
Wild type 400 49.77 + 11.05 
R38A 0 41.05 -  
R38A 400 42.62 + 1.15 
 
Table 3.6: The shift of Tm of the thermal melting profile of wild type and R38A mutant 






          A total of 17,969 single chemicals from four compound libraries (ChemBridge fragment 
library, ChemBridge kinase library, NIH clinical collection and MicroSource Discovery 
spectrum collection) were screened using the optimized FP-based high throughput screening 
assay. To minimize false positives due to compound-induced fluorescence enhancement or 
quenching, hits that had greater than a +/- 30% change in total fluorescence compared with 
controls were removed from consideration. After the primary and secondary screening, 27 
compounds were identified showing greater than 40% dsRNA displacement, without disrupting 
dsRNA. Among them, 6 true hits were identified with dose-response activity and average IC50 
values less than 10 μM. They are: compounds 4141340 and 5792605 from fragment library, 
compound 7869182 from kinase library, tannic acid and aurin tricarboxylic acid from the 
spectrum collection, and compound SAM001247031 from the clinical collection. The overall 
hit rate is around 0.03%.  
          The compounds 4141340 and 5792605 are related by a different functional group at the 
position 8 of quinoline. The full name of 4141340 is 3a,4,5,9b-Tetrahydro-3H-cyclopenta[c] 
quinoline-4-carboxylic acid. The same compound was also identified as a potent inhibitor of a 
family of human MAPK-specific protein tyrosine phosphatases using a high throughput 
screening (Eswaran, von Kries et al. 2006). Three other derivative compounds of 4141340 
found through SciFinder Scholar show similar IC50 against NS1A and NS1B. That indicates the 
carboxyl group in this inhibitor class may interact in a similar way with the active-site residues 
of NS1, probably arginines or lysines. An unsettling aspect of this inhibitor class is that only 
the aged compounds have inhibitory effects; the freshly dissolved ones can not displace 
dsRNA. We did notice a color change and additional absorbance peak at 624nm in the aged 
compounds. However, the color change could be misleading in that only a tiny fraction of 
colored chemicals could easily change the appearance of compound. As shown in Figure 3.10, 
a very distinctive 1H NMR spectra of freshly dissolved and aged compound 4141340 strongly 
suggests that some chemical changes happened when the compound aged. Unfortunately, we 
were unable to identify the transformed structure. We tried soaking the aged 4141340 into 
NS1(1-73) crystals, as well as cocrystallization with NS1(1-73). Even though the crystal turned 











          Figure 3.11 shows the docking mode of compound 4141340 in NS1-RBD by the program 
ICM. It shows good shape complenentarity with the NS1 dimer interface. The docking model 
predicts a binding mode with hydrogen bonds from between the carboxylic acid group of 
4141340 and side chains of Arg19, Arg35 from each monomer. The predicted binding mode of 
5792605 can almost superimpose to that of 4141340 with the fluorine at the position 8 of 
quinoline pointing toward the solvent. From our FP assay results, the substitution at position 8 
on the quioline ring to larger moiety (such as benzyl or carboxyl) did not affect the IC50 of the 
compound. The presentation of this position 8 group toward solvent in the docking model may 
rationalize this observation. Because of the aging effect of compound 4141340 series, we do 
not know the actual composition of compound that displaced the dsRNA binding.  In this 
regard, a recent paper reported  an incorrect structure of a registered compound in the 
ChemBridge compound library (Inglese, Shamu et al. 2007). The compound “Mirin” was 
identified from a chemical screening of 10,000 compounds from ChemBridge by Eastman’s 
laboratory. It turned out the structure of “Mirin” provided by ChemBridge is not the real 
structure of the compound in the screening plate. In other words, the compound in the screening 
plate is not exactly what the vendor claims, and this makes us wonder about the true identity of 
compound 4141340.  
          The compound 7869182 was identified as a hit from the ChemBridge kinase library; it 
had an IC50 around 0.8 μM against NS1A, and 0.6 μM against NS1B. The scientific name of 
compound is 2,3-di-2-furyl-N-(2-furylmethyl)-6-quinoxalinecarboxamide. The same compound 
was also identified as an inhibitor of tau fibrillization with an IC50 in the low micro molar range 
(l–3 μM) (Crowe, Ballatore et al. 2007). As shown in table 3.7, five derivates of compound 
7869182 were found through a search using SciFinder Scholar. We were surprised to find that 
only the derivative D4 showed slight inhibition at a nominal concentration of 50 μM, since all 
five derivatives share the same 2,3-di(furan-2yl)-quinoxalines scaffold. This phenomenon may 
suggest a possible structure–activity relationship. Figure 3.12 shows the docking mode of 
compound 7829182 and its derivative D4 in NS1-RBD by ICM. Because of the structure 
similarity, all derivatives have very similar docking poses to that of 7829182. It is very hard to 
rationalize the differences in inhibition effect from the predicted docking modes. In addition, 
the docking scores of 7829182 and its derivatives were very poor (>0), considering a value of -
35 is the default threshold value set by ICM for strong binding. An X-ray structure of NS1 with  
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Figure 3.11: The docking model of (a) 4141340; (b) 4141340 and 5792605 in NS1-RBD by 
ICM. The residues of different monomer were labeled in red and black respectively. The 
















































































Figure 3.12: The docking model of 7829182 and its derivative D4 in NS1-RBD by ICM. 










7829182 would help to reveal the actual interaction between the two molecules. A cell based 
plaque reduction assay was carried on by Dr.Krug’s laboratory; compound 7829182 did not 
affect virus replication. 
          One common name for the compound SAM001247031, identified from the NIH clinical 
collection, is epigallocatechin gallate (EGCG). It is one of the most abundant polyphenolic 
antioxidant metabolites in green tea, and has been extensively studied for its antiviral, cancer 
preventive activities (Brown 1999; Chen, Daniel et al. 2004; Chen and Zhang 2007; Wolfram 
2007). EGCG had an IC50 around 0.29 μM against NS1A, and 0.18 μM against NS1B, without 
disrupting dsRNA. More importantly, the thermal melting profile of EGCE with wild type and 
R38A mutant NS1A(1-73) suggested that EGCG stabilizes the structure of NS1A by interacting 
with the critical residue Arg38. Exhaustive soaking and co-crystallization of EGCG with 
NS1A(1-73) have been tried, but were unsuccessful. Figure 3.13 show the predicted docking 
mode of EGCG in NS1-RBD by the program Surflex. It shows good shape complenentarity 
with the NS1 dimer interface. The docking model predicts a binding mode with hydrogen 
bonds from between the hydroxyl groups of 3-galloyl group of EGCG and side chains of 
Asp12, Ser42 and Arg45; hydroxyl groups of catechin skeleton and side chain of Arg19 and 
Arg45. Modeling results suggest that EGCG binding to the NS1-RBD is plausible, so we are 
unsure why complexes have not formed. The reason may be the interaction between the two is 
very dynamic, or the concentration of EGCG in the crystalline environment is not high enough 
to populate the site. That is, the micro environment for a successful crystal may not always be 
consistent with ligand binding.  
          A cell based plaque reduction assay was carried on by Dr. Krug’s laboratory; it showed 
that EGCG can reduce influenza viral replication by 30%. The same anti-influenza viral 
activity of EGCG has been observed against three major types of human influenza viruses, 
including H3N2, H2N2 and H9N2 by Seong’s lab in 2007 (Song, Park et al. 2007). Those 
authors evaluated EGCG and three derivative compounds regarding their ability to inhibit 
influenza virus replication in cell culture, see figure 3.14. They found that the 3-galloyl group 
of catechin skeleton plays an important role on the observed antiviral activity, whereas the 5’ 
hydroxyl group at the trihydroxy benzyl moiety at 2-position plays a minor role (Song, Lee et al. 
2005; Song, Park et al. 2007). It is very interesting to see that our docking model is  
 consistent with Seong’ observations. (1): The 2-trihydroxyl benzyl group did not interact with 
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Figure 3.13: The docking model of (a) EGCG in NS1-RBD, (b) the predicted interaction of 






(a).                                                                     (b). 
          
(c).                                                                     (d). 
              
Figure 3.14: The chemical structures of (a) epigallocatechin gallate (EGCG), (b) epicatechin 









NS1 directly in the predicted binding mode. Besides, the docking pose of ECG was nearly 
identical to that of EGCG. This may explain why EGCG and ECG have similar inhibition 
effects on virus replication. (2):  The docking model predicts four hydrogen pairs formed 
between the 3-galloyl group of catechin skeleton and NS1-RBD. The binding affinity would 
significantly decrease without the entire 3-galloyl group. That could explain why EGC and EC 
only have slight inhibitory effects in plaque inhibition assay.  
          We can not rule out the possibility that EGCG may interact with some proteins other than 
NS1 to cause this anti-influenza viral activity, since EGCG has been reported to interact with 
many proteins (Ichikawa, Matsui et al. 2004; Wolfram 2007; Kim 2008; Shin, Park et al. 2008). 
Our results strongly suggest that the anti-influenza viral activity of EGCG is at least partially 
due to the fact that EGCG interacts with the RBD of NS1 in a way that precludes RNA binding. 
          Tannic acid and aurin tricarboxylic acid were identified from spectrum collection 
showing IC50 values of 0.48 μM and 0.5 μM respectively. Both tannic acid and aurin 
tricarboxylic acid have been well studied. Tannic acid is a polyphenol found in the bark of 
redwood, and functions as a natural defense against infestation, wild fire and decomposition. It 
is known to exert an anti-cancer activity, and recently reported to be a potent inhibitor of 
epidermal growth factor receptor tyrosine kinase (Marienfeld, Tadlock et al. 2003; Yang, Wei 
et al. 2006). Because of the bulky structure (10 benzyl rings) and massive mass (1.7Kd), Tannic 
acid does not seem to interact with NS1 specifically. It is more likely that tannic acid non-
specifically coats the protein surface in a way that precludes the dsRNA binding. Therefore, 
tannic acid is not a good candidate for further drug development.  
          Aurin tricarboxylic acid (ATA) is a general endonuclease inhibitor which inhibits protein 
biosynthesis at the initial stages. It is also known as a platelet adhesion inhibitor and an anti-
AIDS compound (Gan, Weaver et al. 1990; Kim, Kim et al. 2008). Interestingly, ATA has been 
recently discovered to be an inhibitor of influenza virus neuraminidase (Hung, Tseng et al. 
2009). The authors found that ATA reduced the influenza viral yield by more than 1000 fold. 
Because the neuraminidase inhibition assay in Hung’s paper was a cell-based assay, itis 
possible that the displacement of RNA to NS1 by ATA may also contribute to the inhibition 
effect of ATA on influenza virus replication. Figure 3.15a shows the docking mode of ATA in 
NS1-RBD by ICM. It shows good shape complenentarity with the NS1 dimer interface. The 
three-ring structure of ATA somehow resembles that of EGCG; they even share similar  
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Figure 3.15: The docking model of (a) ATA, (b) ATA (red) and EGCG (blue) in NS1-RBD by 
ICM.  
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docking modes predicted by ICM (figure 3.15b). That could explain why the two compounds 
have close IC50(s) against NS1-RBD. Although ATA has three carboxylic groups on each of 
benzyl rings, it has very poor solubility in aqueous solution. This could be the reason we failed 
to get a complex structure either by soaking or co-crystallization. 
          In summary, we have identified six true ligand hits for the RBD of NS1, with reasonable 
dose-response activity, and without disrupting dsRNA itself. Four of these show an average 
IC50 less than 1 μM. In addition, one compound, EGCG, has been shown to reduce influenza 
virus replication in a biological assay, presumably by interacting with the RNA binding domain 




























          Virtual screening, also called docking, is a computational technique widely used in the 
field of structure-based drug discovery. It uses high performance computing programs to 
analyze large databases of chemical compounds in order to identify possible drug candidates. 
Basically, virtual screening places a ligand into the binding site of a receptor in a manner that is 
appropriate for optimal interactions with the receptor. The compounds that are virtually 
screened, or docked, may be commercially available or may be simply model compounds. 
Virtual screening in fact does not replace experimental research, and to be useful, the selected 
compounds from virtual screening need to be validated by real experiments. The goal is to 
identify some active compounds with non-promiscuous-binding behavior, and then refine them 
into a series of structures with relevant biological and drug-like activity, known as leads which 
will be served as drug design platform.  
          Research in Dr.Krug’s laboratory showed that the inhibition of dsRNA binding to NS1A 
inhibits viral replication (Min and Krug 2006).  Our goal was to find a molecule that can bind 
to NS1A RBD in such a way that it precludes dsRNA binding. The x-ray structure of NS1 RBD 
reveals a small, nonpolar pocket within the NS1 RNA binding channel; this pocket sits on the 
NS1 molecular two-fold axis. The bottom of this small pocket is largely defined by the side 
chains of symmetrically related Leu 15 residues.  Preliminary docking of 30 aromatic 
compounds against the entire surface of the NS1A73 dimer by the program eHiTs, showed that 
most of the compounds fall into that deep hydrophobic pocket.  One of the top scoring 
compounds, fluorene, lies in the center of the pocket as shown in Figure 4.1. Interestingly, no 
other cavity on the dimer surface was found to bind those compounds.  In addition, docking 
with 2000 compounds from the Sigma Aldrich compound library revealed that of the top 5% of 
compounds, the vast majority docked into the hydrophobic pocket. Some top ranked 
compounds display symmetric, or pseudo symmetric, properties.  Their molecular centers 
aligned near the 2-fold of the NS1A dimer. These results establish that this hydrophobic pocket 









Figure 4.1: Predicted orientation of fluorene to the NS1A dimer. The NS1 dimer is represented 
as a surface on this stereogram.  Each monomer has a distinct color, and the tricyclic fluorene is 















          From previous docking experience, different docking programs show different 
performance on different proteins (Kellenberger, Rodrigo et al. 2004; McInnes 2007; Hawkins, 
Warren et al. 2008). Currently, there is a wide range of docking soft ware available for 
screening virtual compound libraries f. In order to choose the best docking program(s) suitable 
for virtual screening of NS1A inhibitors, we will compare the known binding affinity of 
compounds from the physical high throughput FP screening with the ranking given by the 
virtual screening from four docking programs: eHiTs, GOLD, ICM and Surflex. The program 
giving the best correlation between computed ranking score and experimental ligand binding 
affinity was to be used for larger library virtual screenings, such as the ChemBridge Diversity 
set which contains around 50,000 compounds. Highest-scoring compounds could be validated 
by FP assay and put into an inhibitor design pipeline.  
4.2 Materials and methods 
4.2.1 Compound database 
          Five databases from the five different vendors are available in our data base.  These 
include: ChemBridge (Fragment library, 3963 compounds), National Institutes of Health 
(Clinical collection, 446 compounds), Maybridge (Diversity library, 53038 compounds), 
Sigma-Aldrich (Diversity library, 49020 compounds), and MicroSource Discovery Inc 
(Spectrum collection, 2000 compounds) totaling 106667 potentially available compounds.  
Most of the libraries were downloaded from corresponding vendor web sites as 2D SDF 
representations. The 2D SDF format files were converted to 3D SDF format by the program 
Internal Coordinate Mechanics (ICM). For convenience of docking results analysis, the 
compound name/ID was copied to first line of each compound SDF file by an in-house Perl 
script. Open Babel was used for manipulating the various chemical formats of ligands. PyMol 
from DeLano Scientific was used for visual inspection of results and graphical presentations.  
4.2.2 Receptor X-ray structure 
          The 3D coordinate of the crystal structure of N-terminal domain of NS1 is available as 
PDB code: 1AIL. The symmetric related molecule was generated by using the molecular 
graphics program O. The dimer molecule was used as receptor model in virtual screening 
programs. All water molecules were removed. 
4.2.3 Computer workstation 
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          Virtual screening was carried out on TI3D Drug Discovery Cluster. The cluster contains 
16 HP Proliant BL35P blade servers, each with 2 dual core AMD Opteron 2.4 GHz processors 
for a total of 64 processors.  Each blade contains 8 GB of memory and a 6 GB ATA hard disk 
drive.  The front-end of the cluster is an HP xw9300 Workstation, equipped with a dual core 
AMD Opteron 2.4 GHz processor, an NVIDIA Quadro FX4500 graphics card, 4 GB memory, 
and two 500 GB SATA hard drives.  Also attached to the cluster is an HP Proliant DL380 G4 
storage server with an Intel Xeon Processor (3.4 GHz) which supports a RAID5 network 
attached storage system with five 500 GB SATA disk drives.  
4.2.4 Docking with eHiTs  
          eHiTs automatically evaluates all of the possible protonation states for ligands and 
enzymes, therefore no special preparation of the NS1 RBD dimer was carried out (Zsoldos, 
Reid et al. 2006; Eitner, Gaweda et al. 2007; Zsoldos, Reid et al. 2007). Initially, docking 
proceed with 30 ring structures (our in house drug platforms) against the entire surface of 
NS1A73 dimer without defining a particular active site using the ‘receptor’ and ‘ligand’ 
parameter. Five percent of the best scoring compounds from the first run were then re-docked 
with a higher accuracy setting (set to 6) and scored with eHiTS_Score, which is included in the 
eHiTS software package.  The eHiTS score mimics the free energy of binding and so the more 
negative scores reflect better predicted binding. 
4.2.5 Docking with GOLD 
          GOLD uses a genetic algorithm to explore the possible binding modes for protein-ligand 
docking (Verdonk, Chessari et al. 2005; Olsen, Jost et al. 2006; Thomas, McInnes et al. 2006). 
The receptor was prepared with all hydrogens added by using Openbabel. The active site was 
centered around the dyadic pocket near the Leu15 on both monomers. The default setting was 
used; therefore, 10 dockings were performed for each compound with a total of 10000 genetic 
algorithm operations. Each docking is followed by Simplex minimization in which ligand 
orientations are refined to the nearest local optimum. Here ‘Goldscore’ is used as main scoring 
function to rank the affinity of the ligand for the receptor. GOLD is optimized for parallel 
execution on processor networks.  The GOLD score is adjusted to a positive value, so higher 




4.2.6 Docking with ICM 
          ICM employs a Monte-Carlo Minimization algorithm to find the optimal binding modes 
of a ligand in the active site represented by a pre-calculated potential grid (Abagyan, Totrov et 
al. 1994; Borchert, Kishan et al. 1995; Totrov and Abagyan 1996). The coordinates of NS1 
RBD dimer were converted to ICM objects with hydrogen atoms added. Then the receptor was 
optimized using Monte Carlo simulation and energy optimizations. A binding site was defined 
and a grid map (5 Å) that included the active site amino acids was generated. The compound 
database was converted into an indexed ICM object for batch docking. Like eHiTS, the ICM 
score mimics the free energy of binding and so the more negative scores reflect better predicted 
binding.; the authors suggest -35 as a cut off for a good ligand.  
4.2.7 Docking with Surflex 
          Surflex is a new implementation of the Hammerhead methodology described by Jain 
(Jain 2003; Jain 2004; Krishnan, Caligaris et al. 2004).The active site of NS1 RBD domain was 
defined by generating a protomol, a pseudo binding site, using the ‘proto’ parameter. The 
definition of the protomol is a tricky step, as parameter ‘proto_bloat’ defines how far from a 
potential ligand the site should extend and parameter ‘proto_thresh’ defines how deep the 
atomic probe should go into the protein. Surflex-Dock was operated with parameters ‘-premin -
remin’and ‘-ndock_final 1’. The Surflex-Dock poses were sorted and extracted according to the 
highest Surflex Raw Score by an in-house Perl script. Like GOLD, the Surflex score is adjusted 
to a positive value, so higher scores are better; experience with other systems suggests a score 
of 4 is good. 
4.2.8 Data analysis 
          All the data analysis and file manipulations, including sorting scores, extracting 
interesting compound poses, extracting common compound coordinates, are done by in-house 
Perl scripts. Correlation diagrams are generated by Sigmaplot.  
4.3 Results  
4.3.1 Virtual screening of the fragment library  
          The ChemBridge fragment library was designed by the distributors based on the 
commonly accepted Astex Rule of Three (MW ≤ 300, H-bond donors ≤ 3, H-bond acceptors ≤ 
3, cLogP ≤ 3). As one of the most lead-like fragment libraries, it contains fragments with both 
free and protected functionality. The initial goal of virtual screening of the fragment library 
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(3,963 compounds) was to select a docking program that showed the best correlation between 
computer ranking scores and ligand binding affinity as observed in the HT FP assay. 
          Figure 4.2 compares the results of  docking the fragment library by eHiTs, Surflex, Gold 
and ICM.  The Y axis is the “inhibition percentage”, that is the % of probe displacement, for 
the top 50 compounds derived from HT screening;  the X axis is the corresponding docking 
score for each compound generated by the various docking programs. The calculated 
correlation coefficients are: -0.09 for eHiTs, 0.01 for GOLD, -0.3 for ICM, and 0.15 for 
Surflex. These numbers are too low to be considered significant. The inhibition percentage was 
calculated based on only one fixed compound concentration, 50 μM. Therefore, the Y axis in 
the correlation diagram is not the ideal binding affinity of compound to protein, but it is still a 
useful indicator of receptor affinity.  
          A second form of analysis was carried out by comparing docking scores for the 18 
compounds confirmed as hits from secondary FP screening. As shown in table 4.1, the two 
compounds (4141340 and 5792605) showing 100% inhibition in the HT screening were found 
in the top 5% of compounds ranked by ICM. For eHiTs to find these hits 66% of the list must 
be included, 44% for Surflex and 21% for GOLD. In terms of enrichment rate, ICM also did 
the best for the other five compounds that showed around 50% inhibition in HT screening. 
Therefore, ICM seems to be the best docking program for NS1 RBD in terms of enrichment 
rate for top hits.  
4.3.2 Virtual screening of Sigma-Aldrich diversity library  
          A more diverse collection of drug-like molecules, the Sigma-Aldrich diversity library 
(with 49,020 compounds) was chosen for virtual screening. The Sigma-Aldrich diversity library 
set is selected based on 3D pharmacophore analysis to cover the broadest part of biologically 
relevant pharmacophore diversity space while still maintaining drug-likeness, as all compounds 
satisfy the standard of Lipinski’s rule of 5 (MW ≤ 500, H-bond donors ≤ 5, H-bond acceptors ≤ 
10, cLogP ≤ 5 and rotatable bonds ≤ 5). Because computational speed is critical while docking 
with large database, the program eHiTs was ruled out due to its slow docking algorithm and 
poor performance on the Fragment library test. The 49,020 compounds were docked against 
NS1 RBD by GOLD, ICM and Surflex on the TI-3D 64-CPU cluster. Comparing the top 5000 














































































Figure 4.2: Correlation between the inhibition percentages derived from HT screening of 
ChemBridge fragment library and docking scores generated by virtual screening program (a) 










10uM eHiTs Score Ranking Enrichment Rate 
5792605 100 9 -2.44 2423 0.66 
4141340 100 95 -3.23 623 0.17 
5377792 54 44 -2.29 2782 0.75 
5556613 51 9 -2.69 1816 0.49 
5265182 49 40 -2.40 2528 0.69 
5378142 49 38 -2.95 1144 0.31 
7683034 47 47 -3.48 318 0.09 
5465122 45 27 -1.78 3479 0.94 
6190191 43 22 -2.79 1549 0.42 
5212524 42 28 -2.44 2415 0.66 
9071210 41 30 -2.55 2137 0.58 
9008236 39 33 -3.30 520 0.14 
7702036 33 25 -3.60 226 0.06 
5738566 33 2 -2.44 2414 0.65 








10uM GOLD Score Ranking Enrichment Rate 
5792605 100 9 39.58 849 0.21 
4141340 100 95 41.01 639 0.16 
5377792 54 44 38.89 990 0.25 
5556613 51 9 36.91 1416 0.36 
5265182 49 40 36.16 1593 0.40 
5378142 49 38 36.60 1490 0.38 
7683034 47 47 42.04 504 0.13 
5465122 45 27 27.49 3143 0.79 
6190191 43 22 41.25 616 0.16 
5212524 42 28 29.89 2929 0.74 
9071210 41 30 30.31 2866 0.72 
9008236 39 33 26.85 3183 0.80 
7702036 33 25 41.13 627 0.16 
5738566 33 2 32.11 2575 0.65 













10uM ICM Score Ranking Enrichment Rate 
5792605 100 9 -13.90 203 0.05 
4141340 100 95 -16.30 72 0.02 
5377792 54 44 -9.89 750 0.19 
5556613 51 9 -9.09 922 0.23 
5265182 49 40 -9.93 742 0.19 
5378142 49 38 -10.57 624 0.16 
7683034 47 47 -10.84 576 0.15 
5465122 45 27 3.46 3465 0.88 
6190191 43 22 -3.19 2470 0.62 
5212524 42 28 -12.31 371 0.09 
9071210 41 30 -9.08 925 0.23 
9008236 39 33 -4.64 2130 0.54 
7702036 33 25 -4.87 2074 0.52 
5738566 33 2 -3.93 2317 0.59 








10uM Surflex Score Ranking Enrichment Rate 
5792605 100 9 4.73 1756 0.44 
4141340 100 95 4.82 1643 0.41 
5377792 54 44 2.7 3807 0.96 
5556613 51 9 3.43 3384 0.85 
5265182 49 40 2.96 3703 0.93 
5378142 49 38 3.56 3272 0.83 
7683034 47 47 4.76 1714 0.43 
5465122 45 27 6 476 0.12 
6190191 43 22 4.17 2492 0.63 
5212524 42 28 3.84 2940 0.74 
9071210 41 30 3.86 2909 0.73 
9008236 39 33 4.65 1856 0.47 
7702036 33 25 5.09 1301 0.33 
5738566 33 2 5.12 1264 0.32 
Average ranking for I% at 50uM > 45 2754 0.69 
 
Table 4.1: Enrichment profiles of 18 hits from ChemBridge fragment library by docking 






















































Figure 4.3: Correlation between docking scores of 77 compounds generated by (a) GOLD and 
ICM, (b) ICM and Surflex, (c) GOLD and Surflex. 
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overlaps between ICM and Surflex, 976 overlaps between GOLD and Surlfex, and 77 overlaps 
among all three programs. The coordinates and docking scores of the overlap compounds were 
extracted from final docking results generated by each program. Among those 77 compounds, 
the binding mode of each compound generated by three programs looks similar in most cases, 
but the docking scores do not agree with each other very well. As show in Figure 4.3, the 
docking score generated by one program was plotted against the docking score of the same 
compound generated by another program to see if there is any sign of correlation. The 
calculated correlation coefficients are: -0.027 for ICM and GOLD, 0.041 for Surflex and 
GOLD, and 0.124 for ICM and Surlfex. Therefore, none of them is considered as statistically 
significant. In other words, the scoring algorithms of those three programs are uncorrelated. 
This indicates the importance of choosing the right docking program for the specific targets.  
4.3.3 Virtual screening of NIH clinical collection, MicroSource Discovery spectrum 
collection and MayBridge diversity library by ICM  
          As shown in the results of virtual screening and high throughput screening of fragment 
library, ICM did best in terms of enrichment rate for top hits. Therefore, ICM was used in 
virtual screening of NIH clinical collection (446 compounds), MicroSource Discovery 
spectrum collection (2000 compounds) and MayBridge diversity library (53,038 compounds). 
The compounds in NIH clinical collection are drugs that have been in phase I-III clinical trials, 
and have highly developed properties of drug-likeness. The 2000 compounds in the spectrum 
collection consist of known drugs (50%), experimental bioactives (20%), and pure natural 
products (30%). The MayBridge diversity library is a highly diverse pharmacophore-rich 
collection of hit-like and drug-like compounds. Compounds with ICM score lower than -30 
were pooled together.  
 A total of 224 compounds were extracted; 208 from MayBridge diversity library; 15 
from MicroSource Discovery spectrum collection and 1 from NIH clinical collection. A visual 
inspection of those compounds revealed three symmetric molecules:ZINC0096886, 
ZINC01045105 and ZINC01324187, see table4.2. They all bound over the NS1A RBD center 
of symmetry, and made reasonable polar and hydrophobic interactions. Two derivatives were 
found for each of the three compounds through SciFinder Scholar, as shown in table 4.2. The 
FP assay shows that only compound ZINC0096886 displaced the dsRNA probe without  
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Figure 4.4: FP signal of dsRNA displacement by compound ZINC0096886. The dose-response 
against GST-NS1A(1-215) is shown in blue, and the dose-response against GST-NS1B(1-145) 













disrupting dsRNA. It has an IC50 around 19 μM against NS1A, and 13.8 μM against NS1B, see 
Figure 4.4.  
4.4 Discussion 
          It’s a well known fact that inventing and developing a new drug is a long, costly and 
highly risky process. On average, it takes 1.4 billion dollars and 12 to 24 years for a single new 
medicine, from starting a project to the launch of a drug product. Since we already know that 
drugs interact with their target protein in a highly specific manner, virtual screening or docking 
can, in principle, serve as a computational filter. It may significantly reduce the size of a 
chemical library needed to be screened experimentally in order to reveal promising inhibitors 
(Sun 2008). The docking results can also be used to select scaffolds and to help design the 
actual chemical library to be synthesized. Compared with large scale experimental screening, 
virtual screening is much more affordable in an academic environment, as most compound 
library databases are free, and physical assay costs are greatly reduced. Virtual screening can be 
used with any target, as along as there is a structure or reasonable model.  Some virtual 
screening strategies have already proven to be a successful in a few drug targets, including 5-
lipoxygenae and the ATP-sensitive potassium channel (Fechner, Franke et al. 2003; Mikhailov, 
Campbell et al. 2005).  
          Here, aiming to find potential compounds that will displace dsRNA binding on NS1, we 
used four docking programs (eHiTs, GOLD, ICM and Surflex) to dock small compounds to 
RNA binding domain (RBD) of NS1. eHiTs is an exhaustive docking program that takes a 
systematic divide and conquer approach to explore the full pose and conformational space 
(Zsoldos, Reid et al. 2006; Eitner, Gaweda et al. 2007; Zsoldos, Reid et al. 2007). The program 
splits the ligands into groups of rigid parts and flexible chains, then docks each rigid parts into 
the receptor independently. A fast graph matching algorithm was applied to score all matching 
solutions to reconstruct the original molecules.  
          GOLD (Genetic Optimization for Ligand Docking) used a genetic algorithm that mimics 
the process of evolution by applying genetic operators to a collection of putative poses for a 
given ligand (Verdonk, Chessari et al. 2005; Olsen, Jost et al. 2006; Thomas, McInnes et al. 
2006). It provides two consensus docking protocols, Goldscore  and Chemscore , in terms of 
docking accuracy and speed.  
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          ICM (Internal Coordinate Modeling) is a combination of the internal coordinate docking 
methodology with a global optimization scheme (Abagyan, Totrov et al. 1994; Borchert, 
Kishan et al. 1995; Totrov and Abagyan 1996). With its fast and empirically adjusted scoring 
functions, the program claims to have an average yield of lead candidates in top 10% of scored 
compounds.  
          Surflex uses a systematic approach docking methodology that combines Hammerhead’s 
empirical scoring function with a molecular similarity method to generate docking poses of 
ligand (Jain 2003; Jain 2004). Those four programs use distinct docking and scoring 
algorithms, and each one has its own unique features. We did an in-house evaluation of the 
programs by using eleven known binding affinity complexes of trypsin and its inhibitors; the 
docking modes and true Kd values are known for all the inhibitors. It turned out all four 
programs can reproduce the X-ray binding modes of ligands correctly. In addition, both GOLD 
and Surflex give decent correlation between the docking scores and experimental binding 
affinities. It is possible that the scoring functions of GOLD and Surflex were already trained by 
those trypsin-inhibitor complexes. To choose a program works best for NS1 target, we 
conducted a pilot HT screening of 4,000 compounds from ChemBridge fragment library. The 
screening results were used to select a docking program showing the best correlation between 
ranking score and ligand binding affinity. 
          The actual physical screening results for the fragment library did not correlate well with 
the docking results by any of the four programs. The successful experience with trypsin and its 
inhibitors might be exceptional. Perisoff and Head’s research group had evaluated 10 docking 
programs and 37 scoring functions for their rank-ordering by affinity for lead optimization 
(Warren, Andrews et al. 2006). None of the docking programs or scoring functions made a 
useful prediction of ligand binding affinity (Warren, Andrews et al. 2006). In fact, it is still very 
difficult for docking programs to accurately predict the binding free energy of protein ligand 
complex. One major reason is that the binding free energy includes a loss in configurational 
entropy upon ligand binding (Chang, Chen et al. 2007; Gilson and Zhou 2007). The decrease in 
freedom of ligand and protein will cancel much of the energy gained that drives binding. 
Therefore, neglecting the loss of configurational entropy will overestimate the binding 
affinities. Gilson reported that the energy terms in a physics based scoring function have to be 
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scaled down around 10 fold to bring the results into range with experimental binding affinities 
(Chen, Chang et al. 2004).  
          As an aid to the practical identification of inhibitors, the enrichment rate calculation is a 
more appropriate measure for the comparison of programs. ICM showed the best performance 
in terms of enrichment rate for top hits in a HTP screen for NS1-NTD. The two compounds 
(4141340 and 5792605) showing 100% inhibition in the HT screening were found in the top 
5% of compounds ranked by ICM. That indicates ICM could be the best docking program for 
virtual screening inhibitors against NS1(1-73).  
          We were disappointed to find out that there was no correlation among the docking scores 
given by GOLD, ICM or Surflex in the virtual screening experiments of Sigma-Aldrich 
diversity library. That indicates that not all docking programs are equally valuable for a given 
target. As a result, choosing the right docking program(s) for the specific target could be 
critical. Accurately predicting how a small molecule binds to a protein is difficult, and no 
program can guarantee success. Correctly scoring and ranking ligands according to their 
experimental binding affinities is even more difficult, and that’s why some program provides 
trainable scoring function to improve the accuracy and enrichment results by taking advantage 
of available experimental data for a particular target of interest. eHiTs was acclaimed to have 
this attractive feature, but our in-house evaluation didn’t reveal that benefits. Because of its 
slow docking speed, eHiTs was not selected in the high throughput screening of NS1 inhibitors.  
          ICM has shown great success with protein kinases, and has also been used to identify 
antagonists for the thyroid hormone receptor and EGFR (Schapira, Raaka et al. 2003; Kovacs, 
Chacon et al. 2004; Cavasotto, Kovacs et al. 2005; Nicola, Smith et al. 2007). Because of its 
higher enrichment rate in the virtual screening of fragment library, we used ICM to screen a 
total of 55,484 compounds from three libraries (NIH clinical collection, MicroSource 
Discovery spectrum collection and MayBridge diversity library). As mentioned above, three 
compounds were selected for further testing based on their ICM scores and symmetric 
properties.  ZINC0096886 (4-{3-[(3-carboxyacryloyl)amino]anilino}-4-oxo-2-butenoic acid ) 
showed an IC50 around 20uM in FP assay. That compound was also identified as LPA 
(lysophosphatidic acid) antagonist against LPA3 receptor through virtual screening (Fells, 
Tsukahara et al. 2008). The virtual docking of ZINC0096886 produced an ICM score of “-37”. 
No fully documented inhibitor of NS1 RBD is available, so we could not use its docking score 
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as a threshold value, as is commonly practiced (Cavasotto, Kovacs et al. 2005; Nicola, Smith et 
al. 2007). As shown in Figure 4.5, the two carboxyl groups of compound ZINC0096886 are 
predicted by ICM to interact with Arg38 of one NS1 monomer and Arg19 of the other 
monomer respectively. Without an X-ray structure it is hard to tell how accurate this docking is. 
We were surprised to find out that the two derivatives of compound ZINC0096886, especially 
the 4-{3-[(3-carboxyacryloyl)amino] anilino} -4-oxo-butanoic acid (Z1 in table 4.2), could not 
displace dsRNA at concentration of 100 μM. The only difference between compound 
ZINC0096886 and compound Z1 is the bond between C2 and C3. The C2-C3 double bond 
makes compound ZINC0096886 very rigid, while the C2-C3 single bond gives compound Z1 
more rotational freedom at carboxyl end. If the docking conformation of ZINC0096886 is 
correct, the C2-C3 double might play a critical role to hold the Arg38 and Arg19 in a fixed 
conformation to preclude the binding of dsRNA.    
          Most docking programs on the market treat the protein as a rigid object, while the truth is 
protein flexibility often plays an important role in accommodating ligands. Using a fixed 
receptor structure may be a great limitation if the protein undergoes an induced fit upon ligand 
binding. The recent X-ray structure of NS1(1-73) with dsRNA complex (Cheng, Wong et al. 
2009) revealed that a dramatic conformational change occurred in the orientation of the side 
chain of Arg38 before and after dsRNA binding (Cheng, Wong et al. 2009). As shown in 
Figure 4.6, the Arg38 pair acts as a lid to cover the deep pocket  upon dsRNA binding, whereas 
they project into the solvent in the absence of dsRNA. All four docking programs (eHiTs, 
GOLD, ICM and Surflex) address the problem of ligand flexibility by a variety of algorithms, 
but the issue of receptor flexibility remains a great challenge.  
 ICM is able to implement partial receptor flexibility, but the computation rate is very 
slow, and only a single ligand at a time can be tested. Furthermore, the user is responsible for 
choosing the specific static receptor conformations generated by program. It’s very likely the 
actually conformation of receptor upon ligand binding is not included in the selection list. In 
addition, this partial receptor flexibility was implemented in ICM through rotating of receptor 
side-chain torsion angles by biased-probability sampling method (Abagyan and Totrov 1994; 
Abagyan, Totrov et al. 1994). However, even if the global optimization of ligand side-chain 
interaction is convergent, the deformations of the protein backbone may still be crucial to 
accurate prediction of protein ligand association. The lack of a flexible binding model could be  
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Figure 4.5: Stereo images of the docking pose of compound ZINC0096886 in NS1(1-73). The 




Figure 4.6: Stereo images of superposition of NS1A-RBD dimer in dsRNA bound state (red) 
and in dsRNA free state (blue).  
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the reason we get so few hits from virtual screening 55,484 compounds. Docking with full 
protein flexibility is currently not feasible because of the vast computational increase required.  
          Epigallocatechin gallate (EGCG), which did well in the HTP assay, was among the 
55,484 compounds virtually screened by ICM. We were disappointed to find out that ICM 
failed to dock EGCG to NS1-RBD even with a threshold value +35 (default is -35). In ICM, the 
user can adjust the size or position of docking box during receptor preparation. This docking 
box represents the region in which maps will be generated; it needs to be large enough to 
encompass the binding pocket but not including regions of receptor which are not relevant for 
the ligand to bind. By adjusting the size of docking box, ICM was able to dock EGCG to NS1-
RBD with a final fitness score -13. This result raised a concern regarding the general utility of 
docking by ICM. ICM employs a Monte-Carlo Minimization algorithm to find the optimal 
binding modes of a ligand in the active site (Abagyan, Totrov et al. 1994). The Monte-Carlo 
Minimization algorithm, also called Monte-Carlo simulation, was firstly introduced as a 
minimization procedure in molecular dynamics application (Fishman 1995). It was reported to 
be one of the best algorithms to accurately determine the binding constants for protein ligand 
interaction (Schapira, Totrov et al. 1999; Huang, Kalyanaraman et al. 2006). In ICM, this 
search algorithm randomly selects a conformation in internal coordinate space inside the 
docking box and then makes a step to a new position by a pseudo-Brownian move according to 
a predefined continuous probability distribution followed by a force-field based energy 
minimization (Abagyan, Totrov et al. 1994). The minimal energy conformations are returned to 
the user. This algorithm assumes that the convergence to the best structure should occur from a 
large class of initial conformations, and only one of which needs to be considered (Abagyan, 
Totrov et al. 1994; Totrov and Abagyan 1997). This Monte Carlo method is not guaranteed to 
search exhaustively, so that the best conformation may be missed. That could explain why we 
did not get the docking pose for EGCG at the first trial. In contrast to EGCG, ICM was able to 
successfully rank aurin tricarboxylic acid, the proven hit identified from HT FP screening, 
among the top 2% of 2,000 compounds in MicroSource Discovery Spectrum collection.  
          The five proven hits (except tannic acid) derived from the HT FP screening were pooled 
together and docked against NS1-RBD by GOLD, ICM and Surflex respectively. The docking 
scores were listed in table 4.3. The corresponding correlation coefficients between docking 
scores and IC50(s) were calculated, see table 4.3. It is surprising to find out that GOLD showed 
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better correlation (r = -0.84) than that of ICM (r = -0.45) or Surflex (r = -0.53). Although five 
data points might not truly reveal the correlation between docking scores and IC50(s), it at least 
suggests that GOLD may be more valuable than we originally thought. The docking pose of 
EGCG by ICM showed better shape complementary than that for either  GOLD or Surflex 
(figure 4.7). As shown in figure 4.7 panel b, the EGCG was completely buried in the deep 
hydrophobic pocket between the dimer interface; did not interact with Arg38 from either 
monomer. But our CD experiment proves that Arg38 is directly involved in the interaction 
between EGCG and NS1-RBD. It further reminds us to understand the limits and scope of any 
virtual screening program. 
          In conclusion, the four docking programs (eHiTs, GOLD, ICM and Surflex) differ in 
their performance on docking small compound to NS1-RBD. The compound ZINC0096886 
was identified as an inhibitor showing IC50 around 19 μM against NS1A, and 13.8 μM against 
NS1B. Currently, we still do not have direct structure evidence to guide us choose the docking 
program most suitable for HT virtual screening of inhibitors against NS1-RBD. The dynamic 
motion of critical residue Arg38 on protein receptor surface could be the bottleneck for 
accurate docking of small compounds to NS1-RBD. Although ICM did a better job in terms of 



















 IC50 (μM) GOLD ICM Surflex 
4141340 8 41.01 -16.3 3.00 
5792605 7 39.58 -13.9 2.76 
7869182 0.8 52.353 1.69 2.81 
ATA 0.5 60.263 -14.73 3.61 
EGCG 0.3 48.45 -13.19 6.13 
Correlation coefficient (r) -0.84 -0.45 -0.53 
Table 4.3: Docking score profiles of 5 hits from HT FP screening by docking program: GOLD, 























          The most well known benefit of using crystallography in drug discovery is the 
development of the structure based drug design cycle: structure, synthesis, testing, and back to 
structure. Compounds identified as inhibitors can be soaked or co-crystallized with the 
corresponding target protein. An X-ray structure of the complex will reveal the binding mode 
of inhibitors and serve as basis for further lead refinement.  
          The X-ray structure of the N-terminal 73-residue RNA binding domain of NS1A was 
reproduced from the published crystallization conditions. Hit compounds are used in 
experiments to form useful complexes with it.  
 The X-ray structure of the NS1A effector domain (residues 79-205) of the mouse-
adapted influenza A/PR8/34(PR8) virus strain was solved in 2006 (Bornholdt and Prasad 
2006). However that particular NS1A strain does not bind CPSF30.  It is likely that this arises 
from two mutations (F103S and M106I) in the F2F3 recognition site. As the CPSF30 binding 
site is crucial for virus replication, and is a proven target for new antiviral drug development, it 
is important to analyze the structure of an NS1effector domain that does interact with CPSF30 
(Twu, Noah et al. 2006). Besides the effector domain, crystallization efforts will be made 
toward crystallizing the nearly full length NS1A protein from Udorn strain.  
          From previous results, the N-terminal GST tagged NS1A(1-215) fusion protein has a 
much tighter binding affinity to dsRNA than the protein without a GST tag.  Therefore, it 
would be very interesting, and useful, to see the structure of the fusion protein, since the GST-
NS1A(1-215) has been chosen as the HT screening target.  Such a structure would be very 
helpful for virtual screening and rational lead optimization.  
5.2 Materials and methods 
5.2.1 Construction of various NS1 constructs 
          The 126 amino acids (residue 79-205) of NS1A was PCR amplified with primers 
GACGACGACAAGATGACCATGGCCTCCACACC and GAGGAGAAGCCCGGTTTAGC 
TTCCCCAAGCGAATC. The product was cloned into pET-46 Ek/LIC (Novagen). The first 
145 amino acids of CPSF30, was purified by first amplifying the DNA with primers 
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CGCGGATCCATGCAGGAAATCATCGCCAGC and CCGCTCGAGTTATCTCCGTGTGT 
GCCGG. And the product was digested with BamHI and Xhol restriction endonucleases, and 
cloned into pGEX4T3 plasmid DNA (GE Healthcare) cleaved with BamHI and Xhol. The 205 
residues NS1A(1-205) was PCR amplified with primers TACTTCCAATCCATGGATTCCAA 
CACTGTGTCAAGTTTTC and TATCCACCTTTACTGTTAGCTTCCCCAAGCGAATC. 
And the PCR product was cloned into pNIC28-Bsa4 (Plasmid pNIC28-Bsa4 was kindly 
provided by Dr.Opher Gileadi at University of Oxford). 
5.2.2 Construction of plasmid mutations 
          The mutations were introduced in plasmid pET46 and pNIC28-Bsa4 by site-directed 
mutagenesis, according to the Stratagene protocol (Stratagene). Around 50 ng of plasmid and 
150 ng of each primer were combined with reaction buffer (20 mM Tris–HCl (pH 7.5), 8 mM 
MgCl2, 7.5 mM DTT, 50 μg/ml of bovine serum albumin (BSA)), 150 μM dNTP mix, 1 units 
of KOD Hot Start DNA Polymerase (Novagen), and deionized water to final volume of 50 μl. 
Primer sequences of effector domain mutant (W817A and W187Y) and NS1A(1-205) mutants 
(R38A-K41A and R38A-K41A-W187A) are shown in table 5.1. Reaction mixture was further 
treated with 10 units of DpnI (New England Biolabs) at 37 °C for 2hrs. Then 1 μl of treated 
reaction mixture was transformed into E. coli DH5α competent cell. The presence of the 
expected mutations was confirmed by DNA sequencing.  
 









Table 5.1 Primer sequences of effector domain and NS1A(1-205) mutants 
 
5.2.3 Protein purification 
          The GST fusion protein, the wild type and mutants, of the NS1A effector domain and 
NS1A(1-205) were expressed and purified according to the methods described in chapter 2.  
5.2.4 Fluorescence polarization (FP) assay 
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          The FP assay was performed as described in chapter 2. Here the 46 mer RNA 
oligonucleotides with sequence AAGACUCUUGGGUUUCUGAUAGGCACUGACUCUCUC 
UGCCUAUUG (sense) and CAAUAGGCAGAGAGAGUCAGUGCCUAUCAGAAACCCAA 
GAGUCUU (antisense) was used.  
5.2.5 GST-pull down assay 
          The protein purification procedure is the same for all genes cloned in the pGEX vector. 
Escherichia coli strain Rosetta 2 (DE3) (Novagen) containing the CPSF30(1-145)-
pGEX/pGEX plasmid were grown and harvested as described in Chapter 2. The cell pellet was 
resuspended in 50 ml column buffer (CB: 50 mM HEPES (pH 7.5), 50 mM NaCl) and 
disrupted in a French pressure cell. Cellular debris was pelleted by centrifugation at 5,000g for 
60 min at 4 °C. The supernatant was applied to a column containing glutathione agarose beads 
(3 ml bed volume, equilibrated with CB), and washed with CB until the OD280 of the flow 
through was equal to the background reading. Then 5 ml of purified effector domain protein (2 
mg/ml) was passed over the column twice. The column was washed with CB till the OD280 of 
flow through equal to the background reading, then eluted with 10 ml elution buffer (EB: 
10mM reduced glutathione, 50 mM Tris, pH 8.0). As a control, the purified effector domain 
protein was also applied to a column containing the fresh glutathione agarose beads (3 ml bed 
volume, equilibrated with CB), followed by washing with CB till the OD280 of flow through 
equal to the background reading, then eluted with 10 ml elution buffer (EB: 10mM reduced 
glutathione, 50 mM Tris-HCl, pH 8.0). All eluted fractions were analyzed on 12% SDS-PAGE. 
5.2.6 Screening for crystallization condition 
          A total of 698 conditions were manually screened for crystallization using the sitting 
drop method. Among those conditions, 458 came from commercially available crystallization 
screening kits (Hampton Research), including: Screens I and II, Index, PEG/Ion I and II, 
Natrix, Grid screen PEG 6000/AS/NaCl/MPD, and Quick screen phosphate. The other 240 
conditions came from 10 in-house grid-screening kits. The wild type effector domain and two 
mutants of NS1A(1-205) were also sent to the Hauptman-Woodward Institute (Buffalo NY) for 
a high-throughput screening with 1,536 conditions.  
5.2.7 NS1-RBD and NS1-ED crystallization conditions 
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          Crystals of the RBD of Udorn NS1A were grown from a solution of 50 mM NaH2PO4, 
100 mM NaCl, 1mM NaN3, 10% (w/v) PEG6000 and 20 mg/ml protein by hanging drop 
method. This condition was optimized based on the published crystallization condition. 
5.2.8 NS1-ED wild type and mutant (W817A, W187Y) crystallization conditions. 
          One crystal form (I) of the influenza A/Udorn/72 NS1A effector domain (wild type) was 
grown at room temperature using the batch method by mixing 5 µl 10 mg ml-1 NS1A effector 
domain in 50 mM HEPES pH 8.0, 0.1 M NaCl with 5 µl 20%(w/v) PEG 400, 0.1 M sodium 
acetate pH 5.5, 0.1 M MgSO4. This condition was identified from screens carried out in the 
high-throughput crystallization screening laboratory at the Hauptman-Woodward Medical 
Research Institute (Luft et al., 2003). A second crystal form (II) was grown at 277 K using the 
sitting-drop method. 5 µl protein solution (10 mg ml-1 in 50 mM HEPES pH 8.0, 0.1 M NaCl) 
was mixed with 5 µl reservoir solution and equilibrated against a reservoir containing 800 µl 
12%(w/v) PEG 3350 and 4%(v/v) Tacsimate pH 6.0. This condition was found using the 
Hampton Research PEG/Ion HT Screen kit. 
          Both crystals of the W187A and W187Y mutant NS1-ED were grown at 277 K using the 
sitting-drop method. 5 µl protein solution (10 mg ml-1 in 50 mM HEPES pH 8.0, 0.1 M NaCl) 
was mixed with 5 µl reservoir solution and equilibrated against a reservoir containing 800 µl 
0.3 M Magnesium formate and 0.1 M Bis-Tris pH 5.5. This condition was found using the 
Hampton Research Index HT Screen kit. 
5.2.9 Data collection and processing 
          Crystal form I of the influenza A/Udorn/72 NS1A effector domain was cryoprotected by 
dipping it into an artificial mother liquor containing 30% PEG 400. Crystal form II was 
similarly cryoprotected with an artificial mother liquor containing 20% PEG 3350. Crystals of 
mutant effector domain were also cryoprotected by dipping into an artificial mother liquor 
containing 30% PEG4000. Crystals mounted in a cryoloop (Hampton Research) were flash-
frozen by dipping them into liquid nitrogen andthen placing the frozen loops in the liquid 
nitrogen cold stream on the X-ray detector goniostat. Diffraction data were collected at 100 K 
on a MAR 345 image-plate detector (MAR Research) with X-rays generated by a Rigaku 
Micromax007 rotating-anode generator (Rigaku, The Woodlands, Texas, USA) operated at 
40 mV and 30 mA. Diffraction data were collected using a crystal-to-detector distance of 
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200 mm. Diffraction data were integrated and scaled using HKL-2000 (Otwinowski & Minor, 
1997).  
5.2.10 Structure determination and refinement 
          The initial molecular replacement model for the primitive cell crystal was obtained using 
the PR8 protein as a model (Bornholdt and Prasad 2006); the search was conducted using the 
program MOLREP (Vagin and Teplyakov 1997). Subsequent density modification and 
refinement were carried using CNS (Brunger, Adams et al. 1998)  and Refmac (CCP4 1994).  
Individual atomic isotropic temperature factors were refined. Molecular visualization and 
rebuilding were done using COOT (Emsley and Cowtan 2004). Water and other solvent 
molecules (sulfate) were identified using COOT based on an Fo-Fc difference map. Five 
percent of the diffraction data were set aside throughout refinement for cross-validation 
(Brunger 1993). PROCHECK was used to make the Ramachandran plots (Laskowski, 
MacArthur et al. 1993). Model pictures were made using PYMOL (Delano Scientific, San 
Carlos, CA). 
5.3 Results and discussions 
5.3.1 RNA binding domain of NS1A 
          The N-terminal 73 amino RNA binding domain of influenza A/Udorn/72 NS1A was 
cloned into the pET28b vector. The protein was purified, and digested with tobacco etch virus 
(TEV) protease to remove the 6xHis tag at the C-terminus of the protein. The protein was 
crystallized using published crystallization condition with an additional 10% PEG6000. The 
crystal was found to belong to space group P43212, at pH 6.0, with cell constants, a = 41.07, b = 
41.07, c =77.88Å. There is one molecule per asymmetric unit, giving a Vm value of 2.21 Å3/Da. 
X-ray data and refinement statistics for the structure are shown in Table 5.2.  A section of the 
final 2Fo-Fc electron density map used for model construction from the pH 6.0 crystal is shown 
in Figure 5.1. Following refinement, a Ramachandran plot of the primitive cell crystal showed 
96.8% of residues to be in the most favorable region and 3.2% in additional allowed space. The 
refined structure includes 23 solvent molecules.             
          The structure of the NS1A(1-73) monomer contains three continuous α-helices. The first 
helix is almost anti-parallel to the second helix, and the third helix crosses the first two helices 
with a crossing angle of 90° and 60° respectively. The six additional C-terminal amino acids, 
which are part of the TEV protease recognition site, are left after TEV protease digestion. There  
 94
Data Collection  
Wavelength (Å) 1.5418 
Space group  P43212 
Cell dimensions  
   a, b, c (Å) 41.07, 41.07, 77.88 
Resolution (Å) (last shell) 30 – 2.4 (2.36-2.44) 
Rmerge (%) (last shell) 4.5 (15.6) 
<I/σI> (last shell) 58.1 (5.8) 
Completeness (last shell) 97.9 (83.7) 
Redundancy 12.0 (5.0) 
Refinement  
No.reflections 2732 
Rworking (last shell) 0.208 (0.229) 
Rfree (last shell) 0.298 (0.306) 
Average B factor for 
protein atom (Å2)  
36.8 
R.m.s deviation from 
ideality 
 
   Bond lengths (Å) 0.013 
   Bond angles (°) 1.331 
Table 5.2: Data collection and model refinement statistics of NS1A(1-73) 
 
 
Figure 5.1: Electron density for the NS1A(1-73). This is a section of a 2F0-Fc map contoured at 
1σ to show the interface of the RBD dimer. 
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is no electron density for those 6 amino acids, probably because they are flexible and do not 
pack uniformly in the crystal. The overall structure is almost identical to the published X-ray 
structure of NS1A-RBD (1ail.pdb). A superposition of NS1A(1-73) with the published NS1A-
RBD gives an rms distance between 70 equivalent Cα atoms of 0.18 Å. The most striking 
difference is that the side chain of Arg38 in our structure has shifted toward the dimer cleft by 
almost 90° compared to the published structure of NS1A-RBD (1ail.pdb), and 45° compared to 
the published structure of NS1A-RBD dsRNA bound state (2zko.pdb), see Figure 5.2. This 
shift could be due to the presence of the additional 10% PEG6000 in crystallization buffer, 
which makes the solution more viscous than the original crystallization condition.  
          The Arg38 pair in our NS1(1-73) X-ray structure covers the nonpolar pocket beneath, see 
figure 5.3. This could explain why soaking of identified inhibitors from our HT screening did 

























Figure 5.2: Stereo images of superposition of (a) NS1A(1-73) with published NS1A-RBD 
structure (1ail.pdb), (b) NS1A(1-73) with published NS1A-RBD (1ail.pdb) and NS1A-RBD 
dsRNA bound state (2zko.pdb). Our NS1A(1-73) is shown in blue, 1ail.pdb is shown in red, 








(a)                                        (b)                                        (c) 
 
Figure 5.3: Surface presentation of NS1A dimer from (a) dsRNA bound state (2zko.pdb), (b) 
















5.3.2 NS1A effector domain (wild type)  
          Recombinant, His tagged, effector domain (residue 79 to 205) can be expressed in good 
yield from E. coli (~10 mg/ liter of cell culture).  A screen of crystallization conditions showed 
two useful forms.  Both types are orthorhombic but one cell is primitive and the other centered.  
The best crystals of NS1A effector domain (residues79-205) formed in space group P212121, at 
pH 5.5, with cell constants, a = 47.9, b = 61.5, c =132.1Å. There are two molecules per 
asymmetric unit, giving a Vm value of 3.04 Å3/Da.   The second form is space group C2221, at 
pH 6.0, with a = 62.8, b = 74.0, and c = 121.9 Å. Like the pH5.5 crystal, there are two 
molecules in the asymmetric unit, giving a Vm value of 2.21 Å3/Da.  X-ray data and 
refinement statistics for the two structures are shown in Table 5.3.  A section of the final 2Fo-
Fc electron density map used for model construction from the pH 5.5 crystal is shown in Figure 
5.4.           
          Following refinement, a Ramachandran plot of the primitive cell crystal, at pH 5.5, 
showed 87.1% of residues to be in the most favorable region and 12.9% in additional allowed 
space. The refined structure includes two sulfate ions and 136 solvent molecules. The centered 
cell crystal, at pH 6.0, had a Ramachandran plot with 87.3% of residues in the most favorable 
region and 12.7% in additional allowed space. That refined structure includes 20 solvent 
molecules. 
          The structure of the Udorn NS1A effector domain shows an α-helix β-crescent fold 
generally similar to that of PR8 NS1A effector domain (Bornholdt and Prasad 2006), and of the 
recently solved effector domain from an avian influenza virus NS1 (Hale et al, 2008).  A ribbon 
drawing of an effector domain monomer is shown in Figure 5.5.  There are seven β-stands and 
three α-helices in each monomer. Six of the β-stands surround a long central α-helix and make 
an extensive network of hydrophobic interactions with it. It is these interactions around one 
side of the helix that gives rise to the rough crescent shape.   
          As show in Figure 5.5, the first β-strand (a) lies on the convex side of crescent and is 
connected by a short helix A to strand b. Then the five β-strands (b, c, d, e and f) sequentially 
connect to each other to form an antiparallel twisted β-sheet that surrounds the central helix B. 
Helix B is the longest α-helix of the structure; it connects strand f to strand g, which lies 
adjacent and antiparallel to strand d. Strand g is followed by the last helix C lying on the sharp  




Data Collection   
Wavelength (Å) 1.5418 1.5418 
Space group  P212121 C2221 
Cell dimensions   
   a, b, c (Å) 47.92, 61.46, 132.13 62.82, 74.03, 121.88 
Resolution (Å) (last 
shell) 
30 – 2.1 (2.13-2.21) 30 – 2.6 (2.59-2.68) 
Rmerge (%) (last shell) 6.6 (22.9) 6.0 (14.9) 
<I/σI> (last shell) 28.5 (2.6) 32.0 (3.7) 
Completeness (last shell) 87.7 (29.7) 85.7 (26.3) 
Redundancy 6.1 6.8 
   
Refinement   
No.reflections 17766 7261 
Rworking (last shell) 0.197 (0.234) 0.197 (0.284) 
Rfree (last shell) 0.232 (0.287) 0.235 (0.316) 
Average B factor for 
protein atom (Å2)  
35.4 38.8 
R.m.s deviation from 
ideality 
  
   Bond lengths (Å) 0.011 0.014 
   Bond angles (°) 1.236 1.482 
 




Figure 5.4: Electron density for the NS1 effector domain 
 
 
Figure 5.5: Ribbon drawing of the effector domain of Udorn NS1A.  
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the side chains of Q199 and R193.  
          The influenza A/Udorn/72 NS1A effector domain and PR8 effector domain share 89% 
sequence identity and consequently (Figure 5.6), the overall folding of the two monomer 
structures is quite similar. The superposition of the two structures gives an rms distance 
between 81 equivalent Cα atoms of 0.29 Å; the superposition is shown in Figure 5.7. The most 
obvious differences between two monomer structures lie at the N-terminus and in two loops 
regions; these are indicated by labels.  In Figure 5.7, S87 is near the N terminus and marks that 
region; residues 135-143 (including labeled F138) are shifted up to 5Å toward strands a and d . 
The second loop region, L163 to G168 (labeled with P167), is shifted toward strand b  ~3 Å in 
the Udorn structure. W187, crucial to effector domain function, is shown for reference. 
          The NS1 effector domain behaves as a dimer in solution based on its chromatographic 
properties, and the asymmetric unit of the crystals is also a dimer (Nemeroff, Qian et al. 1995).  
In both of our crystal structures, the main stabilizing interaction for non-crystallographic dimer 
formation appears to be the  pseudo-symmetrical insertion of the W187 indole ring into the 
hydrophobic F2F3  binding pocket of its dimer partner; the dimer interface is shown in Figure 
5.8.   Figure 5.8a shows a space filling model of a monomer, with the W187 side chain of the 
other monomer fitting into it; Figure 5.8b shows more details about the interactions of the 
buried W187 side chain with the receptor pocket. The pocket is formed by main chain residues 
G183 to N188 together with side chains from residue K108, K110, I117, Q121, and V180. The 
hydrophobic pocket is located at the base of the central long helix, with the side chain of W187 
pointing outward from the periphery. The recently obtained X-ray structure of Udorn effector 
domain with F2F3 complex (Das, Ma et al. 2008) proves that this hydrophobic pocket is indeed 
the CPSF binding pocket.  This is consistent with the observation that residues G184 to N188 
are crucial for binding to the CPSF subunit and are highly conserved among human influenza A 
virus, including the A/Hongkong/493/1997 virus and A/Vietnam/1203/2004 virus (Twu, Kuo et 
al. 2007). 
          The X-ray structure of an avian virus NS1 effector domain also exhibits a non-
crystallographic dimer very similar to that seen in the two Udorn crystals (Hale, Barclay et al. 
2008).  The authors also realized the importance of the interaction of W187 with the CPSF 




Figure 5.6: Alignment of the protein sequence of NS1A from influenza A/Hong 
Kong/483/1997, A/VieNam/1203/2004, A/PR8/34 and A/Udorn/1997. 
 
Figure 5.7: Superposition of Udorn effector domain and PR8 effector domain(2GX9). The Cα 
trace of Udorn effector domain is shown in blue bonds, and that of PR8 effector domain is 
shown in red bonds.  The side chain of W187, indicating the area of the effector domain 






 Figure 5.8: The dimer interface for NS1-effector domain.  (a). A space filling model of 
monomer A reveals a distinct, largely hydrophobic pocket that has evolved to bind aromatic 
residues from the F2F3 domain of CPSF30.  Here W187 from effector domain monomer B 
binds in that pocket.  (b). A detailed view of the interactions in the pocket of W187 side chain 
with binding cleft residues. 
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Q121A, and W187A, but only the tryptophan alteration caused the protein to act as a monomer 
in solution.  
          The PR8 effector domain also forms a non-crystallographic dimer and has the same kind 
of interface described here (Bornholdt and Prasad 2006).  The authors of that study focused 
their attention not on the W187 contact, but on the formation of a segment of antiparallel β 
sheet between the N-terminal strands of the neighboring molecules.  That β sheet pairing is not 
seen in either of our structures nor in the avian virus structure, and appears to result from 
adventitious crystal packing forces unique to the PR8 crystal.  The pseudo dimeric interaction 
of W187 with the F2F3 binding site is common to all four structures and is clearly the main 
interaction driving effector domain dimerization, as confirmed by the recent mutagenic studies.  
          Figure 5.9 shows the relative orientations of the non-crystallographic dimers from the 
two crystal forms of Udorn NS1 effector domain. One monomer from each structure is 
superimposed in a least squares sense with an rms deviation of 0.28 Å for Cα atoms.  In each 
case its dimeric partner makes interactions like those described above, burying the W187 side 
chain in the neighboring binding site (the side chains are shown and labeled).  However, subtle 
differences at the interface generate rather large differences for remote regions of the molecule.  
To superpose the second monomer from the two systems requires a rotation of 44°.  The central 
B helices of the monomers are shown as cartoons in Figure 5.9 to facilitate the comparison.  
The orientation of the A PR8 effector domain dimer is similar, but not identical, to that of the 
pH 6 Udorn crystal (red in Figure 5.9).  Again, the dimer interface is basically the same in all 
the crystal structures; however, subtle differences at the interface still allow for larger 
differences in the crystal packing of the entire dimer.   
          In discussing the F2F3 binding site of the effector domain, it is interesting to note that the 
pocket residues K108, K110, I117, Q121, V180, and G183 to W187 are conserved among 
almost all influenza A viruses, including those having an intrinsic defect in binding CPSF. It 
appears that proteins, like PR8, that are defective in CPSF binding lack the consensus amino 
acids Phe 103 and Met 106. The recent structure of the effector domain with F2F3 fragment of 
CPSF bound reveals that F103 and M106 are not part of the CPSF binding pocket but are 
involved in intermolecular interactions that stabilize the complex at a site remote from the 
hydrophobic pocket. F102 and Met 106 are not involved in the dimerization of the Udorn 








Figure 5.9: Superposition of the Udorn effector domain at pH5.5 (blue ribbon) and the PR8 









          As described in the introduction section, NS1 is a functional dimer with two major 
domains (Nemeroff et al., 1995). We recently solved the structure of the NS1A N-terminal 
domain, residues 1-79, but found that it was the same as that described previously for residues 
1-73 (Liu et al., 1997). In our structure we note that residues beyond 73 are not observed, 
presumably because they are disordered. In the C-terminal effector domain reported here, 
residues 79-83 are not observed in either crystalline form, again because they are likely to be 
disordered. This suggests that there is a flexible linker region of about ten amino acids (residues 
74-83) between the two domains. 
          The NS1 dimer is maintained by dimerization of the N-terminal domain (Wang et al., 
1999) and it may be that the effector domains of NS1 also participate in NS1 dimerization 
(Wang et al., 2002). It is likely that in the NS1 dimer the effector domains dimerize in a manner 
similar to that which we and others have observed crystallographically. To help understand the 
action of the NS1 effector-domain dimers, in which the biologically important CPSF30-binding 
sites are buried, we constructed a hypothetical model of the intact NS1 dimer. This model is 
illustrated in Figure 5.10. To build the model, we aligned the twofold axes of the N-terminal 
and C-terminal dimers and rotated them so as to bring the C-terminal residues of the N-terminal 
domain near the N-terminal residues of the C-terminal domain. We found that this was very 
straightforward and allowed the domains to be linked plausibly by a ten-residue linker. We 
minimized the energy of the model using CNS (Brünger et al., 1998). In Figure 5.10, the N-
terminal domains are shades of blue for chain 1 and cyan for chain 2. The effector domains are 
shades of red for chain 1 and orange for chain 2. The ten-residue linkers are colored yellow. 
The Trp187 side chains are shown as van der Waals structures and chain 1 is labeled; the indole 
ring binds deep in the pocket of chain 2. We have also added a plausible binding site for 
dsRNA to the NS1 model. RNA is thought to bind in the prominent channel between 
symmetrical helices 2 of the N-terminal dimer. The RNA binding is stabilized by a number of 
ionic interactions (Wang et al., 1999). This notion has been given strong support from site-
directed mutations which show, among other things, that Arg38 is essential to dsRNA binding. 
This key side chain is shown as stick bonds pointing to the dsRNA; Arg38 on chain 1 is labeled 
and also serves to identify helix 2 which forms the binding channel. 
          In the NS1 dimer, it is likely that the effector domains dimerize such that for each subunit 





Figure 5.10: Hypothetical model of intact NS1. One chain has the N-terminal domain colored 
blue and the effector domain colored red; the second chain is colored cyan and orange, 






CPSF30 is likely to require a large quaternary structural change to the effector-domain dimer. 
Initially, the CPSF30-binding pocket is probably blocked by the Trp187 side chain of its 
dimeric partner, as seen in Figure 5.10. In order to bind CPSF30, the Trp187 side chain must be 
displaced and the effector domains rotate to accommodate CPSF30 phenylalanines 97, 98 and 
103. It is clear from our model that the long unstructured linkers would allow the effector 
domains to rotate freely into the solvent from the stable N-terminal domain platform. 
Presumably, there is an equilibrium between the dimerized state that we observe in the crystal 
structure and a more open conformation. If that open form interacts with the F2F3 domain of 
CPSF30, those interactions are presumably much stronger than the internal dimer. The effector 
domains of NS1 proteins that do not bind CPSF30, such as the PR8 NS1, also form dimers with 
Trp187 pointing into hydrophobic pocket of an adjacent monomer and presumably also have 
some open conformation. However, without Phe at position 103 and Met at position 106 to help 
stabilize the F2F3 interactions, the internal effector-domain dimer may be more stable. This 
would explain why all influenza viruses have this conserved hydrophobic pocket, but only 
viruses with Phe at position 103 and Met at position 106 are able to break their internal dimer 
and bind CPSF30 (Twu et al., 2007). 
5.3.3 NS1A effector domain mutants (W187A, W187Y)  
          The C-terminal effector domain (ED) has been reported to interact with the 30 kDa 
subunit of the cleavage and the polyadenylation specificity factor (CPSF30), and resulted in the 
inhibition of the maturation and export of host cellular antiviral mRNAs (Noah, Twu et al. 
2003). NS1 mutations spanning the CPSF30-binding site (residues 184-188) reduce CPSF30 
binding. The recombinant virus expressing these mutations induced a high level of host-cell 
interferon β, while viral replication was attenuated 1000-fold (Noah, Twu et al. 2003). In 
addition, an engineered MDCK cell line which constitutively expresses epitope-tagged F2F3 in 
the nucleus effectively blocked the binding of endogenous CPSF30 to NS1A and thereby 
selectively inhibited influenza virus A replication (Twu, Noah et al. 2006). All these suggest 
that the CPSF30 binding site can be targeted for the development of new antiviral drugs.  
          As shown in figure 5.11, the effector domain (residue 79 to 205) of NS1 was a dimer in 
solution. And from the X-ray structure, we know this dimer was stabilized by the pseudo-
symmetrical insertion of Trp187 indole ring into the CPSF30 binding pocket of its dimer 






Figure 5.11: HPLC profiles of wild type and mutant NS1A-ED. The wild type elution profile is 
shown as a red line, the W187A mutant is shown in green, and the W187Y mutant is shown in 
blue. Absorbance was measured at 280 nm, and the gray dashed lines indicate the position of 
protein standards. From left to right, they are: thyroglobulin (670kD), bovine gamma globulin 











mutant protein of effector domain that still retains the wild type binding affinity toward 
CPSF30 but remains monomeric in solution. In that way, this CPSF30 binding pocket of 
effector domain will be exposed to the solvent and to potential inhibitors.  
          The Trp187 residue was reported to be essential for dimerization of NS1-ED of avian 
influenza virus A/Duck/Albany/76 NS1 (Hale, Randall et al. 2008), which share 70% sequence 
identity with NS1-Ed of influenza A/Udorn/1997 (Figure 5.12). A superposition of the Udorn 
NS1-ED with Duck NS1-ED gives an rms deviation between 123 Cα atoms of 0.43 Å. As 
shown in 5.13, the Trp187 adopts a different conformation in each structure, as the orientation 
of indole ring is flipped 180° compared to each other. Interestingly, Trp187 is highly conserved 
in all NS1 protein of influenza A virus. Therefore, two mutant NS1-ED(s) were constructed 
with Trp187 converted to alanine and phenylalanine respectively.   
          Both recombinant, His tagged, effector domain mutants (W187A and W187Y) can be 
expressed in good yield from E. coli (~10 mg/ liter of cell culture). The multimeric state of the 
NS1-ED mutants was estimated by gel filtration. As shown in figure 5.11, both W187A and 
W187Y mutant proteins eluted in a volume equivalent to the size of a monomer. The SDS-
PAGE analysis showed that the denatured wild type and two mutant proteins all exhibited the 
identical mobility, see figure 5.14.   
          A screen of crystallization conditions showed that both W187A and W187Y mutants 
form diffraction quality crystals in the same condition.  Both types are orthorhombic with space 
group P212121. The cell constants for W187A mutant is a = 47.78, b = 48.19, c =154.59Å. The 
W187Y mutant has a slight larger unit cell, a = 48.0, b = 60.24, and c = 132.66 Å. There are 
two molecules in the asymmetric unit, giving a Vm value of 2.78 Å3/Da for W187A mutant, 
and 3.0 Å3/Da for W187Y mutant.  X-ray data and refinement statistics for the two structures 
are shown in Table 5.4.  A section of the final 2Fo-Fc electron density map used for model 
construction is shown in Figure 5.15. 
          Following refinement, a Ramachandran plot of the W187A crystal showed 89.2% of 
residues to be in the most favorable region and 10.3% in the additionally allowed space. The 
refined structure includes 230 solvent molecules. The W87Y crystal had a Ramachandran plot 
with 87.3% of residues in the most favorable region and 12.7% in additionally allowed space. 






Figure 5.12: Alignment of the protein sequence of NS1A effector domain from influenza 




Figure 5.13: Superposition of the influenza virus A/Udorn/1997 NS1 effector domain (red 





Figure 5.14: SDS-PAGE analysis of wild type and mutant NS1A-ED. 
 
Data Collection W187A mutant W187Y mutant 
Wavelength (Å) 1.5418 1.5418 
Space group  P212121 P212121 
Cell dimensions   
   a, b, c (Å) 47.78, 48.19, 154.69 47.99, 60.24, 132.66 
Resolution (Å) (last 
shell) 
30 – 2.21 (2.21-2.29) 30 – 2.21 (2.21-2.29) 
Rmerge (%) (last shell) 3.7 (9.8) 4.8 (24.2) 
<I/σI> (last shell) 78.9 (23.9) 51.4 (6.0) 
Completeness (last shell) 99.3 (92.8) 99.0 (90.5) 
Redundancy 13.4 10.0 
   
Refinement   
No.reflections 17384 18310 
Rworking (last shell) 0.187 (0.202) 0.226 (0.295) 
Rfree (last shell) 0.233 (0.285) 0.258 (0.305) 
Average B factor for 
protein atom (Å2)  
29.4 37.9 
R.m.s deviation from 
ideality 
  
   Bond lengths (Å) 0.010 0.010 
   Bond angles (°) 1.138 1.190 
 








Figure 5.15: Electron density for the (a) W187A and (b) W187Y mutant of NS1A effector 
domain. (a) This is a section of a 2F0-Fc map contoured at 1σ to show the exposed CPSF30 
binding pocket. (b) This is a section of a 2F0-Fc map contoured at 1σ to show the interface of 
the ED dimer due to crystallographic packing. 
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          The structures of the mutant NS1-ED, including W187A and W187Y, show an α-helix β-
crescent fold generally identical to that of wild type protein (Xia, Monzingo et al. 2009). As 
shown in figure 5.16, a superposition of the mutant ED with wild type ED gives an rms 
distance between 123 Cα atoms of 0.16Å and 0.39Å for W187A mutant and W187Y mutant 
respectively.  
          Although both mutants of NS1-ED behave as  monomers in solution, based on 
chromatographic properties, the asymmetric unit in both crystals  has two molecules. The two 
molecules of the W187Y mutant form a similar dimer to the wild type NS1-ED. As shown in 
figure 5.17a, the main interaction for this noncrystallographic dimer formation appears to be the 
pseudo-symmetrical insertion of Tyr187 phenol group into the hydrophobic F2F3-binding 
pocket of its dimer partner. This pocket is located at the base of long central helix, and formed 
by the side chain residues Lys108, Lys110, Ile117, Gln121 and Val180. Superposition of the 
W187Y mutant dimer and wild type NS1-ED dimer a revealed similar dimer interface, see 
figure 5.18a. The phenol group of the mutant protein Tyr187 lies in the same plane as the 
indole ring of wild typeTrp187 (Figure 5.18b). The hydroxyl end of phenol group shifts 10° 
toward the edge of the hydrophobic pocket of its dimer partner as compared to the orientation 
of indole ring. As phenylalanine is 30% less hydrophobic than tryptophan based on the 
hydrophobicity index of amino acid measured at pH7.0, there is certainly less attraction force 
of this hydrophobic interaction. Because W187Y mutant exits as a monomer in solution, this 
dimer interaction observed is probably very weak and be supported by other crystal packing 
interactions. In contrast, the two molecules of W187A form a different dimer than the wild type 
and W187Y mutant.  Illustrated in figure 5.17b, the hydrophobic F2F3-binding pocket is 
exposed to the solvent in the W187A mutant.  
          CPSF30 contains five C3H zinc finger repeats, from which the second and third finger 
repeats (F2F3) alone are sufficient for efficient binding to NS1A. (Barabino, Hubner et al. 
1997; Twu, Noah et al. 2006). To see if the two mutant NS1A-EDs are  able to bind CPSF30 or 
not, we expressed GST fusions of the N-terminal 145 residues of CPSF30, which includes the 
first four zinc finger repeats, in bacteria and used this GST fusion in pull-down assays with 
wild type and mutant NS1-EDs. As expected, the GST-CPSF30(1-145) can bind wild type 








Figure 5.16: Superposition of wild type effector domain with W187Y and W187A mutant 
effector domains: (a) overview and (b) detailed view of residue 187. The Cα trace of wild type 
effector domain is shown in red bonds, the Cα trace of W187Y mutant effector domain is shown 
in blue bonds, and that of W187A mutant effector domain is shown in grey bonds. The side 
















Figure 5.17: The crystallographic dimer interface for (a) W187Y and (b) W187A mutant NS1-
effector domain.  A space filling model of crystallographic monomer A reveals a distinct, 
largely hydrophobic pocket that has evolved to bind aromatic residues from the F2F3 domain 
of CPSF30. Here this pocket is filled by the Y187 of crystallographic monomer A of W187Y 







Figure 5.18: Superposition of the dimer interface of wild type NS1-ED with W187Y mutant 
ED: (a) overview and (b) detailed view of residue 187. One monomer was displaced in space-
filling mode, while the other monomer is shown in ribbon, with the wild type in red ribbon and 
the W187Y mutant in blue ribbon. 
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in the elution fraction, corresponding to the 43 kD GST-CPSF30(1-145), the 16kD NS1-ED 
and the 26kD GST protein. The expression of GST alone is probably due to a misreading of the 
stop condon or the falling off of the ribosome at the end of GST expression. This leaky 
expression of GST has been observed in the production of other GST fusion proteins in the 
laboratory. The negative control indicates that NS1-ED alone is not trapped in the glutathione 
affinity column. To exclude the possibility that GST itself might interact with NS1-ED, we also 
conducted a pull-down assay with purified GST protein. As shown in figure 5.20, GST did not 
bind NS1-ED. In other words, GST did not contribute to the interaction observed between the 
GST-CPSF30(1-145) and NS1-ED. The GST-pull down assay of mutant NS1-ED(s) showed 
that both mutants are able to bind GST-CPSF30(1-145), see figure 5.21. The binding of 
CPSF30 to W187A mutant might be weaker than that to W187Y mutant, but the conversion of 
tryptophan to alanine did not abolish the interaction between them. It’s very likely that the 
W187Y mutant has the same binding affinity toward CPSF30 as does the wild type protein. 
          In conclusion, we have engineered a W187Y mutant of NS1-ED, which behaves as a 
monomer in solution but is still able to binding CPSF30 with similar binding affinity as the 
wild type protein. This mutant may be a better target for a HT screening assay since the binding 
pocket is more accessible to potential inhibitors. 
5.3.4 NS1A “full length” (residue 1 -205) mutant  
          Exhaustive crystal screening has been conducted for the N-terminal GST tagged 
NS1A(1-215) fusion protein, but no useful crystallization condition has been identified. Our 
initial goal was to analyze the structure of this GST fusion protein, since the GST-NS1A(1-215) 
has been chosen as the screening target for the HT FP assay.  Such a structure would be very 
helpful for virtual screening and rational lead optimization.  
          The recent X-ray structure of R38A-K41A double mutant of full length NS1A from an 
H5N1 strain (A/Vietnam/1203/2004) revealed new insights into the dimer interaction between 
the N-terminal RNA binding domain and the C-terminal effector domain (Bornholdt and Prasad 
2008). It turns out that the two domains of each NS1A molecule separately interact with their 
respective domains from the neighboring NS1A molecules, and form a chain of NS1A 
molecules with alternating dimers of RBD and dimers of effector domain. The authors 




Figure 5.19: SDS-PAGE analysis of binding of GST-CPSF30(1-F4) to wild type NS1-ED. 
Lane 1 is the protein standard marker; Lane 2 is the negative control to see if the effector 
domain will be trapped in the glutathione beads. Lanes 3 to  9 are  fractions of eluted complex 
from the column, they are fraction 2,3,7,5,6,4,8 (from left to right). Lane 10 is the purified wild 
type NS1-ED. 
 
Figure 5.20: SDS-PAGE analysis of binding of GST to NS1-ED. Lane 1 is the protein standard 
marker. Lane 2 to lane 4 are the eluted fractions of GST; and they are: fraction 2,3 and 4 (from 







Figure 5.21: SDS-PAGE analysis of binding of GST-CPSF30(1-F4) to W187Y and W187A 
mutant NS1-ED. Lane 1 is the protein standard marker; Lane 2 is the negative control to see if 
W187Y mutant ED will be trapped in the glutathione beads. Lanes 3 to 5 are the eluted 
fractions of GST-CPSF30(1-F4) and W187Y complex; they are fraction 2,3 and 4 (from left to 
right). Lane 6 is the purified W187Y mutant NS1-ED. Lane 7 is the negative control to see if 
W187A mutant ED will be trapped in the glutathione beads. Lanes 8 to10 are the eluted 
fractions of GST-CPSF30(1-F4) and W187A complex; they are fraction 2,3,4 (from left to 











tructure with dsRNA in the hollow central tunnel. This model explains why NS1A is able to 
sequester varying lengths of dsRNA in infected host cells. To explore  this model, we tested a  
46mer dsRNA with NS1A(1-205) and GST-NS1A(1-215) respectively by fluorescence 
polarization. As shown in figure 5.22, the FP signal reached its plateau once the concentration 
of GST-NS1A(1-215) was above 2 μM. Interestingly, the FP signal continuously increases 
when the concentration of NS1A(1-205) was tested. Judging from the binding curve of 
NS1A(1-205) to dsRNA, it seems there are multiple events going on.  First, the 46mer dsRNA 
recruits NS1A(1-205) dimer from the solution; then, incoming NS1A molecules gradually form 
a chain along the dsRNA. For the GST fusion protein, the N-terminal GST tag appears to 
prevent the formation of alternating dimers and the titration curve reaches a plateau as the 
structure self limits. The binding of GST-NS1A(1-215) to 46mer dsRNA give a Kd around 0.35 
μM, which is comparable to the binding affinity of that to 16mer dsRNA (0.16μM). Our FP 
assay with 46mer dsRNA suggests that the model Prasad proposed is probably correct.  
          The N-terminal 205 residue protein of NS1A from A/Udorn/72 was also cloned into a 
His-tag vector pNIC, with  Arg38 and Lys41  both converted to alanine; this should prevent 
aggregation seen with the wild type protein (Bornholdt and Prasad 2008). The mutant protein 
was expressed in bacteria with good yield, and behaved as a homo dimer as estimated by gel 
filtration, see figure 5.23. Interestingly, once the Trp187 was also converted to alanine, the 
triple mutant (R38A-K41A-W187A) behaved as a monomer in solution (Figure 5.23). That 
indicates that the Trp187 is not only essential for the dimerization of effector domain, but is 
also a major force in the dimerization of the whole protein. We have tried crystal screening for 
the R38A-K41A double mutant and the R38A-K41A-W187A triple mutant of NS1A(1-205), 











Figure 5.22: FP signal of 5’-fluorescein labeled 46mer-dsRNA binding to the GST-NS1A(1-
215) and NS1A(1-205). 
 
 
Figure 5.23: HPLC profiles of R38A-K41A mutant (red line) and R38A-K41A-W187A mutant 
(blue line) of NS1A(1-205). Absorbance was measure at 280nm, and the gray dashed lines 
indicate the position of protein standards. From left to right, they are: thymoglobulin (670kD), 
bovine gamma globulin (158kD), chicken ovalbumin (44 kD), equine myoglobin (17kD) and 
Vitamin B12 (1.35kD).  
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          MobA is an enzyme catalyzing the conjugative mobilization of the plasmid R1162, a 
mobilization plasmid that transfers drug resistance genes across species. Although it is clear 
that MobA catalyzes a single strand cleavage of the plasmid DNA at the oriT site by forming a 
covalent bond between Tyr25 and 5’ phosphate of the nicked strand, the overall reaction 
mechanism is still unknown. This dissertation describes work to further investigate some details 
of this important and unusual enzyme mechanism, including the role of metallic cations.  
           The X-ray structure of the N-terminal 184-residue relaxase domain, called minMobA, 
has been used to guide the mutagenesis studies aimed at identifying key amino acids for the 
transesterification mechanism. The DNA nicking assay results from a series of minMobA 
mutations revealed no obvious candidate for the role of a general base to polarize the active site 
Tyr 25.   On the other hand, MobA is a very unusual enzyme, in that it carries out a single 
reaction turnover. The nicking reaction is not the rate-limiting step compared with DNA 
transfer during bacteria conjugation, which means the activation of the tyrosine nucleophile is 
not mechanistically critical. Therefore, it is not biologically important for MobA to enhance the 
rate of transesterification. 
          In addition, the effects of different divalent metallic cations on minMobA were 
investigated by means of circular dichroism and protein denaturation experiments. The results 
suggest that divalent metallic ions may affect the conformations of active site residues of 








Chapter 6: Introduction 
 
 
6.1 Overview of horizontal gene transfer 
          Horizontal gene transfer (HGT), also known as lateral gene transfer, refers to the transfer 
by and organism of its own genetic materials to another organism which is not the offspring of 
that organism. By contrast, vertical gene transfer occurs when parental traits pass to  progeny 
by sexual reproduction.  
          HGT is particularly common among bacteria, and is thought to be the major factor in 
accelerating the rate of bacteria evolution. HGT is also a significant cause of increased drug 
resistance. Although bacteria can develop drug resistance by mutation of existing genes, it is far 
more common for resistance to be spread by transferring of existent resistant genes (Tenover 
1995; Davies 1996; Wright 2007). Additionally, by HGT, genetic materials can be exchanged 
promiscuously between a broad spectrum of bacteria, archaea and eukarya, including plants, 
fungi and mammalian cells. Thus, it significantly influences both our health and the 
environment, and receives centered attention from a wide range of scientific disciplines. 
          In prokaryotes, there are three common mechanisms for horizontal gene transfer: 
transformation, transduction and conjugation (Thomas and Nielsen 2005). In transformation, a 
cell is genetically altered by uptake, recombination and expression of foreign genetic materials. 
This stable genetic change, brought by transformation, could gain new functions for the cell or 
lose the activity of the gene which is replaced due to the recombination (Griffith 1928; Avery 
and Macleod 1944). The state of being able to take up exogenous genetic materials (DNA or 
RNA) from the environment is referred to as competence. Bacteria which are naturally 
competent to act as recipients have been discovered to exist in several genera including 
Acinetobacter, Bacillus, Neisseria, haemophilus, Pneumococcus and Pseudomonas (Lorenz and 
Wackernagel 1994). In addition, some bacteria can become competent artificially. In other 
words, cells can be made passively permeable to exogenous genetic materials by laboratory 
procedures, such as electroporation or chemical treatment. (Droge, Puhler et al. 1998). 
          Transduction is a process involving transfer of foreign genetic materials from one 
bacterium to another with the help of phage, virus or virus vector. Transduction can occur 
through either the lysogenic cycle or the lytic cycle (Parkinson 1975). In a lysogenic cycle, the 
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phage or virus chromosome is integrated into the host bacterial chromosome, and thus can be 
transmitted to daughter cells at subsequent cell divisions. In lytic cycles, usually induced by 
UV radiation, lysis of the infected host cell occurs, and results in the release of new phage 
particles or progeny viruses. Because viruses can transfer genetic materials across species 
boundaries, transduction by virus can occur in eukaryotic cell as well. In addition, the HGT by 
viruses is essential for evolutionary progress (Sorensen, Bailey et al. 2005; Thomas and Nielsen 
2005).  
          Unlike transformation and transduction, conjugation is a mechanism involving 
unidirectionally transfer of genetic material between bacteria through direct cell-to-cell contact. 
During conjugation, a piece of DNA from one bacterium (donor) is copied and then transferred 
to another bacterium (recipient) via a temporary connection. In nature, the genetic information 
transferred is often beneficial to the recipient. Those benefits may include resistance to new 
antibiotic, tolerance to new xenobiotic, or the ability to usee a new metabolite. The process of 
conjugation is facilitated by diverse mobilization plasmids and conjugative transposons, and it 
constitutes the major route for HGT (Sorensen, Bailey et al. 2005; Thomas and Nielsen 2005). 
Remarkably, conjugation can occur not only in one species but also between species, in some 
cases, from bacteria to fungal, plant or mammalian cells(Stachel and Zambryski 1986; Droge, 
Puhler et al. 1998; Waters 2001). These properties make conjugation an important source of 
genetic plasticity. 
6.2 Bacteria conjugation 
          Although bacterial conjugation is a highly specific process, the mechanism of 
conjugative transfer appears to be remarkably conserved across a broad spectrum of plasmids in 
both Gram-negative and Gram-positive bacteria. It generally involves the following steps: (1) 
establishment of direct cell-to-cell contact; (2) occurrence of some kind of signal that transfer 
should begin; (3) relaxosome formation at the origin of transfer; (4) nicking of one DNA strand 
at the nic site with the nickase enzyme covalently attached to the 5’ end of DNA; (5) unwinding 
of the cleaved strand from the duplex plasmid; (6) transfer of the cleaved strand in the 5’ to 3’ 
direction to the recipient cell; (7) recircularization of the transferred strand; (8) synthesis of the 
complementary strand in both the donor and recipient cell (Lorenz and Wackernagel 1994). A 
simplified scheme of bacteria conjugation is illustrated in figure 6.1. The relaxosome is a 











plasmid transfer during bacteria conjugation. The direct cell-to-cell contact during conjugation 
is mediated by a specialized multiprotein-complex, called conjugation apparatus. In Gram-
negative bacteria, this physical contact is established by sex pili, a hair like appendage found on 
the surface of bacteria. Whereas, for the majority of Gram-positive bacteria, the means to 
achieve this direct cell-to-cell contact still remains to be identified.  
6.2.1 Conjugation in Gram-positive bacteria 
          In 2000, Zechner and Zatyka  divided conjugative plasmids from Gram-positive bacteria 
into four groups: broad host-range plasmids, pheromone responding plasmids, conjugative 
transposons and plasmids from mycelium-forming streptomycetes (Grohmann, Muth et al. 
2003). The broad host-range plasmids are exemplified by pSK41 family plasmids and pIP501 
plasmid (Allignet and El Solh 1999; Steinmetzer, Kuhn et al. 2002). The pSK41 family 
plasmids were identified in both S. aureus and coagulase-negative staphylococci (Firth, 
Ridgway et al. 1993). They encode resistance genes against neomycin, gentamicin, tobramycin, 
kanamycin, and some antiseptics and disinfectants (Grohmann, Muth et al. 2003). The pIP501 
plasmid, originally isolated from streptococcus agalactiae, encodes resistance genes against 
chloramphenicol and erythromycin (Evans and Macrina 1983). The plasmid can be conjugated 
into Streptococcus, Staphylococcus, Clostridium, Listeria and Pediococcus species. The pAD1 
plasmid isolated from Enterococcus faecalis is a representative of pheromone responding 
plasmids. It is highly conjugative and encodes multiple antibiotics resistance genes, such as 
erythromycin, tetracycline, streptomycin and kanamycin (Nakayama and Suzuki 1997; Spataro, 
Toda et al. 1997). Conjugative transposons combine features of transposons, plasmids and 
bacteriophages, in sense that they excise from and integrate into DNA. They are very common 
among the Gram-positive streptococci and enterococci. The 18kb Tn916 is the most 
extensively studied conjugative transposon; it encodes a resistance gene against tetracycline 
(Marra and Scott 1999; Marra, Smith et al. 1999). During the life cycle of streptomyces, the 
bacteria interact conjugally to promote the transfer of their own DNA. It was reported that all 
plasmids from mycelium-forming streptomyces are conjugative (Tiffert, Gotz et al. 2007). 
Among them, the pIJ101 has been used as a model system to study conjugative plasmids in this 
category. Originally purified from Streptomyces lividans, pIJ101 uses a rolling-circle 
replication (RCR) mechanism, a process that involves a Rep protein and a double-strand origin 
(DSO) of replication. The efficient transfer of pIJ101 is dependent on both the membrane 
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protein encoding Tra gene, and a cis-acting transfer locus (Servin-Gonzalez 1993; Dyson and 
Evans 1998). In 2003, Espinosa proposed to put this type of multicellular bacteria conjugation 
mechanism into a separate category, in contrast to the conjugation mechanism taking place in 
unicellular gram-positive bacteria (Grohmann, Muth et al. 2003).  
6.2.2 Conjugation in Gram-negative bacteria 
          Compared to Gram-positive bacteria, conjugation in Gram-negative bacteria has been 
studied in great detail over the last decades, and most thoroughly through the analyses of 
antibiotic resistance plasmids of Gram-negative bacteria. The plasmids involved in conjugative 
transfer can be categorized into two classes: the self-transmissible plasmids and the mobilizable 
plasmids.   
6.2.2.1 Self-transmissible plasmid 
          Conjugative plasmids are considered to be self-transmissible if they encode a self-
sufficient conjugative transfer system. On the basis of genetic relatedness and pilus structure, 
there are four classes of self-transmissible plasmids: IncF-like plasmids, IncP-like plasmid, Ti 
group plasmids, and IncI-like plasmids (Reddy, Battisti et al. 1987; Waters 1999). The plasmids 
in the first two groups appear to account for most of the drug resistance gene transfer. Here, 
“Inc” is an abbreviation for incompatibility, which is the inability of two plasmids to be 
propagated stably in the same cell line. Incompatibility is a manifestation of relatedness, in 
other words, the sharing of common elements involved in plasmid replication and control. 
          The first group is the IncF-like plasmids. Being a representative of that family, IncF F 
plasmid is the prototype for conjugative plasmids, and is usually referred to as F factor or sex 
factor. In a given bacterium, there can only be one copy of the F plasmid. The 100kb-length F 
plasmid was originally obtained from a host E. coli K-12 strain (Finlay, Frost et al. 1986). It has 
an origin of replication (oriV), an origin of transfer (oriT), a Tra and a Trb locus, which 
together are about 33 kb long and contain about 40 genes (Taylor, Harrison et al. 1990). When 
conjugation is initiated, a relaxase enzyme called TraI creates a nick in one strand of the F 
plasmid at oriT. The cleaved strand is unwound from the duplex plasmid, and then transferred 
in the 5’ to 3’ direction to the recipient bacterium. Once inside the recipient bacterium, the 
transferred strand is recircularized. The complementary strand is synthesized in the donor and 
recipient bacterium, both of which are then capable of plasmid transfer (Finlay, Frost et al. 
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1986; Saul, Spiers et al. 1989). The entire process of F plasmid transfer takes approximately 5 
min to complete (Ippen-Ihler and Minkley 1986).  
          The second group consists of the IncP-like plasmids, including IncP, IncU and IncW 
(Frost, Ippen-Ihler et al. 1994). They are believed to be the most widely distributed broad-host-
range plasmids carrying multiple antibiotic resistance genes. The 60kbRP4 plasmid is the 
prototype of IncP plasmids. Conjugative functions of plasmid RP4 are encoded in two distinct 
regions on the plasmid known as Tra1 and Tra2. Those Tra regions were originally identified 
and evaluated by deletion analysis (Lessl, Pansegrau et al. 1992). There are three genes in the 
Tra1 operon: the primase, the relaxase, and the leader operon. The function of the RP4 plasmid 
can be divided into two parts: DNA transfer and replication (Dtr),  and  mating pair formation 
(Mpf)  (Pansegrau, Lanka et al. 1994). All Dtr genes locate exclusively in Tra1, and function in 
the initial relaxosome formation. The Mpf system is the establishment of direct cell-to-cell 
contact between a donor and a recipient cell during conjugation. The Mpf genes map mostly in 
Tra2 region, and include one Tra1 gene, traF. Transfer of genetic material is thought to be 
initiated via TraI-piloted single-stranded intermediates (Thorsted, Macartney et al. 1998). 
Coated with TraC protein, the protein nucleotide complex is transported through a channel or 
pore at the mating bridge between the donor and the recipient cells.  
          The IncW plasmids are the smallest self-transmissible plasmids naturally found in Gram 
negative bacteria (Bolland, Llosa et al. 1990), but are in the IncP family. The 33kb-length 
plasmid R388 is the prototype of IncW plasmids. Because of its small size and broad host 
range, R388 has been a good example for the analysis of the genetic organization of 
conjugative plasmid (Llosa, Bolland et al. 1991). R338 has the shortest Dtr region, which 
consists of one OriT and three genes (trwA, trwB and trwC). TrwA is a nic-cleavage accessory 
protein that binds to sites around OriT and enhances the relaxase activity. TrwB is a typical 
integral membrane protein that couples the relaxosome to the nucleotide transport system. 
TrwC is the actual relaxase responsible for both double strand nucleotides unwinding and DNA 
nicking. The Mpf region is composed of 10 genes, responsible for mating pair and DNA-
transport complex formation. Another characteristic of IncP-like plasmids is that they contain 
several regions which are sites for interaction with other transfer systems. For example, the osa 
region interferes with the DNA transfer complex of the Ti plasmid (Llosa, Bolland et al. 1994). 
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          The third group, similar to the IncP-like plasmid but with a different pilus structure, is 
referred to as the Ti plasmid group, including IncX and IncN. The 38kb-length plasmid R6K is 
the prototype of IncX plasmid (Bastia, Germino et al. 1981). It contains three origins of 
vegetative replication (a-oriV, b-oriV and g-oriV) and two antibiotic resistance genes 
(ampicillin and streptomycin). Both a-oriV region and b-oriV region contain a palindromic 
sequence, which is involved in the initiation of replication. When used in vitro, all three ori 
sites are used at equal frequency. Interestingly, there two specific nic-cleavage sites observed in 
the vicinity of a-oriV and b-oriV regions. Those properties indicate a coupled regulatory system 
for replication and conjugation (Kolter and Helinski 1982; Shafferman, Kolter et al. 1982; 
Stalker, Kolter et al. 1982). The 51kb-length plasmid R46 is the prototype of IncN plasmid. It is 
originally isolated from Salmonella typhimurium, and carries antibiotics resistance genes to 
ampicillin, tetracycline, streptomycin, and sulfonamides; it also confers protection against UV 
induced damage (Waleh and Stocker 1979; Attfield and Pinney 1982). The specific relaxase 
encoded by R46 is TraI, which is able to catalyze DNA-strand transfer reactions with specific a 
nic sequence.  R46 also encodes another accessory protein, TraJ, which helps unwind super 
coiled dsDNA. Together with TraK and TraH, those proteins form the relaxation complex 
(Zatyka, Jagura-Burdzy et al. 1994). 
          The forth self transmissible group is the IncI-like plasmids, including IncI, IncB, and 
IncK (Droge, Puhler et al. 1998). They have a unique pilus structure compared to the other 
three groups (Komano, Kim et al. 1994). In addition, the organization of Tra genes, their 
specificity and function are quite distinct from the other groups. Plasmid ColIb-P9 is the 
prototype of IncI plasmid. It is known to encode two morphologically distinct types of pilus: a 
thick rigid one and a thin flexible one (Howland and Wilkins 1988). The thick pilus supports 
conjugation on a semi-solid surface; while the thin pilus allows conjugation occur in liquid 
media. The variation of thin pilus in this plasmid group affects the conjugation efficiency of 
different enterobacteria in a liquid environment, possibly by changing the ability of the pilus to 
recognize the surface of different recipient cells. The core region of ColdIb plasmid also 
includes a DNA primase gene (sog) and exclusion determinant (exc) (Howland, Rees et al. 
1989; Hama, Takizawa et al. 1990). The sog gene encodes two sequence-related polypeptides 
with the N-terminal domain having DNA primase activity and C-terminal domain facilitating 
transfer of single-stranded DNA following the initiation of transfer at oriT site.  
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6.2.2.2 Mobilizable plasmids 
          Conjugative plasmids are considered to be mobilizable if they are not self-transmissible, 
but can be transferred when a helper self-transmissible plasmid is also present in the donor cell. 
In other words, mobilizable plasmids carry the genetic information necessary for relaxosome 
formation, but don’t encode any genes required for the establishment of direct cell-to-cell 
contact between a donor and a recipient cell. Therefore, the success of conjugative transfer 
depends on the co presence of a self-transmissible plasmid. Mobilizable plasmids usually carry 
an origin of transfer (oriT) and a mobilization region (mob) encoding specific relaxase 
components. Thanks to the development of DNA sequencing technology, the number of known 
mobilizable plasmids increased rapidly and sequence similarity has replaced the traditional 
incompatibility testing in classifying these plasmids. In 2004, Francia and Cruz classified 
mobilizable plasmid into four main super families based on the amino acid sequence similarity 
of their relaxases (Francia, Varsaki et al. 2004). Those plasmids family includes: MOBQ family, 
ColE1-superfamily, pMV158-superfamily and CloDF13 family. 
          The  MOBQ family shares a common domain structure consisting of an N-terminal 
relaxase domain and a C-terminal primase domain. It is believed that the linkage between both 
domains promote the initiation of complementary strand synthesis in the recipient cell. The 9kb 
plasmid RSF1010 is the archetype of this family (Guerry, van Embden et al. 1974). It belongs 
to the incompatibility group Q, and encodes antibiotics resistance genes to streptomycin and 
sulfonamides. RSF1010 is known for its efficiency of mobilization with the helper plasmids 
from different incompatibility groups, such as IncP, IncI and IncX (Willetts and Crowther 
1981). The RSF1010   enables its replicon is able to interact with the replication machineries of 
a variety of hosts. The replication of RSF1010 can proceed either unidirectionally or 
bidirectionally from a unique oriV with the help of three plasmid-specified proteins, RepA, 
RepB, and RepC, which function as a DNA helicase, primase, and initiator protein, respectively 
(Scholz, Haring et al. 1985; Scherzinger, Kruft et al. 1993). The RepA protein is hexamer of 
30kDa. It has two enzymatic activities: a single-stranded DNA-dependent ATPase and also a 
DNA helicase. The RepB gene encodes two polypeptides of 36kDa and 78 kDa by using two 
alternative start codons and the same stop codon. The 36kDa RepB is a novel type of DNA 
primase by which it does not require ribonucleotide triphosphates for the priming reaction. The 
31kDa RepC protein is a dimer, and binds specifically to the direct repeats in the oriV region. 
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          The second mobilizable family is the ColE1-superfamily, which is best represented by 
the ColE1 plasmid (Scholz, Haring et al. 1985). The 6 kb ColE1 is a multicopy plasmid, and its 
replication requires only proteins from its host bacterium E. coli. It can replicate in E. coli even 
in the presence of protein synthesis inhibitors, such as chloramphenicol, which makes it perfect 
for the construction of bacterial cloning vectors (Engleberg, Cianciotto et al. 1988; Inoue and 
Uchida 1991; Lin-Chao and Cohen 1991). Because of these characteristics, ColE1 have been 
the subject of extensive study and used as vectors of gene therapy (Engleberg, Cianciotto et al. 
1988). ColE1 can also be mobilized by members of many incompatibility groups, like IncP, 
IncF and IncW. The replication of ColE1 plasmid is exclusively unidirectional and relies only 
on host proteins, partially because the plasmid does not encode any enzyme for replication 
(Scholz, Haring et al. 1985). In ColE1 DNA, there is a 600bp region 500bp upstream of oriV, 
which is necessary for initiation of replication. The promoter is also located in this region, and 
is responsible for initiation of the replication primer RNA (called RNAII). The ColE1 
mobilization region is composed of five genes (MbeA, MbeB, MbeC, MbeD and MbeE), of 
which the first four are essential for plasmid mobilization. The MbeE doesn’t play any essential 
role during bacteria conjugation.  
          The third family, is the pMV158-superfamily, contains mobilization plasmids from both 
Gram-negative and Gram-positive bacteria. The 5.5kb-length plasmid pMV158 is the prototype 
of this family (Burdett 1980). It is non-conjugative, but can be mobilized by conjugative 
plasmids of the pIP501/pAMβ1 family as well as by helper plasmids from different 
incompatibility groups, such as IncP, IncF and IncW (del Solar, Diaz et al. 1987; Priebe and 
Lacks 1989). It is known that the relaxase of pMV158 is only encoded by the oriT region and 
MobM.  The pMV158 encoded MobM, also called cladeA, cleaves pMV158 DNA at the 
cleaves the 5P-GpT-3P dinucleotide between co-ordinates 3591 and 3592 within the plasmid 
oriT site, then forms a covalent adduct with the target DNA via Tyr49 (Burdett 1980). The 
DNA region surrounding the oriT of pMV158 is conserved among a group of rolling circle 
replication (RCR) plasmids in Gram-positive bacteria, including an inverted repeat (IR) with 7 
to 10-nucleotides long stem and a six-nucleotide long loop. The nic site is located in the loop of 
the inverted repeat. The cleavage reaction is dependent of the presence of divalent cations, but 
not the presence of additional proteins. Genetic experiments proved that disturbing or removal 
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the oriT region of MobM completely abolished the mobilization (Guzman and Espinosa 1997; 
Moscoso, Eritja et al. 1997).  
          The forth plasmid family is the relatively small sized ColDF13 family. The 9kb plasmid 
ColDF13 is the archetype of this family. It originates from Enterobacter cloacae, but is also 
stably maintained in E. coli (Nijkamp, de Lang et al. 1986). Like all plasmids in the pMV158 
super family, ColDF13 can be mobilized by helper plasmids from different incompatibility 
groups, such as IncP, IncF and IncW (Cabezon, Sastre et al. 1997). Unlike other mobilization 
plasmids, mobilization of CloDF13 does not require the presence of coupling protein encoded 
by the helper conjugative plasmid but only  the Mpf gene products (Nunez and De La Cruz 
2001). CloDF13 encodes two proteins: the 61kDa MobB and the 24kDa MobC. The MobC 
protein is a relaxase; while the MobB protein is made to enhance the relaxase activity of MobC. 
Interestingly, the MobB and MobC protein of cloDF13 are quite different from other 
characterized plasmid Mob proteins in both sequence and biochemical properties (van Putten, 
Jochems et al. 1987; Francia and Clewell 2002). For example, Cruz et al found that both the 5' 
and 3' ends of the nic site are not blocked during nicking process. In other words, the relaxase 
of cloDF13 process the cleavage reaction quite differently from the other Mob plasmids. In all 
these respects, CloDF13 seemed to be rather atypical mobilizable plasmid, which deserved to 
be classified as a separate group (Nunez and De La Cruz 2001).  
6.3 R1162  
         Work in this dissertation focuses on the mobilizable plasmid R1162; it belongs to the 
MOBQ family of the mobilization plasmid. It is almost identical to plasmid RSF1010, except 
that it is isolated from Pseudomonas aeruginosa rather than Escherichia coli (Meyer, Hinds et 
al. 1982; Meyer, Lin et al. 1985). The R1162 plasmid is the archetype for the incompatibility 
group Q (IncQ), which are characterized by their broad host range and relatively small size 
(Rawlings and Tietze 2001). The plasmid encodes resistance to the antibiotics streptomycin 
(strA and strB) and sulfonamide (sulII). It also contains an origin of transfer (oriT), and 
encodes 3 proteins: mobA, B and C, which are all required for plasmid mobilization, see figure 
6.2.  
          The oriT DNA sequence of R1162 consists of  a 35 base oligonucleotide, which was 
mapped by Becker and Meyer and shown in Figure 6.2 (Becker and Meyer 2002; Becker and 







Figure 6.2: The organization of mob genes of R1162 (in kilobases) and the nucleotide sequence 

















a 12 base core region is highly conserved. The 23-base oligonucleotide 5’ to the core region is 
an imperfect inverted repeated (IR), which is commonly found in the R1162 family of 
plasmids. However, the sequence and size of the repeats of the R1162 family varies 
considerably (Becker and Meyer 2000; Becker and Meyer 2002). For R1162, the presence of 
this inverted repeat significantly enhances the binding by MobA, although the core and inner 
arm of IR is sufficient for initiation. Interestingly, Mob A can  bind mutated variants of oriT to 
MobA can be tolerated by complementary mutation at IR region, which suggested that the 
sequence at IR serves as more of a structural role (Parker, Zhang et al. 2002; Zhang, Zhang et 
al. 2003; Parker and Meyer 2007). The nic site is 8bp from the inverted repeat as shown.  
          The Mob proteins assemble at oriT to form a complex called the relaxosome (Meyer, 
Hinds et al. 1982). The most important protein of the relaxosome is the 78 kDa (709 residues) 
MobA protein which has two functional domains. The C-terminal domain encodes a 43 kDa 
protein, called primase, which can also be expressed separately. Both forms of primase have 
been found in host cells. The function of the primase is to lay down primers within oriV, which 
can be further extended by host cell DNA polymerases to replicate the plasmid.  
 The N-terminal domain is a relaxase consisting of about 250 amino acids. It cleaves 
one of the DNA strands within oriT, and forms a covalent adduct with the 5’ end. Tyr25 of the 
N-terminal domain has been identified to be the critical residue (Becker, 2002). It carries out a 
nucleophilic attack on the phosphodiester bond at the nick site, and forms a phosphodiester 
bond with the 5’ end. Once the covalent adduct is formed, the complex is recognized by a T4S 
system, and the cleaved strand is unwound from its complement strand, then transferred in the 
5’ to 3’ direction to the host cell. When the transfer is completed, the MobA protein carries out 
a second transesterification reaction which rejoins of the two ends and releases the protein. 
Once the circular plasmid DNA is formed in the host cell, a complementary strand is 
synthesized in the new cell by the host polymerase. MobA complex is then released (Becker, 
2002).  
          The MobB and MobC are accessory proteins of relaxosome complex. MobB, a 19kD 
protein, is found to stabilize the assembly of MobA and MobC at oriT both in vivo and in vitro 
(Perwez, 1996; Zhang, 1997). It was reported that the frequency of mobilization of R1162 
decreases two to three orders of magnitude in the absence of MobB (Zhang, 2003),  providing 
strong evidence that the function of MobB is to stabilize the relaxosome complex. Parker and 
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Meyer (2007) proposed that MobB inserts into the cell membrane and thus stabilizes the 
association between the relaxase and the type IV transfer apparatus. The function of 10kD 
MobC protein is to enhance strand separation at the site of cleavage, thereby facilitate the 
strand cleavage by MobA. It is reported that multiple copies of MobB and MobC join with 
MobA to assemble on oriT (Zhang, 2003).  While, it is still unknown that how relaxosome is 
assembled. Interestingly, not all mobilization plasmids have homologs of MobB or MobC.  For 
example the 371 residue pSC101 from E.coli is a homolog of the relaxase domain of MobA 
form R1162, but the plasmid does not code for any homologs of MobB or c (Meyer, 2000). 
Obviously, the relaxase is the most important key to understand the mobilization process. 
          The X-ray structure of N-terminal 186 residue MobA (minMobA) was solved in our 
laboratory in 2007 (Monzingo, Ozburn et al. 2007). It consists of five antiparallel beta-sheets 
connecting by four helices lying on both sides of the sheet. The critical residue tyr25 lies on the 
first helix on the front side of the molecule, close to a metal ion. As also shown in figure 6.3, 
this metal ion is bound on the front side of the beta sheet, and chelated by His112, His120 and 
His122. Interestingly, minMobA share a common fold with two other relaxase enzymes, TraI 
and TrwC (Grandoso, Avila et al. 2000; Datta, Larkin et al. 2003). TraI is from the self-
transmissible F factor plasmid, while TrwC is encoded by plasmid R338, which belongs to 
IncW plasmid family (Llosa, Grandoso et al. 1995; Llosa, Grandoso et al. 1996; Matson, 
Sampson et al. 2001; Street, Harley et al. 2003). Superposition of minMobA to the equivalent 
106 residue domain of TraI gives an RMS distance of 2.3 Å between alpha-carbon atoms. 
Similarly, superimpose of minMobA to the equivalent 293 residue domain of TrwC gives an 
RMS distance of 2.4 Å. The relaxase domains of all three proteins share same overall structural 
features and have same biological functions. All three proteins have both a catalytic tyrosine 
residue and an active site metal ion bound by three histidine residues (Grandoso, Avila et al. 
2000; Datta, Larkin et al. 2003). Although there are only 12% and 10% sequence identities of 
minMobA with TraI and TrwC respectively, the conserved structure and function imply that all 
three proteins may share a common ancestor.       
          A hypothetical model of minMobA bound to 33mer single stranded DNA in the stem-
loop conformation has been made in our laboratory, based on the DNA binding observed for 
TrwC, see figure 6.4. The 33mer DNA in this model is composed of a 23 base double stranded 




Figure 6.3: Active site of minMobA. Y25, H112, H120 and H122 are highlighted in stick 
mode; Mn2+ is labeled in red. 
 
Figure 6.4: Stereo image of the surface electrostatic potential of minMobA-33mer model 
complex. Electronegative charges are shown in red, and positive charges are shown in blue. 
The bound DNA is represented in a cartoon mode.  
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this region to reflect that of R1162. As expected, the negatively charged phosphate backbone of 
the 33mer is stabilized by a patch of positively charged amino acids on the protein surface. The 
binding characteristics of the interaction between MobA and the 33mer are in agreement with 
those deduced from experimental studies. For example, the model shows that only the first nine 
nucleotides at the base of the stem interact with protein. This is consistent with previous studies 
that only seven bases of the inner arm of oriT make specific interactions with MobA. With this 
model, it will be helpful for us to design mutagenesis experiments to assign roles to residues 
which are critical for substrate-binding or catalysis. 
6.4 Project goals 
6.4.1 Identify a potential active site base 
          The first goal of this project was to use our structural knowledge of minMobA to guide 
mutagenesis studies aimed at identifying key amino acids for the transesterification mechanism.  
We looked for the chemically interesting residues near Tyr25, which carries out the 
nucleophilic attack on the phosphate of G31 of OriT. It is possible that a carboxylate may 
function as base to deprotonate the Tyr25 hydroxyl and thereby increase its nucleophilicity.  
6.4.2 Analyze the role of minMobA active site metal 
          MobA is known to have a requirement for divalent cations, initially thought to be Mg2+, 
although Mn2+, Ca2+, or Ba2+ could substitute at lesser efficiencies (Scherzinger, Lurz et al. 
1992). However, the physiologically relevant metal for relaxase is still unknown.  It is uncertain 
if the metal is structural or catalytic in nature. To further explore the role of metal ion in 
mobA’s cleavage reaction, we will assess the ability of minMobA to cleave single-strand oligo 
DNA substrate, to bind ssDNA, and to change the circular dichroism spectrum in the presence 
of Ni2+, Mg2+, Zn2+, Mn2+ and Ca2+. 
6.4.3 Express and crystallize related MobA proteins 
          The third goal of this project was to grow useful crystals of a MobA oligonucleotide 
complex, and to crystallize other, related, MobA proteins. This effort involved several 
subprojects. (1): To visualize protein DNA interactions, different lengths of oriT DNAs were 
used to form complexes with the minMobA Y25F mutant enzyme. (2): The minMobA protein 
is able to carry out the initial DNA cleavage, but can not interact with T4SS in gene transfer. A 
longer version of MobA protein named MobA*, which is active in both nicking and transfer, 
was screened for crystallization condition. (3): Efforts were made to crystallize the 371 residue 
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pSC101 enzyme that is homologous to R1162. The pSC101 protein is fully functional in 































Chapter 7: Materials and methods 
 
 
7.1 Construction of various MobA plasmids 
          The minMobA-pTYB2, MobA*-pTYB2 and pSC101-pTYB2 plasmids were kindly 
provided by Dr. Richard Meyer. The 341 residue MobA* was PCR amplified with primers 
GACGACGACAAGATGGCGATTTATCACCTTACGGCG and GAGGAGAAGCCCGGTT 
TAACCTCCCGCAACTC. The product was cloned into pET-46 Ek/LIC (Novagen). The 
MobA* gene was also PCR amplified with primers CATGCCATGGATGGCGATTTATCACC 
TTACGGC and CCGCTCGAGACCTCCCGCAACTC. The product was digested with NdeI 
and Xhol restriction endonucleases, and cloned into pET28b plasmid DNA (Novagen) cleaved 
with NdeI and Xhol. The 371 residue pSC101 was PCR amplified with primers GGAATTCCA 
TATGGCATCCTATCATC and CCGCTCGAGTCGTGAGAATGACC. The product was 
cloned into pET28b plasmid DNA cleaved with NdeI and Xhol. The first 193 amino acid 
fragment of pSC101 was purified by first amplifying the DNA with primers 
GGAATTCCATATGGCATCCTATCATC and TCCCCCCGGGGTGCTGATACCGTTC. The 
product was digested with NdeI and XmaI restriction endonucleases, and cloned into pTYB2 
plasmid DNA (New England Biolabs) cleaved with NdeI and XmaI. The integrity of all cloned 
DNA(s) were confirmed by DNA sequencing. 
7.2 Site directed mutagenesis 
          Various mutations were introduced by site-directed methods, according to the Stratagene 
protocol (Stratagene). Around 50 ng of plasmid and 150 ng of each primer were combined with 
reaction buffer (20 mM Tris–HCl (pH 7.5), 8 mM MgCl2, 7.5 mM DTT, 50 μg/ml of bovine 
serum albumin (BSA)), 150 μM dNTP mix, 1 units of KOD Hot Start DNA Polymerase 
(Novagen), and deionized water to final volume of 50 μl. Primer sequences of minMobA 
mutants (Y25F, E74A, E74Q, E76A, E74A-E76A, E38A, H112A, H120A and H112A) and 
pSC101 mutants (Y22F, E73A and E75A) are shown in table 7.1. Reaction mixtures were 
further treated with 10 units of DpnI (New England Biolabs) at 37 °C for 2hrs. Then 1 μl of 
treated reaction mixture was transformed to E. coli DH5α competent cell. The presence of the 












































7.3 Protein purification 
          The protein purification procedure is the same for all genes cloned into and expressed 
from the pTYB2 vector. Escherichia coli K-12 strain ER2566 (New England Biolabs) 
containing the plasmid was grown overnight in broth medium (1% (w/v) tryptone, 0.5% (w/v) 
yeast extract, 0.5% (w/v) NaCl) containing ampicillin (100 μg/ml) at 37 °C. The cells were then 
diluted 1:100 in 4 × 0.5 l medium and grown to a cell density of approximately 4 × 108 per ml. 
IPTG was added to final 0.3 mM and the cells then grown overnight at 25 °C. Protein was 
purified according to a procedure developed by New England Biolabs. Briefly, cells were 
collected by centrifugation, resuspended in 50 ml column buffer (20 mM Tris (pH 8.0), 
500 mM NaCl, 1 mM EDTA) and disrupted in a French pressure cell. Cellular debris was 
pelleted by centrifugation at 5,000g for 60 min at 4 °C. The supernatant was applied to a 
column containing chitin beads pre- equilibrated with column buffer. Intein cleavage was 
initiated by rapidly flushing the column with 30 ml of CB containing 40 mM DTT, and left at 
4 °C for 48 hours. Protein was then eluted from the column by washing the beads with 15ml 
column buffer. The protein was concentrated by using an Amicon bioseparator fitted with a 
25 mm YM-3 membrane and applying 60–70 lb/in2 N2 for 7–10 h at 4 °C.  
          The protein purification procedure is the same for all genes cloned into and expressed 
from the pET28b vector. Escherichia coli strain Rosetta 2 (DE3) (Novagen) containing the 
plasmid was grown overnight in broth medium (1% (w/v) tryptone, 0.5% (w/v) yeast extract, 
0.5% (w/v) NaCl) containing ampicillin (100 μg/ml) and chloramphenicol (34 μg/ml) at 37 °C. 
The cells were then diluted 1:100 in 2 l medium and grown to a cell density of approximately 
4×108 per ml. IPTG was added to 0.5mM and the cells then grown overnight at 25 °C. Protein 
was purified essentially according to a procedure developed by Novagen. Briefly, cells were 
collected by centrifugation, resuspended in 25 ml column buffer (CB: 50 mM Hepes, pH 8.0, 
300 mM NaCl, 20 mM Imidazole) and disrupted in a French pressure cell. Cellular debris was 
pelleted by centrifugation at 5000 xg for 60 min at 4 °C. The supernatant was applied to a 
column containing Ni-NTA His binding beads (2 ml bed volume, equilibrated with CB), and 
washed with 100 ml of CB, then eluted with 10 ml elution buffer (EB: 50 mM Hepes, pH 8.0, 
300 mM NaCl, 250 mM Imidazole). The protein was concentrated to 1–2 ml using an Amicon 
bioseparator fitted with a 45 mm YM-3 membrane and applying 60–70 lb/in2 N2 at 4 °C.  
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7.4 Fluorescence polarization assay  
          All fluorescence measurements were made using an Envision (Perkin Elmer Inc) 
spectrofluorometer. Six different lengths of oligonucleotides, with sequences listed in table 7.2, 
were (3′-fluorescein) labeled. Samples were excited at 490 nm, and emitted light was collected 
through an orange glass filter (OG 515, Schott). The binding affinity for the minMobA (Y25F) 
and oligo DNA complex were determined in the presence and absence of 1mM metallic cations 
by measurement of the steady-state anisotropy of fluorescence as a function of added protein. 
The binding buffer contains 10 mM Tris–HCl (pH 7.5), 20 mM NaCl. The concentration of 
protein was plotted against anisotropy of fluorescence and fit to a hyperbola equation to get the 
dissociation constants. The nonlinear regression analysis was performed in the program GraFit 










Table 7.2: Sequence of oligonucleotides used in fluorescence polarization assay. 
 
7.5 DNA cleavage assay 
          The DNA cleavage assay was performed as described below. A 35mer oligonucleotide 
(Integrated DNA Technologies) with sequence CCAGTTTCTGAAGAGAAACCGGTAAATG 
CGCCCT was (3′-33P)-labeled with terminal transferase, according to the manufacturer's 
instructions (New England Biolabs). The assay reaction mixtures contained 0.03 μM labeled 
35mer oligonucleotide, 0.1 μM minMobA, 40 mM Tris–HCl (pH 8.0), 20 mM NaCl, and in the 
presence and absence of 1mM metallic cations. For minMobA mutants, the reaction mixtures 
contained additional 50 mM MgCl2.  The reactions were terminated by addition of EDTA to 
40 mM after 0, 1, 2, 4, 6, 9, 11, 15, 20, 25, 28, 36, 45, 55, and 60 min. Reaction products were 
separated by SDS–12% PAGE and imaged on a Molecular Imager FX system (BioRad 
Laboratories, Inc., Hercules, CA). The concentration of protein-DNA covalent adduct was 
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plotted against time and fit to a single exponential equation: [protein-DNA] =A*(1-exp(−kobs* 
t))+C. The nonlinear regression analysis was performed in the program GraFit 5.0 (Erithacus 
Software). The protocol for DNA cleavage assay by pSC101 is almost the same as that of 
minMobA, except that the substrate is 37mer oligonucleotide with sequence TTTCTGAACGA 
AGTGAAGAAACGTCTAAGTGCGCCC T, and the reactions were terminated after 0, 0.5, 1, 
2, 4, 6, 9, 11, 15, and 20 min.   
7.6 Isothermal titration calorimetry (ITC) 
          A MicroCal VP-ITC calorimeter was used to measure the binding affinity of minMobA 
to metallic cation. Protein was dialyzed against 10 mM Na-HEPES (pH 7.5), 25 mM NaCl, 
with 10 g/liter of Chelex beads in the dialysis buffer. Protein, metal and buffer solutions were 
degassed before loading into the calorimeter. For the measurement of Mn2+ binding, 4mM 
MnCl2 was injected into 158 µM minMobA, with a stirring speed at 200 rpm. Data analysis 
was carried out by fitting to both single site and multiple binding sites models as defined in the 
Origin software package. 
7.7 Inductively coupled plasma mass spectrometry (ICP-MS) 
          ICP-MS studies were carried out on an Agilent 7500ce ICP mass spectrometer with an 
Octopole Reaction System for interference reduction, and an electron multiplier detector that 
operates simultaneously in pulse counting and analog modes. All the samples were prepared in 
a class 100 clean laboratory with all reagents being ultra pure. The supernatant of cell lysate 
was dissolved in high concentration of HNO3 and diluted to final 1% HNO3 before analysis. 
Concentrations of all elements were calculated from the calibration curve after proper 
correction for control blank, matrix and drift effects. 
7.8 Circular dichroism measurements 
          Circular dichroism spectra were recorded using a Jasco 715 spectropolarimeter, equipped 
with a thermostated cell holder and a NesLab-111 circulating water bath. CD spectra were 
recorded in cells with an optical path length of 0.1cm. Experiments were performed in 10 mM 
Tris–HCl (pH 7.5), 20 mM KCl, in the presence or in the absence of different concentrations of 
metal ions. Three scans were repeated for each experimental condition. 
7.9 Thermal denaturation experiments 
          Thermal denaturation profiles were obtained by recording the temperature dependence of 
the ellipticity at 220 nm in the range 6–80 °C. The temperature was continuously changed at a 
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rate of 0.5 °C/min. Experiments were performed in 10 mM Tris–HCl (pH 7.5), 20 mM KCl, in 
the presence or in the absence of different concentrations of metal ions. Tm was determined by 
locating the maxima/minima of the first derivative of the curve describing the melting profile 
(CD versus T). 
7.10 Screening for crystallization condition 
          A total of 698 conditions were manually screened for crystallization condition using the 
sitting drop method. Among those conditions, 458 come from the commercially available 
crystallization screening kits (Hampton Research), including: Screens I and II, Index, PEG/Ion 
I and II, Natrix, Grid screen PEG 6000/AS/NaCl/MPD, and Quick screen phosphate. The rest 
240 conditions came from 10 in-house Grid-screening kits. MobA* and pSC101 were also sent 






















Chapter 8: Results 
 
 
8.1 Nicking activity of wild type and mutant minMobA(s)  
          To get a quantitative measurement of the transesterification activity of MobA protein, a 
nicking assay was developed by incubating minMobA with 3’ radiolabeled oligonucleotide. 
The reactions were terminated by addition of EDTA at various time points over one hour 
period, and then the reaction products were separated by SDS- PAGE. As shown in figure 8.1 
panel a, the top bands corresponded to the protein-oligonucleotide adduct, and the bottom 
bands represented the unreacted oligonucleotide. The fractions of radiolabeled covalent adduct 
formed were calculated, and plotted against reaction time. The resulting curve was fitted into a 
single exponential equation.  The parameters provided the observed reaction rate and the 
fraction of covalent adduct. The observed rate constants of nicking reactions are summarized in 
table 8.1.  
          As expected, Tyr25 is critical for catalysis; no covalent adduct was observed once it was 
mutated to alanine (Figure 8.1, panel b). Surprisingly, the conversion of Glu74 to Ala or Gln 
decreases the covalent adduct formation in one hour to 50% and 70% respectively, of wild-type 
activity (Figure 8.1, panel c and d). The conversion of the nearby Glu76 to Ala decreases the 
covalent adducts formation by 45% (Figure 8.1, panel e). Even the double mutant E74A-E76A 
reduces activity only tenfold (Figure 8.1, panel f). This suggests E74 plays only the most minor 
role in catalysis. The same phenomena were observed for pSC101, in which the conversion of 
E73 (corresponding in position to E74 of minMobA) to Ala, or conversion of E75 
(corresponding in position to E76 of minMobA) to Ala only partially reduced enzyme activity 
(40% and 42% of wild-type activity respectively), see figure 8.2 panel c and d. This indicates 
the phenomenon we observed in minMobA is not an artifact of protein truncation.  
8.2 Effects of metallic cations on nicking activity of minMobA  
          The metal ions were replaced in minMobA by an initial exhaustive dialysis against 
EDTA followed by dialysis against the divalent cation of choice. As expected, no covalent 
DNA adduct formed in the absence of any divalent cations; that is, nicking activity has an 




(a). Wild type minMobA                                 (b). Y25F 
 
(c). E74A                                                          (d). E74Q 
   
(e). E76A                                                          (f). E74A-E76A 
   
(g). E38AE74AE76A 
 
Figure 8.1: In vitro cleavage of 35mer oligonucleotide by minMobA (a)wild type and mutants: 
(b) Y25F, (c) E74A, (d) E74Q, (e) E76A, (f) E74AE76A and (g) E38AE74AE76A. In each gel, 
each lane contains the separated components from the reaction stopped after a time ranging 
from 0min (left) to 60 min (right). The top bands corresponds to the protein-oligonucleotide 






minMobA Kobs (uM/min) 








Table 8.1: Observed rate constants of nicking reaction of minMobA wild type and mutant 
proteins. 
 
(a). pSC101 wild type                                       (b). Y22F 
 
(c). E73A                                                            (d). E75A 
   
Figure 8.2: In vitro cleavage of 37mer oligonucleotide by pSC101 (a) wild type and mutants: 
(b) Y22F, (c) E73A and (d) E75A. In each gel, each lane contains the separated components 
from the reaction stopped after a time ranging from 0min (left) to 36 min (right). The top bands 
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Table 8.2: Observed rate constants of nicking reaction of pSC101wild type and mutant proteins 
 
(a). minMobA (H112A)                                 (b). minMobA (H120A) 
     
(c). minMobA (H122A)                                 (d). Mn2+ 
    
(e). Ni2+                                                                                         (f). Mg2+ 
   
(g). Ca2+                                                                                         (h). Zn2+ 






(i). No metal 
 
 
Figure 8.3: In vitro cleavage of 35mer oligonucleotide by minMobA mutant (a) H112A, (b) 
H120A, (c) H122A in the presence of 50mM Mg2+, and by minMobA wild type in the presence 
of different metallic cations: (d) 1mM Mn2+, (e) 1mM Ni2+, (f) 1mM Mg2+, (g) 1mM Ca2+, (h) 
1mM Zn2+, (i) 20mM EDTA; and In each gel, each lane contains the separated components 
from the reaction stopped after a time ranging from 0min (left) to 60 min (right). The top bands 










No metal 0 
 











          As shown in Figure 8.3, Mg2+, Mn2+, Ni2+ and Ca2+ are all able to restore the enzyme 
activity.  At 1 mM concentration, Mn2+ gives the highest reaction rate, while Ni2+ gives the 
most complete reaction (Table 8.3). Surprisingly, 1 mM Zn2+ can not restore enzyme activity, 
as no detectable covalent adduct is formed. The crystal structure of minMobA shows that the 
metal binds with three Histidine residues (H112, H120 and H122) and a water molecule in a 
tetrahedral conformation. The mutation of any of these three Histidine residues to Alanine 
completely abolishes the enzyme activity, in spite of the presence of high concentration of Mg2+ 
(Figure 8.3, panel G-I).  This suggests that the loss of any, or all, of the Histidines precludes 
metal binding at this site. 
8.3 Effects of metallic cations on ssDNA binding activity of minMobA  
          To measure the equilibrium binding strength of ssDNA to MobA independently of 
covalent adduct formation, we mutated Tyr 25 to Phe (Y25F). A fluorescence polarization 
assay was used to analyze the binding affinity of the 35mer single-strand DNA to mutant 
minMobA (Y25F),  in the presence of 1mM Mg2+, Zn2+, Mn2+, Ca2+ and 0.2mM Ni2+ 
respectively.  As shown in figure 8.4, the binding of oligonucleotide to minMobA does not 
require added divalent cations, but the presence of any of the divalent cation improved binding 
affinity by 2 to 3 fold. The oligonucleotide D35 binds to  minMobA(Y25F) with Kd~20 nM, in 
the presence of Mg2+, Mn2+, Ca2+, Ca2+ or Zn2+ (Table 8.4).  We used 0.2mM Ni2+ in our 
experiments because Ni2+ at concentration greater than 0.2mM causes significant fluorescence 
quenching in this system.   
8.4 minMobA Mn2+ binding affinity by ITC  
          Affinities of wild-type and variant minMobA proteins for Mn2+ were measured by 
isothermal titration calorimetry (ITC). As shown in figure 8.5, the stoichiometry of Mn2+ to 
minMobA appears to be 3:1. That is consistent with what we found in X-ray structure, in which 
three metal ions were bound to minMobA; one is chelated by three histidine residues in the 
active site and the other two are chelated by His46 and His98 respectively. The integrated curve 
was fitted to an independent multiple sites binding model, and gave a Kd of 0.2 μM for the 
active site Mn2+, and 40 μM and 45 μM for the Mn2+  ions that bind outside the active site. 
Although the triple mutant E38A-E74A-E76A abolished the nicking activity completely (see 





Figure 8.4: Fluorescence anisotropy assay of binding of minMobA (Y25F) to 3’-Fluorescein 
labeled oligonucleotide in the presence of different metallic cations. 
 
 






No metal 57 
 
Table 8.4: Dissociation constants of minMobA (Y25F) to 3’-Fluorescein labeled 



























Figure 8.5: The representative data for titrations of 4mM MnCl2 into 180μM (a) wild type 
minMobA, (b) E74A mutant minMobA, (c) E38A-E74A-E76A triple mutant minMobA. The 
top panels represent the raw heats of injection; and the bottom panels show the result after 










8.5 Inductively coupled plasma mass spectrometry (ICP-MS) analysis 
          ICP-MS studies were used to identify the most abundant metallic cations in the 
minMobA protein solution, cell lysate, and LB growth media. As shown in Figure 8.6 panel a, 
Mg2+ and Ca2+ are the two most abundant metallic cations in LB media, while Mg2+ is the 
highest metallic cation in the supernatant of cell lysates. Although the absolute quantity of Ca2+ 
is higher than that of Mg2+ in minMobA protein solution, the molar ration of metal to protein is 
almost the same, around 1.4 :1. In other words, Mg2+ and Ca2+ are equally likely to the metallic 
cation which is bound to MobA protein in vitro, see Figure 8.6 panel b. 
8.6 Conformational change by circular dichroism  
          The structure of minMobA was characterized chiroptically by circular dichroism. A 
quantitative analysis of the experimental CD profile suggests the structure is 35.6% α–helix and 
20.7% β-sheet. This is in reasonable agreement with the observed X-ray structure of minMobA, 
which is 31% α-helix and 17% β-sheet(Monzingo, Ozburn et al. 2007). We then assessed the 
effect of divalent cations on the structure.  Ions like Mg2+ and Ca2+ at a concentration of 1mM 
did not induce any changes in the CD spectra at 25°C. However, 1 mM Mn2+ and Zn2+ led to 
slight perturbations of the CD spectra, as shown in Figure 8.7, panel a.  By contrast, 1 mM Ni2+ 
produced a significant decrease in the apparent α-helical content (~8%) at room temperature 
(figure 8.7, panel b).  However there was no apparent alteration of structure at concentrations 
less than 0.5 mM.  
8.7 Thermal denaturation experiments 
          To explore metal induced structural changes more fully, we carried out thermal 
denaturation experiments in the presence of different cations (Figure 8.8).  Monitoring 
ellipticity at 220 nm, we observed that Mn2+ appears to stabilize the structure, increasing the 
Tm by 6 °C at a concentration of 1 mM.   Other cations like Mg2+, Ca2+ and Zn2+ at 1 mM or 
Ni2+ at 0.5 mM, do not alter the Tm of minMobA significantly.  
8.8 minMobA ssDNA binding activity  
          A fluorescence polarization assay was used to analyze the binding affinity of six different 
oligonucleotides (D12, D12m, D19, D24, D31 and D35) to mutant minMobA (Y25F), as shown in 
figures 8.9 and 8.10.  D12 and D12m are the basically the core sequence of oriT, with only one 
nucleotide difference between the two. D24 is the stem loop part of 35mer oriT, and D31, is the 






Figure 8.6: (a) Measured concentrations of different metallic cations (Ca2+, Cu2+, Fe2+, 
Mg2+, Mn2+, Ni2+ and Zn2+) in lysis buffer, minMobA, supernatant of cell lysate and LB 
media. (b) The calculated mole metal per mole minMobA for corresponding metallic cations. 






















































Figure 8.7: Effects of (a) different metallic cations (1mM) and (b) increasing concentrations of 
































Figure 8.8: Effects of different metallic cations (1mM Mn2+, 1mM Ca2+,1mM Mg2+, 1mM Zn2+ 
and 0.5mM Ni2+ ) on the 220nm thermal melting profile of minMobA (10μM) recorded in 
10mM HEPES (pH 7.5), 20mM KCl.  
 
Metallic Cation Tm (°C) ΔTm (°C) 
Mn2+ 48.57 + 5.86 
Ni2+ 42.56 - 0.15 
Mg2+ 44.28 + 1.57 
Ca2+ 43.69 + 0.98 
Zn2+ 42.34 - 0.37 
No metal 42.71  
 










Figure 8.9 Different length of oligonucleotides. The outer and inner arm regions are marked in 
green, and the core region is marked in red. The nicking site is marked with a star. 
 
 
Figure 8.10: Fluorescence anisotropy assay of binding of minMobA (Y25F) to different length 
of 3’-Fluorescein labeled oligonucleotides. 
 








Table 8.6: Dissociation constants of minMobA (Y25F) to different length of 3’-Fluorescein 
labeled oligonucleotides. 
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oligonucleotide with the stem loop binds to protein tighter than the ones without. Although 
there is only one nucleotide difference between D12m and D12, it’s surprising to see that D12m 






























Chapter 9: Discussion 
 
 
9.1 Potential base in the reaction mechanism 
          The structural data of minMobA shows that it shares a common fold with those of TraI 
and TrwC. A mechanism for the transesterification reaction of TrwC has been proposed by 
Roeland.  It was inspired by the structure of TrwC complexed with 27mer DNA comprising the 
hairpin and nicking site (Llosa, Grandoso et al. 1995; Grandoso, Avila et al. 2000; Cesar, 
Machon et al. 2006). Acting as base, the Asp85 of TrwC abstracts a proton from the catalytic 
Tyr18, and activates it for nucleophilic attacking the scissile diphosphate bond (Llosa, 
Grandoso et al. 1995; Grandoso, Avila et al. 2000; Cesar, Machon et al. 2006). As shown in 
figures 9.1 and 9.2, the structure-based sequence alignment reveals that Glu74 in MobA 
corresponds in position to Asp85 of TrwC. It was plausible that Glu74 in Mob A might serve as 
the general base in the mechanism for transesterification. Surprisingly, the conversion of Glu74 
to Ala or Gln only decreases the covalent adduct formation in one hour to 50% and 70%, 
respectively, of wild-type activity. Even the double mutant E74A-E76A still retains some 
activity. This suggests E74 plays only the most minor role in catalysis. The same phenomena 
were observed for pSC101 which naturally lack the primase domain. This indicates the 
phenomenon we observed in minMobA is not an artifact of truncation of protein.  
          Usually, the cleavage of the phosphodiester bond between the phosphate and the oxygen 
at the 3’ position of the deoxyribose sugar would be an SN2 reaction. The completion of this 
reaction requires three chemical entities: a Lewis acid to stabilize the phosphor anion transition 
state, a general acid to protonate the 3’ leaving group and a general base to activate the 
nucleophile. Unlike Asp85 in TrwC, Glu74 does not act directly as a general base in nicking 
reaction of MobA. This is consistent with isothermal titration calorimetry (ITC) experiments, in 
which the mutant minMobA E74A showed the same binding affinity and stoichiometry to Mn2+ 
as wild type protein. Glu76 and Glu38 are two other potential bases in the active sites beside 
Glu74, as shown in figure 9.3. But as for Glu74, neither Glu76 nor Glu38 acts directly as a 
general base. The triple mutant E38A-E74A-E76A abolished the nicking activity completely, 
but still has the same binding affinity and stoichiometry to Mn2+ as the wild type protein. This 





Figure 9.1: The structure-based sequence alignment of minMobA with TraI and TrwC. The 
sequence numbering and secondary structural elements of minMobA are shown on top (H: α 





Figure 9.2: Superposition of minMobA (red) and the Trwc (blue). Tyr25 and Glu74 from 
minMobA are shown as red sticks, while Tyr18 and Asp85 of Trwc are shown as blue sticks. 
 
Figure 9.3: Stereo image of active site minMobA. Tyr25 is shown in grey stick, and the nearby 
Glu38, Glu74 and Glu76 are shown in blue stick. 
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enzyme.  However, it must be recalled that MobA is effectively a single turnover enzyme and 
there is probably no selective pressure to make it a more efficient enzyme.  The normal pKa of 
Tyr is probably sufficient to generate the necessary nucleophile for the transesterification 
reaction. 
9.2 Role of the metallic cation in MobA 
          MobA carries out metal ion-dependent DNA cleavage and rejoining reactions as part of 
its mobilization function. Previously, Scherzinger reported that the nicking activity of MobA, in 
vitro, depended on the presence of a divalent cation, such as Mg2+, Mn2+, Ca2+, or Ba2+.  From 
the X-ray structure of minMobA, the metal ion is chelated by three histidine residues and a 
water molecule in a tetrahedral geometry.  This arrangement is commonly observed for Zn2+ or 
Ni2+ binding proteins(Chivers and Tahirov 2005).  However, the biologically relevant cation, 
and the role of that cation in the nicking reaction is uncertain. 
          In this project we observed that a bound cation is not necessary for minMobA to 
physically bind DNA, but we see that such cation-independent binding does not allow the 
nicking reaction to proceed.   Addition of any of a variety of cations increased the magnitude of 
binding at least 3-fold, and generally allows nicking to occur (Zn2+ being the exception). We 
cannot say if DNA binds in a different orientation in the presence of cations.  However, it 
seems likely that cations organize the MobA active site in a way that improves DNA binding 
and favors an orientation that is potentially productive. Based on our CD measurements the 
magnitude of this organization may be small, and have little effect on the backbone structure. 
(Ni2+ is the exception, causing significant structural changes). In the X-ray structure of 
minMobA, the critical Tyr25 lies at the edge of an α-helix, surrounded by four acidic residues 
(Asp35, Asp37, Glu38 and Glu74) and four basic residues (Arg28, Arg34, Lys22 and Lys31). 
The presence of the divalent metallic cations could easily change the conformation of those 
residues, altering the local protein conformation, stability, and reactivity.  
          It is also possible that the bound cation participates in the chemistry of the nicking 
reaction.  It may function to align the scissile bond for nucleophilic attack by Tyr 25 or it may 
polarize that bond to aid cleavage. The fact that the triple mutant E38A-E74A-E76A abolished 
the nicking activity completely but still had the same binding affinity and stoichiometry to 
Mn2+ also suggests that the role of metallic cation can be purely structural either. It is important 
to recall that MobA is a very poor enzyme, and indeed, its action requires it to carry out a single 
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turnover, forming a covalent adduct that persists during transmission out of the cell.  As a 
consequence, there may not be any pressure to optimize the rate of this reaction.  Our data show 
that Mn2+ gives the fastest reaction, the strongest DNA complex and the greatest thermal 
stabilization.  However, its advantage over Mg2+ and Ca2+ is small, and it may be that any of 
these cations will function well in the mobilization scheme.  We showed that Ni2+ seems to 
create structural aberrations that diminish substrate binding.  Most surprisingly we found that 
Zn2+, a cation that should bind strongly to the tetrahedral geometry of the MobA active site, is 
unable to support the catalytic reaction. 
          It’s still unknown what the physiologically relevant cation is for the relaxase, or indeed if 
several cations can be used efficaciously. The ICP-MS results show that Mg2+ is the metallic 
cation most available to MobA protein in vitro. Although the tetrahedral geometry with three 
Histidine residues and a water molecule, as observed in x-ray structure, is more appropriate for 
Zn2+ and Ni2+, we can not neglect the fact that the presence of a phosphate group of nucleotide 
could provide a better environment for Mn2+ or Mg2+ in a typical octahedral geometry. 
          Metal ligation is affected by the hardness of the metals and the ligands.  The known order 
of the hardness of metallic cations used here is: Mg2+ > Ca2+ > Mn2+ > Ni2+ > Zn2+ (Zechner, 
Eisenbrandt et al. 2000).  The nitrogens of the histidine ligands are soft and should favor the 
softer metals, like Zn2+, while oxygen (from water or phosphate) is a hard ligand.  Our work is 
consistent with the idea that the cation site is not sharply defined, but may be optimized to 
Mn2+.  This is consistent with our crystallization studies as well.  Our largest and most strongly 
diffraction crystals (Monzingo, Ozburn et al. 2007) grow in the presence of Mn2+.  We have 
grown crystals in the absence of cations, but they are too small to diffract, which suggests they 
may not maintain a homogeneous structure. 
          In conclusion, divalent metallic ions affect the conformations of active site residues of 
minMobA; they may organize key side chains and the local backbone structure to favor DNA 
cleavage.  
9.3 Crystallization of related MobA proteins 
          Although a hypothetical model of minMobA with 31-mer oligonucleotide has been 
proposed, the X-ray structure of MobA and oligonucleotide complex would reveal more 
accurate information of how the nucleotide interacts with protein, and possibly greater insight 
into the reaction mechanism of DNA nicking activity. 
 166
          We tried to co crystallize minMobA (Y25F) with six different length oligo nucleotides: 
D12, D12m, D19, D24, D31 and D35. So far, only the complex of minMobA (Y25F) with D12m gave 
some hexagon-shaped crystals after three months. Unfortunately, the crystal didn’t diffract 
well, with the best resolution only 5.0Å. Molecular replacement methods were not successful in 
phasing the X-ray data, because there were eight molecules in one asymmetric unit. All the 
molecular replacement software we tried failed to predict more then four molecules in one 
asymmetric unit. We are still in the process of refine the crystallization condition of this 
complex, hopefully, it may give a crystal which diffracts better.  
           The minMobA protein is able to carry out the initial DNA cleavage, but can not interact 
with T4SS in gene transfer. A longer version of MobA protein called MobA*, which can not 
only cleave oriT, but also support conjugative transfer of the covalent DNA-protein complex 
into a new host, has also been screened for crystallization condition (Becker and Meyer 2002). 
MobA* is a 341 residue N-terminal fragment of MobA; and it has been expressed and partially 
characterized in Dr. Meyer’s laboratory. Because MobA* supports conjugative transfer, it is 
likely that MobA* may have a 150 residue domain that interacts with the Type IV secretion 
system besides the minMobA catalytic domain. From genetic experiments, we know that this 
interaction is vital for initiating the physical movement of the covalent DNA-complex through 
the secretion pore (Becker and Meyer 2002; Becker and Meyer 2003). So far, the structure of 
this putative interaction domain is still unknown. So, the structure of MobA* will reveal some 
important information on the mechanism of drug resistance transfer. MobA* was cloned into 
three different vectors: pTYB2 (C-terminal intein fusion vector), pET46 (N-terminal His-tag 
vector) and pET28b (C-terminal His-tag vector). The protein with either N-terminal His-tag or 
C-terminal His-tag was mis-folded and went into the cell pellet after centrifugation. MobA* 
with a self-splicing C-terminal intein tag was soluble, but no crystallization condition has been 
identified so far.   
          Another protein we produced and attempted to crystallize is the intact MobA from 
pSC101.  It is a 371 residue relaxase  homologous to R1162, and naturally lacking the primase 
domain of the full length MobA from R1162 (Meyer 2000).  It has been shown to have a more 
restrictive specificity than MobA. MobA can bind, cleave and mobilize the pSC101 oriT, but 
the reverse is not true. The pSC101 plasmid has an accessory protein called MobX, which is a 
homologous of MobB protein.  The pSC101 plasmid is competent for conjugal transfer. In 
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other words, it contains a recognition domain for the type IV secretion system. The 
crystallization effort will provides additional opportunity to see this important class of 
structural elements. The pSC101 gene was cloned into both an intein fusion vector and a His-
tag vector. Like MobA*, the His-tagged pSC101 was insoluble. The only crystal found in the 
pSC101screening turned out to be a salt crystal. A truncated version of pSC101 corresponds to 
minMobA, a 193-residue minPSC101, was engineered for crystallization screening. 
Surprisingly, this minpSC101 is unable to carry out the nicking reaction, and no crystallization 
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